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Abstract
Antimicrobial resistance (AMR) is one of the serious global health challenges of our time.
There is an urgent need to develop novel therapeutic agents to overcome AMR, preferably
through alternative mechanistic pathways from conventional treatments. Interdisciplinary
research in inorganic medicinal chemistry with biology is advancing the knowledge and
implementation of transition metal complexes for therapy and is offering a realistic alternative
to traditional antibiotics. Metal complexes with 1,10-phenanthroline (phen) ligands have
demonstrated promising therapeutic capabilities with diverse biological activity. Consequently,
there has been a resurgence in research of these complexes as possible alternatives or adjuvants
to established antimicrobial clinical therapeutics. The antibacterial activity of novel metal
complexes (metal = Cu(II), Mn(II), and Ag(I)) incorporating phen and various dicarboxylate
ligands was the focus of this research.
The first objective of this study was to screen all metal complexes and their phen derivatives
against common Gram-positive and Gram-negative resistant clinical isolates. Overall, superior
toxicity was evident in complexes that incorporate the phen ligand compared to the activities
of their simple salt and dicarboxylate precursors. The chelates incorporating 3,6,9trioxaundecanedioate (tdda) were the most effective, and the varied toxicity depended on the
metal centre. Whole-genome sequencing was carried out on reference Gram-positive and
Gram-negative strains, Staphylococcus aureus (ATCC 29213), and Pseudomonas aeruginosa
(PAO1). The strains were exposed to sub-lethal doses of lead metal-tdda-phen complexes to
form mutants with induced resistance properties. Various mutations were detected in the
mutant P. aeruginosa genome, causing amino acid changes to proteins involved in cellular
respiration, the polyamine biosynthetic pathway, and virulence mechanisms.
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To further investigate the anti-pseudomonal potential of the novel metal complexes, clinical P.
aeruginosa isolates from cystic fibrosis (CF) lungs of Irish patients were obtained since
inherited CF is prevalent in Ireland. The bacteria's capacity to form a biofilm in its pathogenesis
is highly virulent and leads to decreased susceptibility to most antibiotic treatments.
The second objective was to investigate the activity profiles of the Cu(II), Mn(II), and Ag(I)
complexes

{[Cu(3,6,9-tdda)(phen)2].3H2O.EtOH}n

(Cu-tdda-phen),

{[Mn(3,6,9-

tdda)(phen)2].3H2O.EtOH}n (Mn-tdda-phen) and [Ag2(3,6,9-tdda)(phen)4].EtOH (Ag-tddaphen) towards clinical isolates of P. aeruginosa derived from Irish CF patients compared to
two reference laboratory strains (ATCC 27853 and PAO1). The effects of the metal-tdda-phen
complexes and established antibiotic gentamicin on planktonic growth, biofilm formation (pretreatment), and mature biofilm (post-treatment) alone and in combination with gentamicin were
investigated. The effects of the metal-tdda-phen complexes on the individual biofilm
components; exopolysaccharide, extracellular DNA (eDNA), pyocyanin, and pyoverdine are
also presented. All three metal-tdda-phen complexes showed comparable and often superior
activity to gentamicin in the CF strains compared to their activities in the laboratory strains
concerning biofilm formation and established biofilms. Combination studies presented
synergistic activity between all three complexes and gentamicin, particularly for the posttreatment of established mature biofilms, and were supported by the reduction of the individual
biofilm components examined.
The ability of metal-tdda-phen complexes to act on P. aeruginosa clinical isolates
synergistically with gentamicin prompted in vivo studies. Therefore, the final objective was to
assess the efficacy of individual treatments of Cu-tdda-phen, Mn-tdda-phen, and Ag-tdda-phen
and in combination with gentamicin in larvae of Galleria mellonella infected with clinical
isolates and laboratory strains of P. aeruginosa. All test complexes were tolerated by G.
mellonella in concentrations up to 10 µg/larva and affected the host's immune response by
ii

stimulating immune cells (hemocytes) and enhancing the expression of genes that encode for
immune-related peptides, specifically transferrin and inducible metalloproteinase inhibitor
(IMPI). Combining the metal-tdda-phen complexes with gentamicin further intensified this
response at lower concentrations, clearing a P. aeruginosa infection previously resistant to
gentamicin alone. Therefore, this work highlights the anti-pseudomonal capabilities of metaltdda-phen complexes alone and combined with gentamicin in a valuable pre-clinical in vivo
model.
In summary, this research demonstrates the potential of novel metal complexes incorporating
dicarboxylate and 1,10-phenanthroline ligands with low toxicity and high efficacy that could
become part of the therapeutic arsenal in the battle against multidrug-resistant bacteria,
particularly for strong biofilm formers such as P. aeruginosa.
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Chapter 1.

General Introduction

1

Antimicrobial resistance – A global crisis
Sir Alexander Fleming warned us of the rise of antimicrobial resistance in his Nobel Prize
speech (11th December 1945) for discovering the world's first antibiotic, penicillin. In his
remarks, he included a hypothetical situation of the negligent use of non-lethal doses,
changing the nature of the microbe and conferring resistance to the drug (Fleming, 1945).
Since then, the multidrug-resistance (MDR) of microorganisms to antibiotics as the now
therapeutic mainstream medicines has become a global crisis. The consequences of
antimicrobial resistance (AMR) are widespread. It threatens the effective prevention and
treatment of an increasing range of infections caused by bacteria, parasites, fungi, and
viruses that are no longer susceptible to the standard medicines used to treat them. AMR
also contributes to different complications in vulnerable patients undergoing
chemotherapy, organ transplantation, surgeries, dialysis, intensive care for a pre-term
newborn, and many other activities (Nanayakkara et al., 2021; Turner, 2021).
Furthermore, growing resistance will heavily affect people with chronic conditions like
diabetes, asthma, and rheumatoid arthritis.
As seen with the global pandemic of the Coronavirus Disease 2019 (COVID-19) caused
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the global
monitoring of infectious agents with the research and development of new therapeutics
to deal with them is paramount. Moreover, this outbreak has exacerbated the existing
AMR crisis due to the pre-emptive use of antimicrobials to incorrectly treat SARS-CoV2-infected patients (Pelfrene et al., 2021). The Achilles heel of antibacterial agents is the
proficiency at which target pathogenic bacteria can develop resistance, and this has been
rapidly accelerated due to increased use and misuse of antibiotics in human and veterinary
medicine worldwide, along with other global issues including poor sanitation systems,
overpopulation and high international migration (Chokshi et al., 2019; Hernando-Amado
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et al., 2020). This is further perpetuated by evidence that research on novel antibiotics is
slowing down, and there is an apparent lack of novel drug development by the
pharmaceutical sector.
The problem of AMR is especially urgent due to antibiotic resistance in bacteria and has
been a long-time concern for government and health agencies, including the United
Nations (UN) and the World Health Organization (WHO). The European Centre for
Disease Prevention and Control (ECDC) and Organisation for Economic Co-operation
and Development (OECD) published a report on bacterial resistance in the European
Union (EU). They stated that the health burden of infections due to bacteria with AMR
in the EU/EEA population is comparable to that of influenza, tuberculosis, and HIV/AIDS
combined (ECDC, 2019). Due to resistant bacteria, approximately 670,000 infections
occur in the EU/EEA each year, with 33,000 directly attributable deaths and costing €1.1
billion in extra healthcare costs (ECDC, 2020). The Centers for Disease Control and
Prevention (CDC) reported that more than 2.8 million antibiotic-resistant infections occur
annually in the USA, resulting in 35,000 deaths (CDC, 2019). A recent systemic analysis
estimates 4.95 million fatalities worldwide associated with bacterial AMR in 2019,
including 1.27 million deaths directly attributable to bacterial resistance alone (Murray et
al., 2022), which is expected to increase to 10 million by the year 2050 (Neill, 2014).
In addition to the ongoing struggle of rising AMR, it is well-documented that there is a
limited pipeline of new antimicrobials under development to compete with this increasing
resistance (Tacconelli et al., 2018; Theuretzbacher et al., 2019; Theuretzbacher, 2020;
Butler et al., 2022). The WHO established the Global Antimicrobial Resistance
Surveillance System (GLASS), an operational framework for resistance surveillance.
They also published a list of antibiotic-resistant priority pathogens to promote and expand
research on these highly resistant microorganisms and produce new technologies and
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drugs (WHO, 2017). Infections caused by these microorganisms pose a severe worldwide
hazard, and the 2020 WHO clinical antibacterial pipeline analysis report stated that the
demand had not been met. In addition, the WHO highlighted that of the 12 antibiotics
approved by the FDA and EMA since 2017, over 80% are derivatives of existing
antibiotics where resistance mechanisms are well established, and rapid emergence of
resistance is predicted (WHO, 2021). Therefore the report also included a comprehensive
overview of non-traditional antibacterial medicines in the pipeline to encourage more
research on novel medicinal approaches (WHO, 2021). It is recognised that there is a
critical urgency to develop novel therapeutic agents to overcome antibiotic resistance for
selected pathogenic organisms of concern preferably through novel classes, targets or
modes of action and without known cross-resistance (Miethke et al., 2021).

Antibacterial agents
1.2.1 The history of antibacterial agents
It is commonly stated that antibiotics were not discovered until 1928 however, evidence
of antibacterial use can be traced back for centuries. Many ancient cultures, for example,
China, Egypt, Greece, and Serbia, used the crusts of mouldy bread and applied them to
open wounds to prevent infection (Lemire et al., 2013). In the middle ages, the warriors
would apply honey to arrow wounds for the same reason. Nonetheless, weapons against
bacterial ailments were tenuous until the latter half of the 19th century, when the 'germ
theory of disease' was proposed (Kong et al., 2010). Scientists such as Lister, Pasteur,
and Koch suggested that microorganisms were responsible for various infections plaguing
humanity, transforming the understanding and treatment of these diseases. By 1910, the
first synthetic antimicrobial agent had been successfully established. It was a 3-ammino4-hydroxyphenyl-As(III) chemical dye, as seen in Figure 1.1, called Arsphenamine and
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later salvarsan, developed by Paul Ehrlich (Ehrlich 1912; Ehrlich & Bertheim 1912).
Heralded as the father of chemotherapy, his principle was that a chemical agent should
have a specific affinity for pathogens and directly affect its proliferation at a tolerable
concentration by its host. He deemed this the 'magic bullet' that is now described as
selective toxicity. To uncover a magic bullet, large-scale synthesis of organoarsenic
derivatives and systemic screening was initiated with colleagues Bertheim and Hata
(Ehrlich & Hata 1910). The 606th preparation of the arsenobenzene compound was tested
in syphilis-infected rabbits and was highly effective at clearing the infection.
Following Erhlich's approach, Bayer laboratories in Germany discovered and developed
sulfonamides. More specifically, the red dye known by its commercial name of Prontosil
(as seen in Figure 1.1) was tested for its antimicrobial potential in a murine model of
Streptococcus pyogenes systemic infection (Domagk, 1935). Further studies established
that the sulfonamide was a prodrug and that the active component, sulfanilamide (Figure
1.1), was already utilized in the dye industry, and the patent had expired for many years.
This, along with the cheap production cost, enabled many laboratories to synthesize and
mass-produce derivatives of the drug within quick succession. Despite the many benefits
of sulfonamides, there were also usage impediments due to the toxic products formed
when it is metabolized. An additional legacy of sulfanilamide was a significant
modification with diethylene glycol in 1937. The drug was released without any
toxicology analysis and caused the death of 105 people in the United States, prompting
the introduction of a legislative framework for drug release (Wax, 1995). This set of laws,
the Federal Food, Drug, and Cosmetic Act of 1938, was the first of its kind. It is still the
drug regulatory authority of America today, although now called the US Food and Drug
Administration (FDA, 2018).
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(A)
(D)

(E)
(B)

(C)

Figure 1.1 The chemical structure of Salvarsan (A-C) with the initially proposed
structure (A), the known structure derived from a mixture of (B) and (C), and the prodrug
Prontosil (D) that is metabolised into its active form sulphanilamide (E). Diagram adapted
from (Li et al., 2015)

1.2.2 The golden age to the discovery void of antimicrobial agents
Fleming made his vital medical breakthrough in 1928 by serendipitously discovering
penicillin in a Staphylococcus aureus plate contaminated by Penicillium chrysogenums
that inhibited bacterial growth (Fleming, 1929). However, the toxic fungal metabolite
application as a therapeutic agent was not brought into existence until the 1940s, when
Florey and Chain overcame the problems of purifying the active ingredient in sufficient
quantities for clinical trials (Chain et al., 1940). Later 6-aminopenicillianic acid (6-APA)
was identified as the bioactive intermediate of penicillin, and this discovery
revolutionized drug development by providing the starting material for semi-synthetic
penicillin. This set up the paradigm for drug discovery for the subsequent three decades
leading to the 'Golden Age' of antibiotic pioneering and deployment in the clinic, as
presented in Figure 1.2 below. The ensuing years saw a surge in antibacterial discovery
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in which several new classes of antibiotics originated from soil bacteria and moulds (βlactams, aminoglycosides, tetracycline, macrolides, and chloramphenicol) or were
chemically synthesized (quinolones and sulfonamide) (Silver, 2011; Gould, 2016). As
screening for natural bioactive products became less fruitful and repeat discoveries were
more commonplace, the pharmaceutical companies backing the research of novel
antibiotics withdrew support (Silver, 2011). From 1986 until the present day, only a
handful of new antibiotics have been registered, and this period is referred to as the
'discovery void' within the scientific community. The escalating resistance difficulties
during this period have forced researchers to modify the already existing arsenal to
enhance activity, increasing sensitivity toward resistance while reducing toxicity (Chopra
et al., 2002; Fair and Tor, 2014).
Nonetheless, this approach has not halted the evolution of bacterial resistance to
antimicrobial agents (Figure 1.2). With the advent of bacterial genomics in the early
1990s came the potential for target-based antibacterial drug discovery and the
pharmaceutical sector's renewed interest in developing novel antibiotics (Hutchings et al.,
2019). Intense efforts to discover new antibacterial compounds were performed using
high-throughput screens, and hundreds of novel bacterial targets were identified.
However, no successful drug candidates emerged from these screens, and the larger
pharmaceutical companies abandoned the mission to discover novel antibacterial
compounds (Baker et al., 2018).
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Figure 1.2 A timeline displaying antibiotic deployment into the clinic (on top) and the
subsequent discovery of resistance (on the bottom). The first discovery of methicillinresistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE),
vancomycin-resistant Staphylococcus aureus (VRSA), and the mobile colistin resistance
(mcr) gene, enabling bacteria to be highly resistant to polymixins such as colistin, are also
highlighted, adapted from (Hutchings, Truman and Wilkinson, 2019).

1.2.3 Classification of antibacterial agents
The central success of antibacterial agents is their selective nature for pathogens without
adversely affecting the host. Such selective toxicity depends on identifying differences
between the invading organism and the host that can be exploited. There are several ways
that antibacterial drugs can be classified, including the following criteria; source, the
spectrum of activity, effect on the target pathogen, chemical or molecular structure, and
mechanism of action (Etebu and Arikekpar, 2016; Pancu et al., 2021). While the route at
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which the drug is administered, such as injectable, oral, and topical treatment, represents
an alternative classification.
Depending on the range of microorganisms susceptible to these drugs, antibacterial agents
can be categorized as a broad- or narrow-spectrum (Acar, 1997; Najafpour, 2007). As
the name suggests, broad-spectrum antibiotics exert their toxicity against various
pathogens, including Gram-positive and Gram-negative bacteria. The narrow-spectrum
antibacterial agents are considered effective against a specific pathogen, for instance,
Gram-positive or Gram-negative bacteria. Narrow-spectrum antibiotics are generally
preferred over broad-spectrum toxic drugs due to their specificity and reduced bacterial
resistance (Ullah and Ali, 2017).
Due to the differences by which antibacterial agents eradicate the infection, they can also
be classified as bactericidal or bacteriostatic. Bactericidal compounds trigger cell death
via inhibiting cell wall synthesis, cell membrane function, or protein synthesis (Ullah and
Ali, 2017), while bacteriostatic agents affect bacterial cellular activity and growth without
triggering death. In clinical practice, however, these two categories are much more fluid.
A bactericidal agent is unlikely to kill every bacterium within a host, and a bacteriostatic
agent may destroy a high proportion but not all of the disease-causing bacteria within the
host.
Antibacterial activity can also be classified into five different mechanisms, including; (i)
interfering with bacterial cell wall synthesis, (ii) disruption of bacterial plasma
membrane, (iii) inhibition of bacterial protein synthesis, (iv) inhibition of bacterial
nucleic acid transcription and replication, and (iv) antimetabolite activity (Fair and Tor,
2014; Kapoor et al., 2017; Peterson and Kaur, 2018). These antibacterial mechanisms are
demonstrated as cellular targets depicted in Figure 1.3 below. Furthermore, the classes
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of antibiotics according to their chemical structure, acting on these specific cellular
targets, and elucidating their mechanism of action are presented in Table 1.1.

Figure 1.3 Cellular targets of established antibacterial agents; (i) Cell wall inhibitors –
blocking synthesis and repair, (ii) Damage to plasma membrane – causing loss of
selective permeability, (iii) Protein synthesis inhibitors acting on ribosomes – 30S subunit
and 50S subunits, (iv) DNA/RNA inhibitors – inhibiting DNA gyrase and RNA
polymerase, and (v) Block pathways and inhibit metabolism
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Major target

Antibacterial class

Mechanism of action

Cell wall synthesis

β-lactam
Glycopeptide

Bind cell wall cross-linking enzyme (PBPs,
transpeptidases)
Block cell wall glycosyltransferases by
binding D-Alanine-D-Alanine (D-Ala-DAla)

Bacitracin

Blocks lipid carrier of cell wall precursors

Protein synthesis

Aminoglycoside

Bind 30S ribosomal subunit
Block translocation of peptide chain
Cause misreading of mRNA
Tetracycline
Bind 30S ribosomal subunit
Inhibit peptide elongation
Oxazolidinone
Bind 50S ribosomal subunit
Inhibit initiation of peptide synthase
Mupirocin
Blocks isoleucyl tRNA synthesis
Chloramphenicol
Bind 50S ribosomal subunit
Block aminoacyl tRNA positioning
Lincosamides
Bind 50S ribosomal subunit
Block peptide bond formation
Macrolides
Bind 50S ribosomal subunit
Block peptide chain exit
Streptogramins
Bind 50S ribosomal subunit
Block peptide chain exit
Nucleic Acid
Fluoroquinolones
Inhibit DNA enzymes, gyrase and
Synthesis
topoisomerase IV, creating enzymes-DNAdrug complex inhibiting DNA replication
Rifamycins
Inhibit RNA polymerase
Folate synthesis
Sulfonamides
Inhibit dihydropteroate synthetase
Trimethoprim
Inhibits dihydrofolate reductase
Plasma membrane
Polymyxin
Bind LPS and disrupt outer and
cytoplasmic membranes
Lipopeptide
Produces membrane channel and
membrane leakage
Table 1.1 Mode of action of different classes of antibacterial agents. Key; penicillinbinding protein (PBPs), lipopolysaccharide (LPS).
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1.2.3.1 Antibacterial drugs inhibiting cell wall synthesis
The cell wall is the main osmotic pressure bearing and shape-maintaining element,
preventing mechanical, chemical, or enzymatic damage. A significant cell wall
component is peptidoglycan, and Gram-positive (50-100 peptidoglycan layers) bacteria
have a thicker layer than Gram-negative bacteria (2 peptidoglycan layers). Peptidoglycan
is assembled from alternating units of N-acetylmuramic acid (NAM), and Nacetylglucosamine (NAG) cross-linked through pentapeptides at the lactic acid residue of
NAM, and this is important for the shape and physical strength of the bacterium (Irazoki
et al., 2019). The lactic acid of NAM is further linked to four amino acids in the series LAlanine, D-Glutamate, L-Lysine, and D-Alanine by peptide bonds. This cell wall is not
found in eukaryotes; therefore, drugs that target this entity are selectively toxic, creating
extraordinary clinical efficacy and safety in controlling bacterial infection.
The β-lactam antibiotic family encompasses penicillin, cephalosporin, carbapenem, and
monobactam subfamilies and their derivatives. Each structure within these subfamilies
possesses the characteristic β-lactam core structure and varies by side chain attached or
additional cycles. The biosynthesis of the peptidoglycan polymer is an intricate threestage process where β-lactams target the final stage of development. More succinctly,
they interfere with transpeptidation by binding to penicillin-binding proteins (PBPs),
preventing the cross-linking of muramic acid residues and glycan chains in
peptidoglycan, altering its structural integrity and promoting death (Rice, 2012; Dik et
al., 2018).
Similarly, glycopeptides such as vancomycin inhibit peptidoglycan synthesis in Grampositive bacteria by binding to the substrate of transpeptidases and forming a complex
with D-Alanine-D-Alanine (D-Ala-D-Ala) of peptidoglycan precursors (Périchon and
Courvalin, 2009; Olademehin et al., 2021).
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1.2.3.1 Antibacterial drugs targeting protein synthesis
Protein biosynthesis (also known as translation) occurs on ribosomes, macromolecular
enzymatic complexes, that catalyse the formation of polypeptide chains based on the
genetic code of messenger RNA (mRNA) (Polikanov et al., 2018). This complex process
involves multiple steps; initiation and elongation comprise the entry of aminoacyl tRNA
with anticodon reading of the mRNA codon leading to the peptidyl transfer of each amino
acid to a growing polypeptide chain, the translocation of the ribosomes for each mRNA
codon and then termination of the process. The prokaryotic 70S ribosome is composed of
a small subunit (30S), which consists of the 16S ribosomal RNA (rRNA) chain and 21
proteins, and a large subunit (50S) that contains the 5S and 23S rRNA chains and 34
proteins (Steitz and Moore, 2003). Initiation of protein synthesis begins with the accurate
positioning of the start codon (AUG) of mRNA to the decoding centre of 16S rRNA in
the 30S subunit, which facilitates interactions with the anticodons of transfer RNA
(tRNA) (Rodnina, 2018). This assembles the initiation complex, which also encompasses
the binding of initiator tRNA with a UAC anticodon loop and carrying a methionine
amino acid at the 3' end and three initiation factors (IF1, IF2, and IF3). Subsequently, the
50S subunit, which contains the peptidyl transferase centre (PTC) of the 23S rRNA for
peptide-bond formation, combines with this complex forming the now active 70S
ribosome. The ribosome has three tRNA binding sites designated the aminoacyl (A),
peptidyl (P), and exit (E) sites found in the larger subunit. (Rodnina, 2018). During the
elongation phase, the A-site and P-site bind corresponding tRNA, whereby incoming
tRNA carrying the amino acid enters the aminoacyl site (A-site), and the amino acid is
transferred to the growing polypeptide chain held in the peptidyl site (P-site). At the same
time, the E-site removes the deacylated tRNAs from the ribosome (Bennison et al., 2019).
Termination of protein synthesis occurs when a stop codon (UAA, UAG, UGA) in the
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mRNA is reached at the A-site and recognized by protein release factors resulting in the
dissociation of the translational apparatus. The ribosomes of eukaryotic cells cytoplasmic
are bigger (80S) and structurally distinct from those found in prokaryotes, consisting of a
larger 60S subunit and a smaller 40S subunit. Classes of antibiotics that target protein
synthesis are therefore selective and can be further divided into protein synthesis
inhibitors that target the small 30S or the large 50S ribosomal subunit.
Aminoglycosides are used as bactericidal agents for the treatment of Gram-negative
infections. Their primary target is the 16S rRNA A-site of the 30S small ribosomal
subunit. The binding of the antibacterial agent here leads to disruption of the decoding
process and misreading of mRNA, interfering with codon recognition and translocation
(Borovinskaya et al., 2007; Polikanov et al., 2018). Tetracyclines passively diffuse into
the bacterial cell and bind close to the A-site, blocking the association of aminoacyltRNAs with the 30S small ribosomal subunit, thus preventing the polypeptide chain from
growing (Mccoy et al., 2011; Chukwudi, 2016).
Chloramphenicol is lipid-soluble and therefore passes through bacterial cell membranes.
It binds reversibly to the A-site of the 50S subunit of bacterial ribosomes, inhibiting
peptide bond formation and resulting in protein synthesis by preventing amino acid
transfer to expand peptide chains, potentially by suppressing peptidyl transferase activity
(Dinos et al., 2016). Oxazolidinones exhibit their antibacterial effects through binding to
the A-site of 23S rRNA of the 50S subunit of the ribosome blocking the incoming
aminoacyl-tRNA complex from binding to the A-site. This prevents the translation of
bacterial proteins required for critical processes such as DNA replication and cell
division, preventing bacteria from multiplying (Zhanel et al., 2015). Macrolides also bind
to the 23S rRNA of bacterial 50S ribosomal subunits. They inhibit the transpeptidation
or translocation process of protein synthesis, blocking it and interfering with the emerging
14

polypeptide as it is being synthesized, resulting in the premature separation of incomplete
peptide chains, preventing bacterial protein synthesis (Parnham et al., 2014).
1.2.3.2 Antibacterial drugs targeting nucleic acids
Genetic material must be replicated for the survival and posterity of bacterial cells.
Therefore, the metabolic pathways that result in synthesising nucleic acids are essential.
Most bacterial species encode two distinct type II topoisomerases, DNA gyrase
(topoisomerase II) and DNA topoisomerase IV. These enzymes play essential roles in
nucleic acid processes, which modulate the chromosomal supercoiling required for DNA
synthesis, transcription, and cell division (Cebrián et al., 2021). DNA Gyrase and
topoisomerase IV preserve genomic integrity during the unwinding of DNA by attaching
to each DNA strand of the intact double helix and passing it through a transient doublestranded break (DSB) generated in a separate segment the of DNA (Vos et al., 2011).
Subsequently, the enzymes form covalent bonds between the 5′-terminus of each DNA
strand, generating topoisomerase-DNA cleavage complexes (D'Atanasio et al., 2020).
Both enzymes are in an A2B2 heterotetramer with gyrase composed of GyrA and GyrB
subunits, and topoisomerase IV has ParC and ParE subunits (Forterre et al., 2007).
Although they have similar homology, they differ in physiological action. Gyrase is
uniquely responsible for introducing negative supercoils into DNA, thereby relaxing the
helix (Gubaev et al., 2016), while topoisomerase IV removes knots that accumulate in the
bacterial chromosome and the decatenation of the interlocked daughter chromosomes at
the end of replication (López et al., 2012). Antibiotics that interfere with this process
target the specific topoisomerases of bacterial cells and have been successfully exploited
as molecular targets.
Quinolones are quinine‐derived structural units that are potent synthetic antibacterial
agents, and the addition of fluorine at position 6 is called fluoroquinolone. Gyrase and
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topoisomerase IV function to generate DSBs in the bacterial chromosome. As described
above, quinolone and fluoroquinolones avail of this process as the DNA is weakened and
binds to the cleavage complexes noncovalently (Correia et al., 2017). When DNA
tracking systems, such as the replication fork or transcription complexes, collide with the
newly formed quinolone–topoisomerase–DNA ternary complex, the DSBs are converted
to permanent ones promoting cell death (Millanao et al., 2021). Rifamycin is a semisynthetic bactericidal agent of the rifampicin class and non-covalently binds to the βsubunit of the DNA-dependent RNA polymerase. This directly blocks the elongation of
RNA, thus inhibiting transcription and causing cellular death (Mosaei and Zenkin, 2020).
The DNA-dependent RNA polymerase in eukaryotes is unaffected as the drug binds to a
peptide chain not present in the mammalian RNA polymerase.
1.2.3.3 Antibacterial drugs damaging plasma membrane
The bacterial cell membrane is a crucial structural and functional component that
regulates most cell processes required for the stability of the bacterial cell. However,
mammalian cells also possess a plasma membrane, so this is not a selective target.
Therefore, antibacterial agents that target the plasma membrane exert toxicity towards the
host but have been revisited recently as a last resort due to mounting resistance.
Daptomycin is a lipopeptide that performs in a calcium-dependent manner on Grampositive bacteria by inserting into phosphatidylglycerol (PG) rich regions of the cell
membrane, causing it to be permeabilised and disrupting membrane function leading to
the loss of bacterial cell stability and subsequent death (Hachmann et al., 2011).
Polymixins also target the cell membrane, but they are specific to Gram-negative
infections as they interact with lipid A of the bacterial lipopolysaccharides, concentrating
on the outer membrane followed by penetration into the inner membrane leading to loss
of cell membrane integrity and then cellular lysis (Epand et al., 2016). The cationic
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polypeptides consist of a lipid tail that is paramount to its toxicity in causing membrane
damage through a detergent-like mode of action.
1.2.3.4 Antibacterial drugs targeting metabolic pathways
Antibacterial agents express antimetabolite activity by targeting folate metabolism.
Tetrahydrofolate is imperative in both prokaryotes and eukaryotes as it is an enzyme
cofactor involved in synthesising pyrimidine nucleotides by providing a carbon unit.
Pyrimidine nucleotides are bases for DNA replication, repair, and other vital cellular
processes.
The sulfonamides are a group of synthetic antimicrobial agents that are structural
analogues of para-aminobenzoic acid (PABA). They act as competitive inhibitors of
dihydropteroate synthase. This enzyme converts PABA as a substrate to dihydrofolic acid
(folic acid) and blocks the biosynthesis of tetrahydrofolate in bacterial cells (FernándezVilla et al., 2019). Another enzyme, dihydrofolate reductase, sequentially converts
dihydrofolate to tetrahydrofolate (folinic acid). Diaminopyrimidines such as
trimethoprim inhibit dihydrofolate reductase further into the folic acid synthesis pathway
(DeJarnette et al., 2020).

Bacterial resistance to antibiotics
The resistance of microorganisms to a harmful agent is a natural process required for the
survival of the species. However, the increased misuse and overuse of antibacterial agents
across the globe have significantly accelerated this process and contributed to the
emergence of highly resistant strains, severely limiting effective treatment options
(Chokshi et al., 2019; Hernando-Amado et al., 2020). The primary forms of resistance
are intrinsic, acquired, or phenotypic.
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Intrinsic antibiotic resistance is a trait within the genome of bacterial species, independent
of previous antibiotic exposure and not related to horizontal gene transfer (Cox and
Wright, 2013; Reygaert, 2018). The mechanisms are typically chromosome-encoded and
include the overexpression of non-specific efflux pumps, limited outer membrane
permeability and drug inactivating enzymes (Chetri et al., 2019). Acquired resistance
mainly occurs through the transfer of antibiotic resistance genes between bacterial
populations by genetic exchange mechanisms. These mechanisms include transformation
with free DNA, transduction by bacteriophages, or bacterial conjugation involving
resistance plasmids (F plasmids), collectively referred to as the horizontal gene transfer
mechanisms (Arnold et al., 2022). Phenotypic resistance can be achieved without genetic
variation and occurs when susceptible bacteria become transiently resistant by either
developing persistence or growth in biofilms. Persister cells are a subpopulation that
enters a metabolically dormant state and effectively stops growing (Fernandes et al.,
2022). A microbe formation of biofilms by a homogeneous or heterogeneous bacterial
population is another mechanism to form protective resistance measures against
antibiotics and other harmful substances (Sharma et al., 2019).
1.3.1 Mechanisms of antibiotic resistance
Resistance mechanisms exploit every possible way of preventing a drug from hitting its
target. They typically occur by one or more of the following processes: (i) limiting drug
uptake, (ii) modification of drug target, (iii) inactivation of drug, or (iv) increase in active
drug efflux (Munita and Arias, 2016; Reygaert, 2018; Peterson and Kaur, 2018). These
resistance mechanisms are presented in Table 1.2 below and are separated by their
primary bacterial cell target (as described previously in Section 1.3.2).
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Major target

Antibacterial class

Cell wall synthesis

β-lactams

-

Alteration of PBP target
Drug inactivation by β-lactamases
Reduced diffusion through porin
channels

Glycopeptides

-

Bacitracin

-

Alteration of the target from D-AlaD-Ala to D-Ala-D-Lactate or D-AlaD-Serine
Active efflux

Aminoglycosides

-

Tetracyclines

Chloramphenicol
Lincosamides
Macrolides

-

Streptogramins

-

Protein synthesis

Mechanism of resistance

Oxazolidinones
Mupirocin

Nucleic acid
synthesis

Folate synthesis

Cell membrane

Rifamycins

-

Sulfonamides

-

Trimethoprim

-

Polymixin

-

Daptomycin

-

Quinolones

Drug modifying enzymes – AMEs
Methylation at ribosome binding site
Decreased permeation at target due to
active efflux
Active drug efflux
Ribosomal protection proteins
Altered rRNA binding site
Methylation of ribosome binding site
Acquired resistant tRNA synthetase
Altered native tRNA synthetase target
Drug modifying enzymes - CAT
Methylation at ribosome binding site
Target modification through
methylation at the ribosome binding
site
Active drug efflux
Target modification through
methylation at the ribosome binding
site
Active drug efflux
Alteration of target - QRDR
Active efflux
Protection of target from drugs
Altered target
Acquired resistant dihydropteroate
synthetase (drug bypass)
Acquired resistant dihydrofolate
reductase
Altered cell membrane charge with
reduced drug binding
Altered cell membrane with reduced
drug binding

Table 1.2 Resistance mechanisms to currently used antibacterial agents. Key:
Aminoglycosides modifying enzymes (AMEs), penicillin-binding protein (PBPs),
Chloramphenicol acetyltransferases (CAT), Quinolone-resistance determining region
(QRDR), Lipopolysaccharide (LPS)
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1.3.1.1 Limiting drug uptake
The distinction between Gram-positive and Gram-negative bacteria lies in the
composition of their cell envelope, as illustrated in Figure 1.4. Gram-negative bacteria
are naturally less permeable to specific antibacterial agents due to their outer membrane.
This layer is effectively a second highly hydrophobic lipid bilayer composed with the
addition of an amphiphilic lipopolysaccharide (LPS), lipoprotein and β-barrel
transmembrane protein (Okuda et al., 2016). LPS consists of three structural components:
hydrophobic lipid A (endotoxin), hydrophilic core oligosaccharide, and Opolysaccharide. The core oligosaccharide of LPS is negatively charged, resulting in a
strong affinity for divalent cations such as calcium and magnesium. Porins are β-barrel
structures that form channels to orchestrate the movement of small hydrophilic molecules
across the outer membrane. The threshold size of transportable molecules depends on the
porin and bacterial strain but is generally restricted to 600 Daltons (Choi and Lee, 2019).
This size-exclusion makes the outer membrane a very effective and selective permeability
barrier impeding the accessibility of antibacterial agents to their intracellular targets. This
is notably highlighted when compared to the size exclusion of a Gram-positive cell wall,
>10,000 Daltons. Hydrophilic glycopeptide antibiotics (such as vancomycin) are
ineffective against Gram-negative bacteria, resulting from the permeability barrier
imposed by the outer membrane (Antonoplis et al., 2019). Alterations of the outer
membrane permeability influence the diffusion of hydrophobic antibiotics, resulting in
poor uptake. For instance, in P. aeruginosa, mutations in the LPS transport pathway
decrease membrane permeability, resulting in increased tobramycin resistance (Van den
Bossche et al., 2021).
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Figure 1.4 General comparison of Gram-positive (left) and Gram-negative (right)
bacterial cell wall structure.

1.3.1.2 Modification of drug target
The alteration of the drug target is a common mechanism by which microbes develop
resistance to antibacterial agents (Reygaert, 2018). Gram-positive bacteria primarily
develop resistance to β-lactam drugs via alterations in the structure and the amount of
PBPs. The mecA gene mediates methicillin resistance in S. aureus, which is harboured on
the mobile genetic element staphylococcal chromosomal cassette (SCC) and encodes the
penicillin-binding protein 2a (PBP2a) (Rolo et al., 2017). The alternative transpeptidase
has reduced binding affinity to virtually all β-lactams, enabling cell wall synthesis to
continue even in the presence of typically inhibitory concentrations of the antibiotic
(Belluzo et al., 2019). Resistance to glycopeptide antibiotics is acquired by
reprogramming peptidoglycan precursor biosynthesis, replacing the terminal D-Ala with
D-lactate (D-Ala-D-Lac) or D-serine (D-Ala-D-Ser), thus reducing the antibiotic affinity
for its molecular target (Ahmed and Baptiste, 2018). The most clinically relevant operons
related to resistance in Enterococci and Staphylococci are the vanA gene, conferring
resistance to vancomycin and teicoplanin (glycopeptide) antibiotics, and enterococci
containing vanB gene that demonstrate high resistance to vancomycin and susceptibility
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to teicoplanin (Yushchuk et al., 2020). Resistance to fluoroquinolones occurs through
spontaneous mutations in the quinolone resistance determining regions (QRDR) of gyrA
and parC genes within DNA gyrase and topoisomerase IV, respectively (Rice, 2012), and
more recently through plasmid-mediated quinolone resistance (PMQR) (Tao et al., 2020).
Mutations in QRDR and PMQR genes result in amino acid substitutions that structurally
change the target protein, reducing the drug-binding affinity of the enzyme (Shaheen et
al., 2021).
1.3.1.3 Inactivation of drug
One of the most common mechanisms bacteria employ to evade antibiotics involves the
production of enzymes that irreversibly destroy or neutralize them. Such enzymes are
particularly prevalent among Gram-negative pathogens. They comprise those that destroy
the active antibiotic site (such as β-lactamases) (Tooke et al., 2019) or that modify vital
structural elements of the drug that hinder its interaction with the target site (such as
aminoglycoside modifying enzymes) (Ramirez and Tolmasky, 2010). β-lactamases
remain the most critical resistance mechanism among Gram-negative pathogens. They
spread through horizontal gene transfer and concentrate within the periplasm, hydrolysing
the β-lactam ring formation before reaching its PBP target (De Oliveira et al., 2020).
There are two major classification systems for β-lactamase enzymes, the Ambler
molecular classification (Ambler, 1980) and the Bush-Jacoby-Medeiros functional
classification (Bush et al., 1995). There are four classes (A to D) of β-lactamases in the
Ambler system that are grouped according to primary amino acid sequence homology.
Class A, C, and D are serine hydrolases, whereas class B are zinc metalloenzymes. In the
functional classification of Bush-Jacoby-Medeiros, β-lactamases are classified into
groups 1 to 3 depending on the degradation of β-lactam substrates and the active-site
serine β-lactamases (classes A, C and D) and the zinc-dependent β-lactamases (class B)
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(Tooke et al., 2019). Resistance to the clinically essential aminoglycoside antibiotics
results from the procurement of mobile genetic elements encoding for aminoglycoside
modifying enzymes (nucleotidyltransferase, phosphotransferases, or acetyltransferases)
that deactivate the drug preventing its interaction with the ribosomal subunit (Werner et
al., 2013).
1.3.1.4 Increase in active drug efflux
Many antibiotics are transported out of the cell by bacterial efflux pumps, frequently seen
in Gram-positive and -negative clinical isolates (Reygaert, 2018). Various efflux pumps
are categorised by their structure and energy supply. The five primary families are (i) the
adenosine triphosphate (ATP)-binding cassette (ABC) superfamily (Orelle et al., 2019),
(ii) the major facilitator superfamily (MFS) (Lee et al., 2016), (iii) the small multidrugresistance family (SMR) (Kermani et al., 2020), (iv) the multidrug and toxic compound
extrusion family (MATE) (Kusakizako et al., 2020), and (v) the resistance-nodulationdivision family (RND) (Colclough et al., 2020). The ABC family requires ATP as an
energy source to remove antibiotics, whereas the other families utilize the proton motive
force as the energy source. The MFS superfamily, primarily present in Gram-positive
bacteria and the RND family, are characteristic of Gram-negative bacteria and is mainly
associated with antibiotic resistance (De Oliveira et al., 2020).
1.3.1.5 Biofilms
In addition to the aforementioned resistance mechanisms, it is recognised that growth
within biofilms can further impede antibacterial activity (Høiby et al., 2011; Høiby, 2017;
Gebreyohannes et al., 2019). The nature of biofilm structure and the physiological
attributes of organisms within the biofilm can confer an inherent resistance to
antimicrobial agents. In addition, the biofilm organisms have higher horizontal gene
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transmission than their planktonic counterparts (Ciofu and Tolker-Nielsen, 2019; De
Oliveira et al., 2020).
Biofilms are structured multi-cellular sessile communities, organized as micro-colonies,
encased within a self-produced extracellular matrix (ECM) that forms the scaffold for its
three-dimensional architecture (Christophersen et al., 2020). This porous and complex
structure is composed of water and extracellular polymeric substances which possess
bacterial secreted biopolymers such as polysaccharides, extracellular DNA (eDNA),
proteins, lipids, and metabolites (Seviour et al., 2019). Over several decades, biofilms
have been extensively studied as they are a critical factor in the persistence of varied
infections, reported to cause 65–80% of human infections (Rasamiravaka et al., 2015).
They are particularly prevalent with tissue-related infections, such as chronic wounds,
endocarditis, urinary tract infections and lung infections in cystic fibrosis patients (Høiby
et al., 2011).
Figure 1.5 presents an example of a biofilm formed by P. aeruginosa strain PAO1 on
respiratory epithelial cells and its structured ECM. Due to the protective and altered
nature of the matrix, pathogenic biofilms from infected patients demonstrate up to 1,000fold reduced susceptibility compared to their planktonic form (Hughes and Webber, 2017;
Ciofu and Tolker-Nielsen, 2019). The formation of these aggregated communities with
their resistance to antibiotics and host immune attacks are at the root of many persistent
and chronic bacterial infections. For instance, for patients with CF infected with P.
aeruginosa, antibiotic treatment often relieves the symptoms but does not necessarily cure
the infection (Stefani et al., 2017). The acquisition of chronic P. aeruginosa infection is
associated with worsened disease progression and increased mortality.
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A

Figure 1.5 An SEM photomicrograph of PAO1 biofilm structure (A) within and on the
underlying cilia of a respiratory epithelium showing exopolysaccharide matrix and (B)
water channels (white arrow). Pictures are taken from (Woodworth et al., 2008)

The formation of a biofilm is a well-regulated, multi-step, endless cycle (as displayed in
Figure 1.6), including (i) initial reversible attachment of bacterial cells with biotic or
abiotic surfaces, followed by (ii) irreversible attachment within quick succession leading
to (iii) the development of the immature biofilm architecture as the bacteria undergoes
numerous physiological and phenotypic changes. The aggregation and accumulation of
adherent bacteria lead to (iv) the formation of multiple cell layers to form a mature biofilm
with water channels (Figure 1.5.B) responsible for distributing nutrients and signalling
molecules within the biofilm. Finally, due to extrinsic or intrinsic factors, the bacteria (v)
convert back to a planktonic state to allow dispersal of the cells and colonization in a new
cycle of biofilm formation (De la Fuente-Núñez et al., 2013; Rabin et al., 2015; Sharma
et al., 2019).
Upon sensing a stress signal, planktonic cells initiate interaction with a surface and
produce extracellular polymers that facilitate attachment and matrix formation, resulting
in an alteration in the phenotype of the organisms for growth rate and gene transcription.
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Cell attachment is mediated by fimbriae, pili, flagella and extracellular proteins, which
irreversibly trigger an alteration in gene expression, favouring the maturation from a
motile to a sessile state (Veerachamy et al., 2014). Quorum sensing (QS) is a cell densitybased communication mechanism within bacteria that allows for a coordinated response
to environmental cues across the entire population (Yan and Wu, 2019). These chemical
signals encourage further aggregation of cells resulting in multiple layers of bacteria
starting to grow on top of each other, producing microcolonies maturing the formation of
a matrix. The microcolonies are encased in a self-secreted matrix consisting of proteins,
nucleic acids, polysaccharides, and water (Tuon et al., 2022). This process is carried on
as cells in the biofilm reform to a planktonic state and break away from the biofilm to
initiate a new cycle, enabling spread and colonization.

Figure 1.6 This diagram depicts the processes involved in forming a biofilm, including
cell attachment, colonization and growth, development and active dispersal.
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Antibacterial agents under clinical development
Although many antibiotics are available to clinicians, many have similar if not the same
cellular target or process, leading to cross-resistance (Dewachter et al., 2019). Despite
this, the number of new antibiotics developed and released onto the market has
diminished steadily over the past few decades (Silver, 2011). WHO published a report in
2021 on antibacterial agents in the clinical and preclinical development pipeline for 2020
to assess which ones might potentially reach patients over the coming decade. The review
highlighted that there are currently 43 traditional antibiotics and combinations with a new
therapeutic entity in the clinical antibacterial pipeline. The 43 traditional antibiotics
comprised 12 agents under development to act against M. tuberculosis, 5 agents
against Clostridioides difficile, and 26 against WHO priority pathogens (Table 1.3). Of
these 26, 13 are active against at least one of the Gram-negative pathogens on the WHO
critical priority list, but most of these are still in phase 1 trials (WHO, 2021). While these
traditional antibiotics represent a viable short-term solution, a new approach is required
for more prosperous longevity. This was captured in the WHO report, as 27 nontraditional antibacterial agents were added for the first time. They are described as agents
that are not small-molecule drugs and do not act by directly targeting bacterial
components necessary for bacterial growth, and include microbiome-modulating drugs,
antibodies, immunomodulation agents, and phage-derived enzymes. Another promising
strategy involves the development of inorganic complexes for the antimicrobial treatment
of bacteria by a mechanism that can inhibit growth or suppress virulence in a multi-modal
fashion (Viganor et al., 2016a; Frei et al., 2020).
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Priority category

Critical

High

Medium

Pathogen

Antibiotic resistance

Acinetobacter baumannii

Carbapenem-resistant

Pseudomonas aeruginosa

Carbapenem-resistant

Enterobacterales

Carbapenem-resistant

Klebsiella pneumoniae,
Escherichia coli,
Enterobacter spp.,
Serratia spp.,
Proteus spp.,
Providencia spp.,
Morganella spp.
Enterococcus faecium
Staphylococcus aureus

Third-generation cephalosporin-resistant

Streptococcus pneumoniae

Vancomycin-resistant
Methicillin-resistant
Vancomycin intermediate and resistant
Clarithromycin-resistant
Fluoroquinolone-resistant
Fluoroquinolone-resistant
Third-generation cephalosporin-resistant
Fluoroquinolone-resistant
Penicillin-non-susceptible

Haemophilus influenzae

Ampicillin-resistant

Shigella spp.

Fluoroquinolone-resistant

Helicobacter pylori
Campylobacter
Salmonella spp.,
Neisseria gonorrhoeae

Table 1.3 World Health Organisation (WHO) global priority pathogens list – pathogen
and their resistance pattern. Pathogens are colour coded in relation to their gram stain;
pink denotes Gram-negative and purple for Gram-positive pathogenic microorganisms.

1.4.1 Novel antimicrobial approaches using inorganic chemistry
Metal-based remedies have played a crucial role in medicine throughout history. Ancient
Egyptians discovered the therapeutic potential of gold salts (Nobili et al., 2009), Chinese
medicine has long established the antiseptic competence of arsenic (Dilda and Hogg,
2007), and the use of silver in wound management can be traced back to the 17th century,
during which silver nitrate was administered to treat ulcers (Klasen, 2000). Paul Ehrlich
and his co-workers developed the first successful metalloid complex in the 1900s, an
arsenic-based therapeutic agent named salvarsan (Figure 1.1). This effectively cleared a
syphilis infection for which no prior treatment was available (Ehrlich 1912; Ehrlich &
Bertheim 1912). Nevertheless, research into metal-based coordination complexes was not
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stimulated until the fortuitous discovery of a platinum complex known as cisplatin by
Barnett Rosenberg. In 1960 Rosenberg observed that certain electrolysis products of
platinum mesh electrodes could inhibit cell division in E. coli (Rosenberg et al., 1965).
The team subsequently discovered cis-[Pt(NH3)2Cl2] demonstrated superior antitumor
activity both in vitro (Rosenberg et al., 1967) and in S180 murine sarcomas with a single
dose (8 mg/kg), resulting in successful regression of the tumours after 8 days (Rosenberg
et al., 1969). Cisplatin entered clinical trials in 1971 and became the first FDA-approved
platinum compound for cancer treatment in 1978 (Mukherjee and Sadler, 2009). This
landmark study brought metal-bearing compounds to the cornerstone of medicinal
chemistry.
Since then, cisplatin has been extensively studied as a chemotherapeutic drug and is
broadly administered to various cancers, including ovarian, lung, head and neck,
testicular and bladder (Dasari and Tchounwou, 2014; Aldossary, 2019). It has been
decidedly competent against testicular germ cell tumours leading to complete remission
in approximately 70-80% of treated patients (Makovník et al., 2021), and combination
treatment with radiotherapy is more successful than radiotherapy alone in non-small cell
lung carcinomas (Nieder et al., 2013). Cisplatin is structurally a coordination compound
with square planar geometry and exerts its antitumor activity via intra-cellular hydrolysis
and subsequent covalent binding to DNA-forming adducts, triggering apoptosis
(Tchounwou et al., 2021). Despite its triumph, cisplatin has several disadvantages and
has been associated with mild to severe nephrotoxicity, neurotoxicity, ototoxicity, nausea
and vomiting (Dasari et al., 2022). These toxic effects and solubility issues limit the dose
applied to patients. Chemoresistance is a multifactorial phenomenon and accredits the
most eminent disincentive in using the platinum drug. The mechanisms involved in its
resistance are vast and numerous. Still, they are thought to be the repercussion of
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intracellular changes that prevent cisplatin from interacting with DNA or interfere with
DNA damage signals from activating the apoptotic machinery (Cocetta et al., 2019;
Kryczka et al., 2021). These issues with cisplatin prompted further research into
alternative Pt complexes. There are now three Pt(II) compounds approved for clinical use
worldwide, Cisplatin (1), Carboplatin (2), Oxaliplatin (3) and three others, Nedaplatin
(4), Heptaplatin (5) and Lobaplatin (6) are used in Japan, South Korea and China
respectively (as seen in Figure 1.7) (Johnstone et al., 2015; Reece and Marimon, 2019).

Platinum drugs approved in Japan (4),
South Korea (5) and China(6)

Platinum drugs approved globally

Figure 1.7 Platinum drugs in clinical use (1–6) with the years they received regulatory
approval (Reece and Marimon, 2019).

Several more metal complexes have been introduced into the clinic in the last two
decades, including gold for treating rheumatoid arthritis (Messori and Marcon, 2004),
lithium for bipolar disorder (Gitlin, 2016), aluminium and zinc were used as antiulcer
agents (Hunt, 1991) and arsenic, bismuth and silver as antimicrobial agents (Mjos and
Orvig, 2014). More precisely, bismuth is co-administered with other antibiotics to treat
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Helicobacter pylori infections, and silver sulphadiazine is used as a topical treatment for
some burn wounds (Mégraud, 2012). A palladium-based photodynamic therapy (PDT)
agent was also approved in 2019 for the treatment of prostate cancer by the European
Medicines Agency (EMA) (Gunaydin et al., 2021).
Metal complexes can adopt a range of coordination geometries and redox states, allowing
for more significant chemical variations when compared with purely organic antibiotics,
with a different and potentially multi-modal mechanism of action that may target
antimicrobial resistance (Boros et al., 2020; Claudel et al., 2020; Nasiri Sovari and Zobi,
2020). For instance, a recent study by the Community for Open Antimicrobial Drug
Discovery (CO-ADD), a global free open-access screening initiative, discussed metalbearing complexes enhanced activity profile (Frei et al., 2020). The group evaluated 906
individual metal compounds within their database (as presented in Figure 1.8), from dblock elements, against critical ESKAPE bacteria and fungi and found an impressive
success rate of the metal compounds (9.9%) in comparison to solely organic molecules
(0.87%). From this panel of metal complexes, 88 demonstrated activity (MIC ≤ 16 µg/mL
or 10 µM) against one of their tested strains (58 against fungi and 30 against bacteria)
while also being tolerated by mammalian cells (CC50 > 32 µg/mL or > 20 µM against
human embryonic kidney cell line) and not demonstrating haemolytic activity (HC10 > 32
µg/mL or > 20 µM). Only 14 of these metal complexes showed activity (MIC ≤ 32
µg/mL) against Gram-negative bacteria, 8 of which also maintained toxicity towards
Gram-positive bacteria. The paper highlighted gallium, palladium, silver, cadmium,
iridium, and platinum as having the highest overall success rate and mentioned two
manganese complexes for their specific activity against E.coli and MRSA. Overall, the
group emphasized the potential antibiotic capabilities of metal compounds due to the
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extent of possible modes of action with broader coverage of three-dimensional chemical
space than their organic counterparts.

Figure 1.8 A diagram from CO-ADD demonstrating (A) the range of metal complexes
submitted to the study. (B) The metal frequency across the 906 metal-containing
compounds received. (C) The metal frequency among the 246 metal complexes that had
activity against one tested ESKAPE pathogens or fungi. (D) The metal frequency among
the 88 compounds that are active with low toxicity towards mammalian cells. (E) The
percentage of submitted metal-containing compounds with antimicrobial activity
compared to the overall hit rate for organic compounds within the CO-ADD collection
(Frei et al., 2020).
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1.4.2 1,10-phenanthroline and its metal complexes
The coordination of a metal ion to a biologically active ligand can serve to facilitate the
uptake of the non-lipophilic metal across the lipophilic cell envelope and/or to act
synergistically with the metal, such that the combined toxic effects of the metal and the
active ligand will exert an enhanced and targeted activity in the problematic cell (Lemire
et al., 2013; Frei et al., 2020). 1,10-phenanthroline (phen) is a heterocyclic and chelating
bidentate ligand for metal ions which has played an important role in advancing
coordination chemistry. The ideally placed nitrogen atoms, as seen in Figure 1.9.A, have
rigid planar structure, hydrophobic, π-electron-deficient heteroaromatic, and acidic
properties allowing the ligand to assist in the stabilisation of a variety of metal complexes
in various oxidation states (Sammes and Yahioglu, 1994; Bencini and Lippolis, 2010).
Phen has long shown antibacterial effects in an in vitro setting, demonstrating excellent
bacteriostatic activity on Gram-positive and Gram-negative species of pathogenic
bacteria (Turian, 1951; Kilah and Meggers, 2012). This antimicrobial action has been
attributed to the chelating capabilities of phen and its sequestering nature of metal ions
(McCann et al., 2012). Thus, it selectively disturbs the essential metal cellular metabolism
interference with metal acquisition and bioavailability for crucial reactions impeding the
microbial nutrition, growth, virulence, and pathogenesis of a variety of microorganisms,
including Leishmania spp., Aspergillus spp., Candida albicans, Fonsecaea pedrosoi and
Streptococcus agalactiae (Santos et al., 2012; Dos Santos et al., 2009). Accordingly,
metal chelators such as phen have been investigated for their therapeutic potential against
microbial infections as metals such as iron, copper, and zinc play an important role in
cellular homeostasis. Moreover, it was shown that the sequestered metals produce a
metal-phen complex, and the emerging complex is driving the toxic effects demonstrated
in previous studies (Husseini and Stretton, 1980). Investigations into the in vitro
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antibacterial activity of phen derivatives (displayed in Figure 1.9), such as 3,4,7,8tetramethyl-1,10-phenanthroline, 5-nitro-1,10-phenanthroline, 1,10-phenanthroline-5,6dione, 2,9-dimethyl-1,10-phenanthroline, and various others have also been undertaken
(Zoroddu et al., 1996). A significant increase in biocidal activity was achieved when the
various ligands were coordinated with copper(II) ions, with the 2,9-dimethyl derivative
being the most active against S. aureus and E. coli.

(B)

(A)

1,10-phenanthroline
(phen)

(C)

3,4,7,8-tetramethyl-1,10
-phenanthroline

(D)

5-nitro-1,10-phenanthroline

(E)

1,10-phenanthroline-5,6-dione
(phendione)

2,9-dimethyl-1,10-phenanthroline
(neocuproine)

Figure 1.9 Structure of 1,10-phenanthroline (phen) and examples of its derivatives

To date, metal complexes containing phen, and its derivatives, have been reported in the
literature for their anticancer (Kellett et al., 2012; Thornton et al., 2016; Rochford et al.,
2018, 2020), antifungal (Santos et al., 2012; Gandra et al., 2017, 2020; Granato et al.,
2017, 2021), antiparasitic (Vargas Rigo et al., 2019; Lima et al., 2021), antibacterial
(Viganor et al., 2016a; McCarron et al., 2018; Ahmed et al., 2019; Ventura et al., 2020;
Vianez Peregrino et al., 2021) and antiviral (Shulman and White, 1973; Mazumder et al.,
1995; Papadia et al., 2005; Chang et al., 2010) competence. The work of polypyridyl
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metal complexes was pioneered by Francis Dwyer and co-workers when they published
a landmark study outlining the biological activity of dicationic ruthenium (Ru), iron (Fe),
nickel (Ni), cobalt (Co), copper (Cu), zinc (Zn), calcium (Ca) and manganese (Mn)
chelates containing phen and its derivatives (Dwyer et al., 1969). Their work established
the in vitro toxicity of the metal-phen chelates against M. tuberculosis, S. aureus, S.
pneumoniae, Clostridium perfringens, E. coli, and Proteus vulgaris (presented in
descending order of activity), while the metal-free phen demonstrated dampened effects.
Furthermore, the toxicity exerted was independent of the metal present, except for M.
tuberculosis. They also identified that the bacteria and fungi did not develop resistance
of any significance to the selected chelates. In vivo bacterial infection treatment studies
using mice and guinea pig models showed that metal-phen chelates were clinically useful
as topical antimicrobials. However, selected compounds were chemotherapeutically
ineffective when administered intravenously due to rapid clearance from the bloodstream.
Although the results were promising, the interest in polypyridyl metal complexes as
potential antibacterial chemotherapeutics was void in the pharmaceutical sector, possibly
due to the vast array of antibiotics in the pipeline or the immensely lower incidence of
antibacterial resistance at the time. In modern times, transition metal-based compounds
have had a revival of interest as possible alternatives or adjuvants to the current
armamentarium of antibacterial agents that cannot contend with the rapid emergence of
resistant bacteria worldwide (Lemire et al., 2013). Metal complexes incorporating phen
as a ligand are at the forefront of that research. However, it is necessary to establish their
mechanism of action and ensure there is a substantial difference from the resistance-prone
antibiotics.
Our research group has been developing and investigating 1,10-phenanthroline (phen),
its derivatives and their metal complexes as potential therapeutic agents for several
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decades. 1,10-phenanthroline-5,6-dione (phendione; Figure 1.9) is a phenanthrene-based
ligand and a derivative of the classical chelating agent phen. The free ligand and its
coordinated copper(II) and silver(I) complexes, [Ag(phendione)2]ClO4 (Ag-phendione)
and [Cu(phendione)3](ClO4)4H2O (Cu-phendione) have been extensively studied by our
research group across a variety of microbial cells. The metal-free phendione and its metal
complexes were able to inhibit the growth of the Candida albicans (McCann et al., 2004),
Phialophora verrucosa (Granato et al., 2017, 2021), Pseudallescheria boydii (Santos et
al., 2012) and Trichomonas vaginalis (Vargas Rigo et al., 2019). Gandra et al. (2017)
tested a range of Mn(II), Cu(II) and Ag(I) dicarboxylate complexes containing phen and
phendione ligands against nine clinical isolates of three species that make up the highly
resistant Candida haemulonii species complex, an emerging opportunistic pathogen
resistant to most antifungal drugs currently used in clinical practice. From this study, the
Ag(I) chelates were the most effective drugs when assessed against planktonic cells
(overall geometric mean of the minimum inhibitory concentration (GM-MIC) ranged
from 0.26 to 2.16 µM), followed by the Mn(II) (overall GM-MIC ranged from 0.87 to
10.71 µM) and Cu(II) (overall GM-MIC ranged from 3.37 to >72 µM) chelates. Although
the same activity was not maintained when testing the strains during a biofilm lifecycle.
The in vivo potential of the chelates to clear C. haemulonii infections utilising Galleria
mellonella larvae was also investigated. Mn(II)- and Ag(I)-phen chelates could conserve
antifungal activity at concentrations that were reasonably non-toxic toward G. mellonella.
Most notable was the {[Mn(3,6,9-tdda)(phen)2]3H2O.EtOH}n complex as it induced the
lowest mortality rate while reducing the fungal burden on infected larvae and also could
affect the virulence of C. haemulonii (Gandra et al., 2020).
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McCarron et al. (2018) reported on a range of manganese(II)- and copper(II)-phen
complexes that inhibited the viability of M. tuberculosis laboratory reference strain
H37Rv and clinically derived CDC1551 strain. The Mn(II) complexes were highly
tolerated by A549 mammalian cells culminating in high selectivity index values. Ahmed
et al. (2019) aimed to enhance this toxicity by synthesizing a new Schiff base ligand,
combining the anti-tuberculosis drug isoniazid (INH) with phendione creating a
hydrazide

ligand

((Z)-N'-(6-oxo-1,10-

phenanthroline-5(6H)-

ylidene)isonicotinohydrazide; Figure 1.10), and further complexed the ligand to Ag(I)
and Mn(II) metal ions. The antimycobacterial activity of this ligand was comparable to
INH alone, and its metal complexes were four times more potent than INH when assessed
against a drug-susceptible and three drug-resistant M. tuberculosis strains. Ahmed et al.
(2022) also synthesized a series of phenanthroline-oxazine ligands (Figure 1.10) by
reacting L-tyrosine amino acid esters and phendione and subsequently formed metal
complexes

[Ag(1)2]ClO4,

[Mn(1)3](ClO4)2

and

[Cu(1)3](ClO4)2

(where

1

=

phenanthroline-oxazine ligand). All metal complexes had enhanced toxicity in
comparison to the starting ligand. However, due to their lipophilicity, both complexes and
ligands were only active against S. aureus, not E. coli.

Figure 1.10 Structure of hydrazine ligand (left) and phenanthroline-oxazine ligand (right)
(Ahmed et al., 2019, 2022)
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1.4.3 Mechanisms of metal-phen complexes
Research into the possible mechanisms by which promising phen-based complexes exert
their toxic effects has been carried out by our research group within in vitro models,
including mammalian, fungal, and bacterial cells and in a range of in vivo biological
models. Figure 1.11 gives a visual synopsis of the proposed modes of antifungal action
by phen and its derivatives. (1) depicts the dysfunction and disruption of the cell
membrane along with the withdrawal of the cytoplasmic membrane, (2) shows druginduced circumvention on the action of cell division (budding), (3) displays damage to
the functional mechanisms of the mitochondria, (4) exhibits chelation and/or sequestering
of trace metal ions which inhibits glycosylphosphatidylinositol (GPI) biosynthesis, (5)
illustrates the rupturing of internal organelles along with the enlargement of the nucleus
and (6) the degrading of nuclear DNA (McCann et al., 2012).

Figure 1.11 Summary of the current potential modes of antifungal action by phen and
derivatives as reported by McCann et al., 2012.
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Our group have also investigated the potential antibacterial capability of metal-phen
complexes and their mechanism of action (Viganor et al., 2016). These findings are
summarized in the following sub-sections, and this thesis aims to further broaden the
current understanding of the antibacterial capabilities and mechanisms of a range of
metal-phen complexes used for the research described.
1.4.3.1 The bacterial cell envelope and activity of metal-phen complexes
The cell wall and outer cell membrane are considered a significant obstacle in developing
novel antibacterial agents that are effective against Gram-negative bacteria as they must
be lipophilic and able to penetrate the outer membrane (Figure 1.4). Contradictory to this,
silver (Ag) has well-documented bactericidal properties. In its cationic form Ag(I), it is
oligodynamic. It displays a broad spectrum of activity dependent upon the slow release
of biologically active ions thought to bind to the bacterial cell surface and interfere with
growth by inhibiting transport across the cell wall and membrane (Lemire et al., 2013;
Domínguez et al., 2020). As charged entities, free metal ions require protein- or
ionophore-mediated transport to cross a lipid bilayer as these transporter proteins encase
the cations in a hydrophobic sleeve to pass. The complexation of metals to a hydrophobic
chelating ligand such as phen can enact the same process allowing their penetration
through the bacterial cell envelope, presenting the chelate to its target biomolecule to
inhibit cell growth or initiate cell death (Raman et al., 2007). Cationic metal-phen chelates
can be bacteriostatic (Dwyer et al., 1969) or bactericidal (Butler et al., 1969) towards
Gram-positive bacteria, including S. aureus and S. pyogenes and C. perfringens.
However, they do not exhibit the same potency against Gram-negative bacteria. The
lipophilicity of a complex is taken as a good measure of its ability to pass into the cell by
diffusion, and in some cases increased lipophilicity correlates with antimicrobial potency
(Wang et al., 2021b). Almost 70 years ago, Dwyer et al. identified this relationship when
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working with mononuclear ruthenium and phen complex, [Ru(phen)3]2+. Initially, this
complex was inactive against all tested bacterial strains however, when methyl
substituents were incorporated into the phenanthroline ligand, [Ru(3,4,7,8-Me4phen)3]2+,
the non-polar surface interaction was increased. This corresponded to increased activity
against all examined bacteria, especially Gram-positive and acid-fast bacteria (Dwyer et
al., 1952).
Over the past decade, there has been renewed interest in the antimicrobial activity of
polypyridylruthenium(II) complexes. Crowley et al. (2016) have used a series of 2-(1-R1H-1,2,3-triazol-4-yl)pyridine “click” ligands (R-pytri) as functionalised analogues of
2,2’-bipyridine (bpy) and phen chelators to synthesise a diverse range of ruthenium
complexes ([Ru(R-pytri)3](PF6)2), and examined their antimicrobial activities. Some of
the Ru(II) R-pytri complexes showed good activity against Gram-positive bacteria but
were significantly less active against Gram-negative species. The mode of action was
determined to disrupt the cell wall and the cytoplasmic membrane. As the ruthenium
complexes displayed low cytotoxicity against human dermal keratinocytes, they may also
be helpful as a topical treatment of recalcitrant infections for slow-growing bacteria
(Kumar et al., 2016).
Keene, Grant Collins and co-workers have extensively researched ruthenium(II)
complexes and their potential as antimicrobials. They developed kinetically inert mono-,
di-, tri-, and tetra-nuclear polypyridylruthenium(II) complexes, whereby the Ru(II) metal
centres are bridged by a flexible and lipophilic bis[4(4'-methyl-2,2'-bipyridyl)]-1),nalkane ligand (bbn) and are collectively termed ‘Rubbn’ complexes, where n = the number
of methyl groups in the bbn linker chain (n = 2, 5, 7, 10, 12, 14 or 16). The antibacterial
activity of this series of complexes is correlated with increasing lipophilicity through
increased length of the bbn chain, and only slight differences were observed with
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enantiomeric forms of the complexes (Li et al., 2012). The dinuclear ruthenium
complexes ‘Rubbn' has been the most extensively studied and has produced exciting
results. The Rubbn complexes enter bacteria energy-dependent as they significantly
depolarise and permeabilise the cellular membrane (Li et al., 2013). There was
preferential uptake of Rubbn in microbes compared to cancerous cells, which was
suggested to result from the greater presence of negatively charged components in the
bacterial envelope (Weber et al., 2016). Rubb16 was found to be the most active with
selective toxicity towards bacteria. This complex condensed ribosomes when they existed
as polysomes by preferentially binding to RNA over DNA in vivo, offering the
interruption of protein synthesis in actively growing bacterial cells as a potential mode of
action (Li et al., 2014).
The corresponding tri- and tetra-nuclear complexes ‘Rubbn-tri’ and ‘Rubbn-tetra' were the
more active, demonstrating MICs four times their dinuclear analogues (Gorle et al.,
2014). Although the level of cellular uptake in Gram-negative bacteria was similar to that
of Gram-positive bacteria, there was significantly less activity in the former species,
which was an interesting observation. The authors suggested that this was a result of the
inherent resistance of Gram-negative bacteria to inert polpyridylruthenium(II)
complexes, particularly P. aeruginosa, in which the outer membrane permeability is 10to 100-fold lower than, for example, that of E. coli (Li et al., 2015). However, while the
antibacterial activity increased as the ruthenium centres and the length of the alkyl chain
in the bbn ligand increased the toxicity toward eukaryotic cells reduced selectivity (Gorle
et al., 2016).

41

1.4.3.2 DNA as an antibacterial target for metal-phen complexes
The design of agents capable of controlled nucleic acid cleavage is of great importance,
and since the initial work of Sigman et al. (1979) there has been a considerable attraction
to artificial metallonucleases. The copper-bis-phenanthroline complex, [Cu(phen)2]2+,
induced oxidative cleavage of DNA in the presence of a reductant, which is unusual for
complexes containing phen as this compound as a singular agent usually intercalates with
DNA. DNA as a target offers a fresh avenue for potential antibacterial agents as it has
been relatively unexplored thus far (Bolhuis and Aldrich-Wright, 2014). A variety of
publications

have

reported

the

enhanced

antibacterial

activity

of

quinolone/fluoroquinolone antibiotics containing metal(II)-phen complexes (metal =
Cu(II), Ni(II), Co(II), Mn(II)) (Psomas and Kessissoglou, 2013). One example is the
combination of Levofloxacin (lvx) with Cu(II) forming the binary complex, [Cu(lvx)]2+,
that significantly increases DNA binding but is not stable at a physiological pH. However,
the addition of phen as an N-donor form a very stable ternary complex [Cu(lvx)(phen)]2+
(Sousa

et

al.,

2012).

Cu(II)/phenanthroline/fluoroquinolone

complexes

have

demonstrated intercalation with DNA, exhibiting nuclease activity, and are taken into the
cell differently from the free fluoroquinolone drug (Fernandes et al., 2014). Furthermore,
when tested against a mutant strain of E. coli lacking porins, it was identified that the
higher the hydrophobicity of the complexes, the higher the need for porins for their uptake
(Gameiro et al., 2007). Marmion et al. rationally developed a family of metalloantibiotics with the general formula [Cu(N,N)(CipA)Cl], where N,N represents a
phenanthrene ligand, and CipA is a derivative of fluoroquinolone antibiotic ciprofloxacin
(Ude et al., 2019). The complexes were active against sensitive and resistant S. aureus
bacteria. They appeared to intercalate DNA via minor groove interactions and mediate
DNA damage by generating ROS with superoxide and hydroxyl free radicals playing
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crucial roles in DNA strand scission. Molecular docking analysis prompted the synthesis
of derivatives [Cu(N,N)(CipHA)]NO3 where CipHA represents a hydroxamic acid of
ciprofloxacin. Proteomic analysis of S. aureus exposed to two lead complexes
[Cu(phen)(CipHA)]NO3

and

[Cu(DPPZ)(CipHA)]NO3

(where

DPPZ

=

dipyridophenazine) suggests that proteins involved in virulence, pathogenesis and the
synthesis of nucleotides and DNA repair mechanisms are most affected (Ude et al., 2021).
Metal-phen complexes without adding the quinolone ligand have also demonstrated
moderate antibacterial activity with DNA binding and/or nuclease activity as the
proposed antibacterial mechanism of action. The metals include Ag(I) (Smoleński et al.,
2013), Cu(I) (Chetana et al., 2016), Cu(II) (Raman and Raja, 2007), Zn(II) (Tabassum et
al., 2012), Pt(II) (Ng et al., 2013), Mn(II) (Shivakumar et al., 2013), and Fe(III)
(Dimitrakopoulou et al., 2007).
1.4.3.3 Induction of oxidative stress by metal-phen complexes
Bactericidal antibiotics have been proposed to contribute to bacterial death by inducing
oxidative stress executed by reactive oxygen species (ROS) (Kohanski et al., 2007). In
this proposed model the agitation of metabolism and respiration stimulated by an
antibacterial agent leads to increased superoxide production, thereby releasing ferrous
iron from damaged iron-sulphur (Fe-S) clusters (Kohanski et al., 2008). Elevated
intracellular concentrations of ferrous iron interact with endogenous hydrogen peroxide
and, through the Fenton reaction, generates lethal hydroxyl radicals, which can directly
damage cellular DNA, lipids and proteins (Dwyer et al., 2007). This action alone as a
mechanism of cell death has been challenged (Imlay, 2015). However, as part of a multimodal effect may be plausible. Although sub-lethal concentrations of antibiotics have
been reported to induce mutagenesis by stimulating the production of ROS, thus
promoting antibiotic resistance (Kohanski et al., 2010). To defend against the increase in
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ROS, bacteria enhance the production of antioxidant enzymes, such as superoxide
dismutase (SOD) and catalase (Imlay, 2008), and antioxidant molecules such as ascorbic
acid and glutathione (Cabiscol et al., 2000) that can detoxify ROS through regulatory
mechanisms (SoxRS, OxyRS, and SOS regulons) to counter the damage (Wang and Zhao,
2009).
Metal-free phen significantly enhances its activity against E. coli after adding hydrogen
peroxide (H2O2) (Asad and Leitao, 1991). This was proposed to result from the reaction
kinetics of Fe scavenging by phen, forming adducts with ferrous iron (Fe2+) and ferric
iron (Fe3+), catalyzing the Fenton reaction and generation of free radicals. It was later
supported by Furtado et al. (1997) by exposing E. coli to both phen and H2O2 preceded
by treatments with metal chelators, bipyridine for Fe2+ and desferal for Fe3+ separately in
the presence of free-radical scavengers, thiourea. They observed that protection was
achieved for radical and Fe2+ scavengers but not Fe3+. The authors also noted that a known
Cu+1 scavenger, neocuproine (2,9-dimethyl-phen; Figure 1.9), offered sufficient
protection supporting the hypothesis that metallonuclease [Cu(phen)2]1+ can play a role
in bacterial cytotoxicity. Metal-phen complexes such as [Cr(phen)3]3+ have been reported
to generate ROS in bacteria, which contributes to its antibacterial capabilities (Páez et al.,
2013).
1.4.3.4 The activity of metal-phen complexes on biofilms
Bacterial biofilm communities differ from planktonic bacteria in various ways, such as
growth rate, gene expression, and protein expression (Sharma et al., 2019). This is due to
biofilms creating an altered microenvironment with higher osmolarity, nutrient scarcity
and increased cell density of heterogeneous bacterial communities (Flemming and
Wingender, 2010; Flemming et al., 2016). Bacteria usually reside in biofilms, and
biofilm-residing bacteria can be resilient to the immune system, antibiotics, and other
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treatments (Fenker et al., 2018; Sharma et al., 2019; Vestby et al., 2020). Therefore,
agents that can navigate the difficult terrain of a biofilm to the bacteria embedded within
or dissociate the extracellular matrix to expose the bacteria are important.
Although there are few reports of metal-phen complexes with anti-biofilm activity, some
advances have been made in developing novel compounds. A range of Cu(II) complexes,
[Cu(IL)(AL)]2+ (where IL represents functionalized 1,10-phenanthrolines and AL
represents 1S,2S- 1,2-diaminoethane or 1R,2R-diaminocyclohexane) were tested on a
number bacterial strains (Beeton et al., 2014). Although the metal complexes generated
higher MICs (2-32 µg/mL) than the control antibiotic vancomycin (MIC = 0.25 µg/mL),
they showed significant activity against S. aureus biofilms and were better in the removal
of biofilms than vancomycin. For example, 100 µg/mL of vancomycin, which is 400 fold
the MIC, reduced biofilm biomass by just 44%, whereas 25 µg/mL of [Cu(5,6-dimethylphen)(SS-dach)]2+ (equivalent to 3-fold the MIC) reduced the biofilm by 68% in only 2
h. This decrease in biomass was similar in all Cu complexes and is metal-dependent as
replacing the centre with Pt(II), or Pd(II) removed both the antibacterial and anti-biofilm
action. Therefore suggests that the potential mechanism of action in both planktonic and
biofilm cells is related to the nuclease activity of Cu, as neither Pt nor Pd possesses this
capability, particularly given that the extracellular matrix contains a considerable quantity
of nucleic acids. A series of complexes incorporating phen and cyanoguanidine (cnge)
have been reported with the general formula M(II)/phen/cnge (where M = Cd, Cu or Zn)
(Falkievich et al., 2022). The cadmium complex, [Cd(phen)2(SO4)H2O]cnge•5H2O,
possessed enhanced activity across the assessed bacterial and fungal pathogen in
comparison to its metal derivatives. This prompted subsequent antibiofilm analysis
against P. aeruginosa laboratory strain ATCC 27853, in which 0.5 x MIC (93.5 µg/mL)
of the metal complex inhibited approximately 40% of the biofilm formation. Moreover,
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there was a reduction in the acute toxicity of the phen ligand when it was incorporated
into the Cd(II)/phen/cnge complex within a crustacean model, Artemia salina.
A derivative of phen, 1,10-phenanthroline-5,6-dione (phendione, Figure 1.9), has also
been investigated for its antibacterial and anti-biofilm capabilities. This compound
contains an o-quinoid moiety and forms strong complexes with transition metal ions at
the N-N terminal with predominance toward Zn(II) and to a lesser extent for Fe(II), Ca(II),
Cu(II), Co(II), and Mn(II) (McCann et al., 2012a). Tay et al. (2015) reported the MIC
and MBC values of phendione for Enterococcus faecalis as 2 μg/mL and 16 μg/mL,
respectively, relating their activity to the ability to sequester the Zn(II) from
metalloenzymes. In order to kill E. faecalis cells embedded in a biofilm structure, a MIC
four times that required to kill planktonic bacteria was required. However, the biofilm
was eradicated at this concentration. Although the authors could not explain the
mechanism of phendione eradicating E. faecalis biofilm, they speculate that it may
weaken the biofilm's extracellular polymeric substances by disrupting Zn(II) balance.
Viganor et al. (2016) also investigated the effect of phen, phendione and metal complexes
Cu-phendione and Ag-phendione (Figure 1.12) on planktonic and biofilm growing P.
aeruginosa. The compounds presented the following potency against susceptible and
resistant planktonic cells, Cu-phendione (7.76 µM) > Ag-phendione (14.05 µM) >
phendione (31.15 µM) > phen (579.28 µM). It was also identified that the compounds
could disrupt a mature biofilm in a dose-dependent manner, especially Ag-phendione
(IC50 = 9.39 µM) and Cu-phendione (IC50 = 10.16 µM). Further investigation
demonstrated that Cu-phendione was an effective inhibitor of the metalloenzyme Elastase
B (lasB), mitigating the toxic effect of lasB-containing bacterial secretions in the in vivo
model, increasing the survival time of G. mellonella larvae (Galdino et al., 2019),
therefore suggesting this as a potential therapeutic target. Metal-phendione complexes
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could interact with double-stranded DNA and promote oxidative damage suggesting
multiple mechanisms of action in P. aeruginosa (Galdino et al., 2022). The same activity
sequence of the test complexes (Cu-phendione > Ag-phendione > phendione) was
maintained when assessed in both planktonic- and biofilm-forming cells of MDR A.
baumannii (Ventura et al., 2020) and K. pneumoniae (Vianez Peregrino et al., 2021)
clinical isolates. The combination of either Cu-phendione or Ag-phendione with
meropenem had synergistic activities, according to their fractional inhibitory
concentration, against K. pneumoniae carbapenemase (KPC)-producing clinical isolates.
Moreover, the combination of the metal complex and meropenem restored the efficacy of
the antibiotic (in terms of MIC) in 87% of phenotypically resistant strains (Vianez
Peregrino et al., 2021). The metal-phendione complexes also had low toxicity in G.
mellonella larvae (Gandra et al., 2020; Granato et al., 2021) and mice (McCann et al.,
2012b), reinforcing that these compounds may represent a novel antimicrobial agent with
potential therapeutic applications across a variety of pathogens.

Figure 1.12 Structure of phendione containing metal complexes [Cu(phendione)3]2+ (left)
and [Ag(phendione)2]+ (right)
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These findings against three Gram-negative bacteria that are on both the WHO priority
pathogen list (Table 1.3) and a part of the ESKAPE pathogens (discussed in the next
section) are of great significance due to their ability to rapidly develop and acquire
resistance to multiple classes of antibiotics severely limiting the currently available drugs
still affective at clearing their infections.

Problematic multidrug-resistant bacteria
Bacterial infections are becoming more challenging to treat due to increasing numbers of
resistant infections to the current arsenal of antimicrobial therapies (Piddock, 2016). This
has given rise to the potential return of many diseases worldwide that were previously
controlled (Sabin et al., 2020). For example, previously controlled tuberculosis (TB) has
re-emerged to become the second leading cause of morbidity and mortality from an
infectious disease worldwide (WHO, 2019). TB is curable and preventable, but there is
an increasing prevalence of multidrug-resistant strains of TB (MDR-TB) with high-level
resistance to the two most potent anti-TB drugs, isoniazid and rifampicin. This resulted
in nearly half a million cases of drug-resistant TB occurring annually, of which 78% had
MDR-TB, with extensively drug-resistant TB (XDR-TB) making up 6.2% of this (WHO,
2019). Our research group has reviewed the growing concern of MDR-TB and the
potential application of metal complexes to address this growing worldwide threat
(Viganor et al., 2015). More recently, Mn(II) complexes containing 1,10-phenanthroline
and dicarboxylate ligands (McCarron et al., 2018) and Ag(I) and Mn(II) complexes with
hydrazide ligands (Ahmed et al., 2019) have been reported for their anti-TB activity in
addition to high mammalian cell tolerance, culminating in high selectivity index (SI)
values.
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In addition to the WHO global priority pathogens list (Table 1.3), reports using data from
hospital-based surveillance studies as well as from the Infectious Diseases Society of
America (IDSA) have established a group of nosocomial pathogens referred to as
‘ESKAPE bugs’ of current global concern (Bassetti et al., 2013). This acronym
encompasses the most worrisome microorganisms in current clinical practice; E. faecium,
S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and Enterobacter species, that
require rapid development of new drugs due to their ability to ‘escape’ the effects of many
commonly prescribed antibiotics (Rice, 2008; Boucher et al., 2009). Enterococci,
Staphylococci and Enterobacterales, especially E. coli and K. pneumoniae, are a part of
the normal microbiome preventing their complete removal from hospital settings, while
the other opportunistic pathogens are environmental contaminants. However, these
microbe's ability to acquire multidrug resistance (MDR) and extensive drug resistance
(XDR) through the promiscuous nature of horizontal gene transfer and, on a lesser scale,
through chromosomal mutations solidify them as a significant threat to public health. The
discovery of the mobile colistin resistance (mcr) gene, enabling bacteria to be highly
resistant to polymixins such as colistin, attracted recent global attention.
Carbapenem resistance is a pivotal event in generating XDR pathogens, creating havoc
in the clinic due to the exhaustion of therapeutic options. The majority of acquired
carbapenemases belong to either Ambler class A, class B (metallo-β-lactamases, MBLs),
or class D (oxacillinases, OXAs) (Karaiskos et al., 2019). Although not conferring
resistance to carbapenems, extended-spectrum β-lactamases (ESBLs) are also
problematic as ESBL- and carbapenemase-encoding plasmids are frequently vectors of
resistance determinants for other antimicrobial classes, such as aminoglycosides and
fluoroquinolones (Ruh et al., 2019; Fournier et al., 2022). Colistin was largely abandoned
as a treatment for bacterial infections in the early 1980s due to toxicity and low renal
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clearance concerns. Now with limitations of current therapeutics and the widespread
emergence of Carbapenem-Resistant Enterobacterales (CRE), clinicians have revisited
colistin as a ‘last resort’ against MDR pathogens and have significantly increased their
dependence on it (Lim et al., 2010; Ahmed et al., 2020a; Gogry et al., 2021). The recent
escalation in the use of colistin in clinical practice, accompanied by its unrestricted use
in agriculture, has contributed to the rapid dissemination of resistance across species and
the usefulness of colistin as the last resort antibacterial is now compromised by the
presence of an increasing number of the transferable plasmid‐mediated colistin resistance
gene, mcr, and its variants. For instance, the first mcr gene, mcr-1 was reported in China
in November 2015 (Liu et al., 2016) and has since been identified in several species of
bacteria in 72 countries across 6 continents (Wang et al., 2018a; Mmatlia et al., 2022).
To date, nine additional variants (mcr-2 to mcr-10) have been identified in different
bacteria isolated from animals, foods, farms, humans, and the environment (Xavier et al.,
2016; AbuOun et al., 2017; Borowiak et al., 2017; Carattoli et al., 2017; Yin et al., 2017;
Wang et al., 2018b; Yang et al., 2018; Carroll et al., 2019). More worrisome is the
presence of mcr in Enterobacterales carrying carbapenem resistance genes such as MBL,
ESBL, and New Delhi metallo-β-lactamase (NDM), progressing them from extensive
drug resistance (XDR) to pan-drug resistance (PDR) (Wang et al., 2017; Hussein et al.,
2021).
In addition to Enterobacterales recent years have also witnessed an increasing prevalence
of MDR and XDR P. aeruginosa strains, with rates of between 15% and 30% in some
parts of the world (Walkty et al., 2017; Sader et al., 2018). The European Centers for
Disease Prevention and Control (ECDC) reported that 30.1% of the P. aeruginosa isolates
in 2020 were resistant to at least one of the examined antimicrobial groups, and 9.8%
were resistant to three or more (ECDC, 2022). Although this has significantly decreased
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since 2015, the report emphasized that P. aeruginosa remains one of the major causes of
healthcare-associated infection (HCAI) in Europe. The bacterium is a biofilm-forming
opportunistic

pathogen

that

causes

life-threatening

chronic

infections

in

immunocompromised individuals with diseases like burn wounds, urinary tract
infections, and respiratory infections (Vestby et al., 2020). In fact, P. aeruginosa was one
of the most common co-infecting bacteria in COVID-19 patients (Lansbury et al., 2020;
Qu et al., 2021). P. aeruginosa is also a critical pulmonary pathogen and the predominant
cause of morbidity and mortality in people with cystic fibrosis.

Cystic fibrosis and Pseudomonas aeruginosa
Cystic fibrosis (CF) remains one of the most prevalent, life-limiting hereditary disorders
in the Caucasian population and affects more than 70,000 individuals worldwide (CFF,
2021). Ireland has one of the highest global incidences of CF, with almost 1,400
individuals registered as living with the disease (Farrell, 2008; CF Registry of Ireland,
2017). Although it manifests in multiple organs, including the pancreas, liver, intestines,
sweat glands and reproductive organs, a progressive pulmonary disease marked by a
severe dysregulated inflammatory response and recurrent bacterial infections is a
significant contributor to morbidity and mortality (Fonseca et al., 2020). Despite the
substantial advances in early diagnosis and treatment, the median life expectancy for
people with CF is 40-50 years in developed countries (Elborn et al., 2016). CF is an
autosomal recessive disorder caused by a mutation in the gene, expressed on chromosome
7 (7q31.2), encoding the cystic fibrosis transmembrane conductance regulator (CFTR)
anion channel (Rommens et al., 1989). More than 2000 gene variants have been identified
and classified into six groups depending on their consequences on the CFTR protein
(Elborn, 2016). Deletion of phenylalanine at position 508 (Phe508del or ΔF508) of the
CFTR protein (Group II) is the most common mutation associated with CF, 91.7% of
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individuals with CF are carriers of a single mutation in Ireland, while 55.5% are
homozygous (CF Registry of Ireland, 2019). Defects caused by Phe508del lead to
misfolding of CFTR and subsequent proteasome-mediated degradation (Fonseca et al.,
2020), preventing the protein from reaching the cell surface and functioning optimally.
As presented in Figure 1.13, CFTR encodes a cAMP-dependent channel that transports
chloride (Cl-) and bicarbonate (HCO3-) across the apical plasma membrane of epithelial
cells while also modulating the sodium (Na+) channel (ENaC) (Elborn et al., 2016). The
absence of HCO3- causes an imbalance in the function and viscosity of mucus so that it
becomes thick and compromises mucociliary clearance. The hyperabsorption of Na+ via
ENaC will lead to insufficient water secretion to the pulmonary epithelial surface,
contributing to mucus hyperviscosity and dehydration. Therefore, the lack of functional
CFTR protein results in an ion imbalance leading to viscous mucus secretions impairing
mucociliary clearance, creating an ideal environment for microbial colonisation. The
most commonly isolated pathogens from CF airway samples are S. aureus (including
MRSA), Haemophilus influenzae, P. aeruginosa, Burkholderia cepacia complex, nontuberculous mycobacteria and Aspergillus fumigatus (CF Registry of Ireland, 2019).
However, S. aureus and P. aeruginosa tend to dominate in this harsh landscape.
Subsequently, S. aureus is the most prevalent pathogen detected during exacerbations of
CF patients in childhood (CF Registry of Ireland, 2019), while P. aeruginosa dominantly
colonizes the airways from adolescence and becomes the most abundant by adulthood,
with approximately 80% of CF patients chronically colonised with the bacterium by the
age of 20 (Beswick et al., 2020). Chronic infection with P. aeruginosa is associated with
a rapid decline in pulmonary function, more frequent exacerbations, and higher mortality
rates (Malhotra et al., 2019), thus treatments aiming to eradicate or dampen the effects of
initial infections are highly sought after.
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Figure 1.13 Cystic fibrosis transmembrane conductance regulator (CFTR) in a normal
airway and CF airway. Imbalance at the pulmonary epithelium due to mutations in the
CFTR channel compromising the flow of chloride (Cl-) and bicarbonate (HCO3-) by
epithelial cells to the extracellular space while also modulating sodium (Na+) via
epithelial sodium channel (ENaC) leading to thick mucus which is optimal for bacterial
growth.

P. aeruginosa is a ubiquitous and opportunistic Gram-negative human pathogen that is
highly successful in colonising a diversity of sites (Gellatly and Hancock, 2013; JuradoMartín et al., 2021). The bacterium is metabolically versatile with an extensive repertoire
of virulence factors, antibiotic resistance determinants and the ability to form robust
biofilms, allowing it to adapt to conditions in the airway and evade antibiotics and host

53

immune attacks (Ciofu and Tolker-Nielsen, 2019; Jurado-Martín et al., 2021; Van den
Bossche et al., 2021). The attributes of P. aeruginosa that aid with colonisation and
inflammation within the lung include lipopolysaccharide (LPS) (Di Lorenzo et al., 2015),
the type III secretion system (T3SS) (Anantharajah et al., 2016), proteases (Galdino et
al., 2017), pyocyanin (Hall et al., 2016) and pyoverdine (Minandri et al., 2016). A P.
aeruginosa cell possesses a single polar flagellum and several type IV pili that facilitate
motility, bacterial chemotaxis, and attachment of the bacteria to a common assialyated
glycolipid (Asialo-GM1) on host cells. Shared by several Gram-negative bacteria species,
the type III secretion system (T3SS) is one of the most clinically relevant virulence
determinants in P. aeruginosa (Sarges et al., 2020), which acts through the translocation
of up to four exotoxins (ExoS, ExoT, ExoU, ExoY) to the host cell by the needle
appendage (Jurado-Martín et al., 2021). ExoU and ExoS are considered the significant
cytotoxins as they have the greatest impact on disease severity, while ExoT and ExoY
play a minor role in virulence. The irreversible attachment of the bacterial cell to the host
cell triggers an alteration in gene expression favouring the maturation from a motile to
sessile state, producing microcolonies and creating a biofilm. As previously discussed
(Section 1.3.1.5), a biofilm is a structured community of bacterial cells enclosed in an
extracellular matrix (ECM) that provides exceptional protection (Ciofu and TolkerNielsen, 2019; De Oliveira et al., 2020). P. aeruginosa produce three exopolysaccharides,
alginate, Psl, and Pel, which play an essential role in forming biofilm and stabilizing its
structure. While planktonic cells are readily cleared, once a biofilm has formed the
effectiveness of both polymorphonuclear neutrophils and macrophages are superfluous.
In addition, biofilms are associated with a high level of tolerance or resistance to
antimicrobials (Billings et al., 2013; Ciofu et al., 2015; Ciofu and Tolker-Nielsen, 2019).
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Quorum sensing (QS) is a cell density-based communication mechanism within bacteria
that allows for a coordinated response to environmental cues across the entire population.
As population density increases, so does the chemical signal molecules, autoinducers,
which in Gram-negative bacteria are N-acyl homoserine lactones (AHL) and alkyl
quinolone (AQ). P. aeruginosa has three main interlinked hierarchical networks
consisting of the Pseudomonas quinolone signal (PQS) and two LuxR/LuxI-type systems,
LasR/LasI and RhlR/RhlI, comprised of a transcriptional regulator (R) and synthase (I)
(Kostylev et al., 2019). The Las system is at the top of the hierarchy, positively controlling
the expression of the other networks. These systems are highly interconnected, and QS
has been reported to regulate motility, EPS production, virulence production such as
proteases, pyocyanin and rhamnolipids, and biofilm formation and is thus highly
influential (Lee and Zhang, 2014).

Research rationale
The emergence of antimicrobial drug resistance necessitates new approaches to challenge
bacterial pathogens, and novel therapeutic strategies are required to compensate for the
diminishing availability of effective antibiotics. Concurrently, transition metal complexes
have had a revival of interest as possible alternatives or adjuvants to the current arsenal
of antimicrobial agents, with complexes containing polypyridyl ligands playing a notable
role. The metal complexes described in this report represent a rationally designed series
of copper(II), manganese(II) and silver(I) complexes incorporating various dicarboxylate
anions as bridging ligands. These metal-dicarboxylate complexes were also derivatised
with 1,10-phenanthroline (phen), yielding an additional set of phen-bearing chelates to
enhance their toxicity.
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1.7.1 Research objectives
Each research objective 1-3 for this project described below resulted in the production of
an article for publication, all three of which were based on the experimental work
described in chapters 2, 3 and 4 of this thesis.
Objective 1 – Paper 1 (Chapter 2)
The first objective of this project was to assess the antibacterial activity of a range of
metal complexes (where metal = Cu(II), Mn(II), and Ag(I)) incorporating phen and a
range of dicarboxylate ligands against a panel of Gram-positive and Gram-negative WHO
priority pathogens that are also problematic within Irish clinical settings. Whole-genome
sequencing was carried out on S. aureus, and P. aeruginosa cells made resistant to suboptimal concentrations of the lead metal-tdda-phen complexes to identify resistance
mutations.
O’Shaughnessy M, Hurley J, Dillon SC, Herra C, McCarron P, McCann M, Devereux
M, Howe O. Antibacterial activity of metal-phenanthroline complexes against multidrugresistant Irish clinical isolates: A whole genome sequencing approach. Accepted to the
Journal of Biological Inorganic Chemistry, 2022.
Objective 2 – Paper 2 (Chapter 3)
The next objective was to further investigate selected metal complexes incorporating
3,6,9-trioxaundecanedioate and 1,10-phenanthroline ligands within a cystic fibrosis (CF)
disease model, utilising clinical isolates of P. aeruginosa derived from Irish CF patients,
both alone and in combination with gentamicin, a prescription antibiotic. The effects on
planktonic growth and the inhibition of biofilm formation and disarticulation were
assessed in terms of biofilm biomass and cell viability once treated. In addition, the
selectivity of these metal complexes to the pathogens over potential host, mammalian cell
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lines Cystic Fibrosis Bronchial Epithelial Cells (CFBE41o-) and BEAS-2B
(SV40/adenovirus 12 transformed normal bronchial epithelium) cells were also assessed
to establish the toxicity of the complexes towards them.
O’Shaughnessy M, McCarron P, Viganor L, McCann M, Devereux M, Howe O. The
antibacterial and anti-biofilm activity of metal complexes incorporating 3,6,9trioxaundecanedioate and 1,10-phenanthroline ligands in clinical isolates of
Pseudomonas aeruginosa from Irish Cystic Fibrosis patients. Antibiotics. 2020;
9(10):674.
Objective 3 – Paper 3 (Chapter 4)
The final objective was to test the therapeutic potential of the three selected metal
complexes alone and in combination with gentamicin in an in vivo model using Galleria
mellonella.
O’Shaughnessy M, Piatek M, McCarron P, McCann M, Devereux M, Kavanagh K,
Howe O. In vivo activity of metal complexes containing 1,10-phenanthroline and 3,6,9trioxaundecanedioate ligands against Pseudomonas aeruginosa infection in Galleria
mellonella larvae. Biomedicines. 2022; 10(2):222.
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Chapter 2.

The antibacterial activity of novel
metal complexes against
multidrug-resistant clinical isolates

Chapter 2 (objective 1) is based on the following paper: O’Shaughnessy M, Hurley J,
Dillon SC, Herra C, McCarron P, McCann M, Devereux M, Howe O. Antibacterial
activity of metal-phenanthroline complexes against multidrug-resistant Irish clinical
isolates: A whole genome sequencing approach. Accepted to the Journal of Biological
Inorganic Chemistry, 2022.
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Introduction
Copper(II), manganese(II), and silver(I) complexes incorporating phen and dicarboxylate
ligands were the focus of this study, specifically on WHO priority pathogens (WHO,
2017) that are also problematic within Irish clinical settings (HPSC, 2019). The panel
comprised Gram-positive bacteria methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant Enterococci (VRE), Gram-negative bacteria carbapenemresistant and ESBL-producing Enterobacterales and Pseudomonas aeruginosa, derived
from patients in Irish hospitals.
S. aureus is a significant bacterial human pathogen that causes a wide variety of clinical
manifestations, ranging from sub-acute skin infection to life-threatening septicaemia
(Tong et al., 2015) and is one of the most common causes of hospital-acquired infections
(Lee et al., 2018). MRSA has been endemic in Ireland since the 1980s, but as a result of
national surveillance and an effective infection control policy and practices, we have seen
the lowest proportion of MRSA specific bloodstream infections in 2020 (11.5%), despite
this Ireland still has one of the highest proportions of MRSA in northern and western
Europe (HPSC, 2022). Enterococci spp. are common inhabitants of the human microbiota
but have adapted to colonizing and persisting in a hospital environment causing invasive
infections (Krawczyk et al., 2021). Enterococcus faecium and Enterococcus faecalis are
the most frequently isolated species in nosocomial settings and display both intrinsic and
acquired resistance to several antibiotic classes, of which vancomycin-resistant
Enterococci (VRE) has become the most alarming (McDermott et al., 2018; Ayobami et
al., 2020). The number of bloodstream infections caused by VRE are continuously
increasing, and since 2008 Ireland, the Health Protection Surveillance Centre (HPSC), as
part of the EARS-Net, has reported the highest percentage of VRE-associated infections
in Europe, with rates in 2020 at 35.1% (HPSC, 2022). The emergence of VRE strains
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resistant to all established antimicrobial agents is now recognized as a public health
priority in Ireland. Enterobacterales (such as Klebsiella pneumoniae and Escherichia
coli) are a family of Gram-negative bacteria and the most common cause of healthcareassociated infections (HCAI) in Ireland, associated with mortality rates of 50% (HSPC
2016). Due to the successful nature in which they harbour and transmit antimicrobialresistance plasmids on an intra- and inter-species level, they are becoming challenging to
treat. Initially, Enterobacterales that produced extended-spectrum β-lactamases (ESBLs)
posed the most prominent health concern (Dangelo et al., 2016), forcing clinicians to
prescribe carbapenems as first-line empirical treatments, which resulted in carbapenemresistant Enterobacterales (CRE) (Suay-García and Pérez-Gracia, 2019). HPSC figures
indicate that the number of ESBL-positive isolates of K. pneumoniae was 14.3%,
increasing yearly since 2013, while ESBL-producing E. coli accounted for 9.9% of
isolates (HPSC, 2022). The emergence of carbapenemase-producing strains of K.
pneumoniae and E. coli was declared a national public health emergency in Ireland in
2017. P. aeruginosa is a highly versatile bacterium associated with a wide range of
infections. The opportunistic human pathogen is frequently isolated from nosocomial
infections, and the increasing occurrence of multidrug-resistant (MDR) strains, in
addition to its adaptive resistance during chronic infections, is causing high levels of
morbidity and mortality (Pang et al., 2019). Invasive P. aeruginosa infections increased
by 54% between 2015 and 2020, and in that time, MDR-isolates accounted for 2.5-9%
(HPSC, 2022).
In this chapter, the antibacterial activity of copper(II), manganese(II), and silver(I)
complexes incorporating 1,10-phenanthroline (phen) and dicarboxylate ligands against
WHO priority pathogens that are also problematic within Irish clinical settings are
presented. The panel comprised Gram-positive bacteria methicillin-resistant S. aureus
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(MRSA) and vancomycin-resistant Enterococci (VRE), Gram-negative bacteria
carbapenem-resistant and ESBL-producing Enterobacterales and P. aeruginosa, derived
from patients in Irish hospitals. For the microbiological screening of the complexes,
European Committee on Antimicrobial Susceptibility Testing (EUCAST) standardised
susceptibility testing methods were utilised as currently, these guidelines are used in all
diagnostic laboratories throughout Ireland. One representative Gram-positive, S. aureus,
and Gram-negative, P. aeruginosa, organism were selected for subsequent acquired
resistance studies to selected metal-phen complexes and were dosed with sub-lethal
concentrations of the complexes. Whole-genome sequencing (WGS) was then performed
on the mutant strains to unveil any genome changes leading to an alteration in the amino
acid sequence of a protein and, therefore, indicative of acquired resistance mechanisms
by the microorganisms.
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Materials and Methods
2.2.1 Test complexes
The formulae, solubility, and respective codes of the metal complexes examined in this
chapter are shown in Table 2.1, and the structures are presented in Figure 2.1. In order
to illustrate that any observed effects were due to the complexes rather than the attached
ligands or free metal ions that may be produced within the cellular environment, the
activity of simple metal salts and the metal-free dicarboxylic acids were also included in
the study as direct comparators. These included the following: copper(II) chloride
(CuCl2), manganese(II) chloride (MnCl2) and silver(I) nitrate (AgNO3), and the free
ligands; 1,10-phenanthroline (phen), butanedioic acid (bdaH2), pentanedioic acid
(pdaH2), hexanedioic acid (hxdaH2), heptanedioic acid (hpdaH2), octanedioic acid
(odaH2), undecanoic acid (uddaH2), phthalic acid (phH2) and 3,6,9-trioxaundecanedioic
acid (tddaH2). All of the complexes were dissolved in their corresponding diluent at a
concentration of 10 mg/mL. Complexes which were only soluble in dimethyl sulfoxide
(DMSO) were made in a 0.1% (DMSO/H2O) solution, while phen and the dicarboxylate
ligands were dissolved in methanol (MeOH) and diluted down to a 1% (MeOH/H2O)
solution. The remaining complexes were fully water-soluble. Working solutions (512
µg/mL) for the bacterial screen were made up in Mueller Hinton Broth (MHB; Cruinn).
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Code

Complex Formula

Solubility

Reference
(Kellett et al., 2012)
(McCann et al., 1995)
(McCann et al., 1995)
(Devereux et al.,
1999)
(Gandra et al., 2017)
(Gandra et al., 2017)

Cu(II) complexes
Cu-ph-phen
Cu-oda
Cu-oda-phen
Cu2-oda-phen

[Cu(ph)(phen)(H2O)2]
[Cu(oda)]H2O
[Cu(oda)(phen)2]8H2O
[Cu2(oda)(phen)4](ClO4)22.76H2O.EtOH

DMSO
DMSO
DMSO
H2O

Cu-tdda
Cu-tdda-phen

[Cu(3,6,9-tdda)]H2O
[Cu(3,6,9-tdda)(phen)2]3H2O.EtOH
Mn(II) complexes

H2O
H2O

Mn-bda

[Mn(bda)].2H2O

H2O

Mn-bda-phen

[Mn2(bda)2(phen)2(H2O)4].4H2O

H2O

Mn-pda

[Mn(pda)].H2O

H2O

Mn-pda-phen

[Mn(pda)(phen)]

H2O

Mn-hxda

[Mn(hxda)].H2O

H2O

Mn-hxda-phen

[Mn(hxda)(phen)2(H2O)].7H20

H2O

Mn-hpda

[Mn(hpda)]

H2O

Mn-hpda-phen

H2O

Mn-tdda

[Mn(phen)2(H2O)2][Mn(hpda)(phen)2(H2O)]hp
da.12.5H2O
[Mn(oda)]H2O
[Mn2(oda)(phen)4(H2O)2][Mn2(oda)(phen)4(oda
)2].4H2O
[Mn(3,6,9-tdda)]H2O

Mn-tdda-phen

{[Mn(3,6,9-tdda)(phen)2]3H2O.EtOH}n

H2O

Mn-oda
Mn-oda-phen

Ag-udda

Ag(I) complexes
[Ag2(udda)]

H2O
H2O
H2O

H2O

Ag-udda-phen

[Ag2(phen)3(udda)].3H2O

H2O

Ag-tdda
Ag-tdda-phen

[Ag2(3,6,9-tdda)]2H2O
[Ag2(3,6,9-tdda)(phen)4]EtOH
Controls
Copper chloride
Manganese chloride
Silver nitrate
1,10-phenanthroline

H2O
H2O

(McCann et al.,
1997a)
(McCann et al.,
1997a)
(Geraghty et al.,
1998)
(Geraghty et al.,
1998)
(McCann et al.,
1997b)
(McCann et al.,
1997b)
(McCann et al.,
1997b)
(McCann et al.,
1997b)
(Casey et al., 1994)
(Casey et al., 1994)
(McCann et al.,
1997c)
(McCann et al.,
1997c)
(Thornton et al.,
2016)
(Thornton et al.,
2016)
(Gandra et al., 2017)
(Gandra et al., 2017)

H2O
H2O
H2O
MeOH

Table 2.1 Metal complexes assessed in this study. phen = 1,10-phenanthroline, bdaH2 =
butanedioic acid, pdaH2 = pentanedioic acid, hxdaH2 = hexanedioic acid, hpdaH2 =
heptanedioic acid, odaH2 = octanedioic acid, uddaH2 = undecanoic acid, phH2 = phthalic
acid, tddaH2 = 3,6,9-trioxaundecanedioic acid
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Cu(II) complexes

Cu-ph-phen

Mn(II) complexes

Cu-oda-phen

Cu2-oda-phen

Cu-tdda-phen

Mn-bda-phen

Mn-pda-phen

Mn-hxda-phen

Mn-hpda-phen

Ag(I) complexes

Mn-oda-phen

Ag-udda-phen

Ag-tdda-phen

Figure 2.1 Structure of metal-phen complexes examined in this study
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Mn-tdda-phen

2.2.2 Clinical isolates and control strains
The clinical isolates assessed were Gram-positive methicillin-resistant S. aureus (n = 5;
MRSA1-MRSA5) and vancomycin-resistant Enterococci (n = 6; VRE1-VRE6) and
Gram-negative Enterobacterales, including extended-spectrum β-lactamase-producer (n
= 1; ESBL1), metallo-β-lactamase-producer (n = 1; MBL1) and K. pneumoniae
carbapenemase-producer (n = 1; KPC1), and P. aeruginosa (n = 4; PA1-PA4) collected
from a range of hospitals throughout Ireland. In addition to the clinical isolates, reference
Gram-positive and Gram-negative strains obtained from the American Type Culture
Collection (ATCC) were included as quality control strains. Gram-positive bacteria
included S. aureus (ATCC 29213) and E. faecalis (ATCC 29212), and Gram-negative
bacteria included E. coli (ATCC 25922), K. pneumoniae (ATCC 10031), and P.
aeruginosa (ATCC 27853 and PAO1). K. pneumoniae (ATCC 700603 and ATCC BAA1705) were also included in the Gram-negative panel as resistant controls of an ESBLproducer and a KPC-producer, respectively. All isolates were obtained from the School
of Biological and Health Sciences TU Dublin-City campus. Under GDPR compliance,
clinical isolates were provided anonymously to the researcher, and no patient data was
processed.
2.2.3 Antimicrobial susceptibility testing by disc diffusion
Antimicrobial susceptibility profiles of clinical isolates were established through the
qualitative Kirby-Bauer disc-diffusion method, performed according to European
Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines (EUCAST,
2017a). Selections of antimicrobial agents were chosen according to EUCAST
recommendations for quality control and are displayed in Table 2.2 below. All
antimicrobial discs were obtained from Oxoid™ Ltd (Thermo Fisher Scientific). Bacteria
were stored on beads in cryogenic vials (Microbank™Cryovials) at -80 ºC and
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resuscitated on 5% blood agar 24 h before experiments. Three to five colonies were
transferred from the agar plate to 5 mL of sterile saline (NaCl) solution and adjusted until
the turbidity matched that of a 0.5 McFarland standard (equivalent to a 1.5 x108
CFU/mL). This was carried out for each strain. When the inoculum matched the 0.5
McFarland standard, a cotton swab was used to spread it on Mueller-Hinton agar (MHA)
plate. The plate was allowed to dry for 3-5 min before the corresponding antimicrobial
disc (Table 2.2) was added to the plate with sterile forceps. After incubation for 16-18 h
at 37 ºC, the zone of inhibition was determined by measuring the inhibition of growth
around the disc at 3 points using a digital calliper. Studies were performed in triplicate,
three independent times, and results are expressed as the mean measurement.
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Strains

Antibiotic (Antibiotic class)
Disc content (µg)
Gram-positive panel
Cefoxitin (Cephalosporin)
30
-S. aureus (ATCC 29213)
Ciprofloxacin (Fluoroquinolone)
5
-Clinical isolates MRSA1Gentamicin (Aminoglycosides)
10
MRSA5
Linezolid (Oxazolidinones)
10
Rifampicin (Ansamycin)
5
Ampicillin (Penicillin)
2
-E. faecalis (ATCC 29212)
Ciprofloxacin (Fluoroquinolone)
5
-Clinical isolates VRE1-VRE6
Gentamicin (Aminoglycosides)
30
Vancomycin (Glycopeptide)
5
Linezolid (Oxazolidinone)
10
Gram-negative panel
-E. coli (ATCC 25922)
Ampicillin (Penicillin)
10
-K. pneumoniae (ATCC 10031)
Cefotaxime (Cephalosporin)
5
-K. pneumoniae (ATCC 700603 Ceftazidime (Cephalosporin)
10
ESBL, ATCC BAA1705 - KPC)
Erthapenem (Carbapenem)
10
-Clinical isolates ESBL1, MBL1
Gentamicin ( Aminoglycosides)
10
and KPC1
Piperacillin-tazobactam (Penicillin36 (30-6)
-P. aeruginosa (ATCC 27853,
β-lactamase inhibitor)
PAO1)
Ceftazidime (Cephalosporin)
10
-Clinical isolates PA1-PA4
Meropenem (Carbapenem)
10
Ciprofloxacin (Fluoroquinolone)
5
Gentamicin (Aminoglycosides)
10
Table 2.2 Antibiotic controls used for disc diffusion assay, chosen per EUCAST
guidelines

2.2.4 Minimum Inhibitory Concentration (MIC)
The minimum inhibitory concentration (MIC) was determined against clinical isolates
and reference strains using the broth micro-dilution method in a 96 well-plate as specified
by EUCAST (2017b). The test complexes were serially diluted two-fold in cationadjusted Mueller-Hinton broth (CAMHB) and mixed with equal volumes (50 µL) of
diluted bacteria in 96-well plates (Cruinn), thus making a final concentration range of the
complexes tested between 0.25 and 256 µg/mL. Each plate contained a positive control
(bacteria and broth) and a negative control (just broth). In addition to the metal
67

complexes, vehicle control (0.1% DMSO, 1% MeOH), starting materials (simple metal
salts, phen and bridging ligands) and common antibiotics (Table 2.2) were assessed in
the same way. The MIC was defined as the lowest concentration to prevent
microorganism growth after incubation at 37 ºC for 16-18 h. Studies were performed in
triplicate, three independent times, and results are expressed as the mean measurement.
2.2.5 Minimum Bactericidal Concentration (MBC)
The minimum bactericidal concentration (MBC) of the metal complexes against test
isolates was determined by sub-culturing 5 μL of test dilution from each well in the MIC
assay, which failed to show turbidity growth, onto antibiotic-free MHA plates. Plates
were incubated for a further 16-18 h at 37 ºC. The MBCs were recorded as the lowest
concentration of agent that prevented the growth (no growth observed) of an organism
after subculture. Studies were performed in triplicate, three independent times, and results
are expressed as the mean MBC value.
2.2.6 Fractional Inhibitory Concentration (FIC)
The antibacterial activity of Cu-tdda-phen, Mn-tdda-phen and Ag-tdda-phen complexes
(Table 2.1) in combination with antibiotics were evaluated using the broth micro-dilution
checkerboard assay (Odds, 2003). Plates were prepared as described in Section 2.2.4.
After incubation at 37 ºC for 16-18 h, the fractional inhibitory concentration (FIC) index
(FICI) for combinations of metal complexes with antibiotics was calculated according to
the equation: FICI = FIC(metal complex) + FIC(antibiotic). Where, FIC(metal complex) = (MIC of metal
complex in combination with antibiotic)/(MIC of metal complex alone) and FIC(antibiotic)
= (MIC of antibiotic in combination with metal complex)/(MIC of antibiotic alone). With
this method, FICI was interpreted as synergy at a FIC index ≤0.5; additive at a FIC index
>0.5 to 1; indifference at a FIC index >1 – <2; and antagonism at a FIC index ≥2
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(EUCAST, 2000). Studies were performed in triplicate, three independent times, and
results were expressed as mean measurement.
2.2.7 Mutant selection
Mutants with decreased susceptibility to lead metal-tdda-phen complexes, Mn(II), Cu(II),
and Ag(I), were generated by serial passage of S. aureus ATCC 29213 and P. aeruginosa
PAO1 to increasing concentrations of the relative complex. See Figure 2.2 for a
schematic overview of mutants.
Briefly, conical flasks containing 2 mL of MHB with two-fold increasing concentrations
of either Mn-tdda-phen, Cu-tdda-phen, or Ag-tdda-phen were inoculated with 1×107
CFU/mL of ATCC 29213 or PAO1. Following overnight incubation at 37 °C aerated at
200 rpm, the MIC was determined by the micro-dilution method as the lowest drug
concentration to inhibit bacterial growth. The conical flasks with the highest drug
concentration that permitted growth were used to inoculate a series of tubes containing
fresh MHB with two-fold increasing concentrations of Mn-tdda-phen, Cu-tdda-phen, or
Ag-tdda-phen adjusted to a starting concentration of 1×107 CFU/mL. These inoculums
were incubated overnight at 37 °C aerated at 200 rpm. Again, the lowest drug
concentration that inhibited growth was determined by the microdilution method to be
the MIC, and the inoculum growing at the highest drug concentration was used to prepare
the inoculum for the following passage. In total, there were 3 passages carried out to
produce mutant strains of ATCC 29213 exposed to metal-tdda-phen complexes (with a
final MIC of 8 µg/mL) and 8 passages to produce mutant strains of PAO1 exposed to
metal-tdda-phen complexes (with a final MIC of 256 µg/mL).
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Figure 2.2 Schematic overview of reducing drug susceptibility of lead metal-tdda-phen
complexes, Mn-tdda-phen, Cu-tdda-phen, and Ag-tdda-phen in reference strains S.
aureus ATCC 29213 (ATCC 29213_Mn, ATCC 29213_Cu, ATCC 29213_Ag,
respectively) and P. aeruginosa PAO1 (PAO1_Mn, PAO1_Cu, PAO1_Ag, respectively).
ATCC 29213_NT and PAO1_NT refer to the control strains that did not receive any
treatment.

2.2.8 Whole-genome sequencing and analysis
The whole-genome sequencing (WGS) of mutant strains S. aureus ATCC 29213 (ATCC
29213_NT, ATCC 29213_Mn, ATCC 29213_Cu, ATCC 29213_Ag, respectively) and P.
aeruginosa PAO1 (PAO1_NT, PAO1_Mn, PAO1_Cu, PAO1_Ag, respectively) were
performed by MicrobesNG (http://www.microbesng.com). The sequence files for this
study have been deposited in the European Nucleotide Archive (ENA) at EMBL-EBI
under accession number PRJEB52838.
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Ms Jasmine Hurley, as a part of her TU Dublin undergraduate research project, carried
out the analysis of WGS data. Briefly, FASTQ files received from MicrobesNG were
imported into Geneious Prime and mapped against reference genomes from the NCBI
Nucleotide database. ‘PAO1, complete genome’ (Accession no. NC_002516) was used
as the reference genome for the P. aeruginosa files. There was no reference genome
available for ATCC 29213 in the NCBI Nucleotide database; instead, ‘NCTC 8325,
complete genome’ (Accession no. CP000253) was used as the reference genome for the
S. aureus files. Variants were detected within Geneious Prime and exported. The settings
used were taken from the WGS guide created by Gautam et al. (2019).
Variants in resistant strains of P. aeruginosa were compared to each other, and the P.
aeruginosa control using Ablebits add-in in Microsoft Excel. Any variants that were
shared between at least two resistant strains and were not present in the control were
noted. BLAST searches were conducted to identify the possible function of any variantcontaining hypothetical proteins.
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Results
2.3.1 Susceptibility profile of all clinical isolates
Clinical isolates were first assessed against various commercial antibacterial agents
commonly used within the clinic. The susceptibility profile of Gram-positive bacteria
represented by S. aureus and Enterococcus species (E. faecium and E. faecalis) and
Gram-negative bacteria, Enterobacterales (E. coli and K. pneumoniae) and P. aeruginosa
are presented in Table 2.3. Each representative bacterial group consists of an ATCC
control strain and clinical strains isolated from patients with bloodstream infections
(BSI’s) in Irish hospitals. These microorganism's susceptibility profiles were assessed per
the EUCAST guidelines (EUCAST, 2017a, 2017c). The zones of inhibition for the ATCC
control strains fell within the accepted ranges (EUCAST, 2017b).
All five clinical MRSA strains (MRSA1-MRSA5) were resistant to cefoxitin and
ciprofloxacin, while two (MRSA1 and MRSA2) isolates were also resistant to gentamicin
(Table 2.3). The clinical, vancomycin-resistant Enterococci strains (VRE1-VRE6)
demonstrated resistance to all standard antibacterial agents. Representative Gramnegative sub-panels included the Enterobacterales panel encompassed by extendedspectrum β-lactamase (ESBL)-producing strains, ATCC 700603 (K. pneumoniae) and
clinical isolate ESBL1, metallo-β-lactamase (MBL)-producing clinical isolate MBL1,
and K. pneumoniae carbapenemase (KPC)-producing strain ATCC BAA1705 and clinical
isolate KPC1. As expected, the ESBL+ strain demonstrated resistance to all β-lactams
tested but remained susceptible to the carbapenem. Similarly, both MBL+ and KPC+
CRE test strains also demonstrated the expected antimicrobial susceptibility testing
(AST) profiles with resistance expressed to all β-lactams, including the carbapenem, a
last resort drug. The P. aeruginosa group incorporated four clinical isolates (PA1-PA4).
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PA1 was susceptible to all test antibiotics except gentamicin, while PA2, PA3 and PA4
were resistant to all examined agents.
Based on the criteria released by the European Centre for Disease Prevention and Control
(ECDC) and the Centres for Disease Control and Prevention (CDC), the bacterial panel
is comprised of several multidrug-resistant (MDR) isolates which are defined as nonsusceptibility to at least one agent in three or more antimicrobial classes (Magiorakos et
al., 2012).
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Species

Strain

Staphylococcus
aureus

ATCC 29213
MRSA1
MRSA2
MRSA3
MRSA4
MRSA5

Enterococcus
faecalis,
Enterococcus
faecium

ATCC 29212
VRE1
VRE2
VRE3
VRE4
VRE5
VRE6

Escherichia
coli, Klebsiella
pneumoniae

ATCC 25922
ATCC 10031
ATCC 700603
ESBL1
MBL1
ATCC
BAA1705
KPC1

Pseudomonas
aeruginosa

ATCC 27853
PAO1
PA1
PA2
PA3
PA4

Antibiotic (zone of inhibition as nm)
Gram-positive panel
Cefoxitin
Ciprofloxacin Gentamicin
Linezolid
27 (S)
24 (S)
21 (S)
24 (S)
10 (R)
0 (R)
8 (R)
23 (S)
13 (R)
0 (R)
8 (R)
22 (S)
11 (R)
0 (R)
19 (S)
24 (S)
15 (R)
0 (R)
21 (S)
24 (S)
13 (R)
0 (R)
20 (S)
24 (S)
Vancomycin Ciprofloxacin Gentamicin
Linezolid
24 (S)
25 (S)
20 (S)
23 (S)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
13 (R)
0 (R)
0 (R)
0 (R)
11 (R)
0 (R)
0 (R)
0 (R)
13 (R)
0 (R)
0 (R)
0 (R)
11 (R)
0 (R)
0 (R)
0 (R)
10 (R)
Gram-negative panel
Ertapenem
Ceftazidime Cefotaxime Gentamicin
32 (S)
26 (S)
27 (S)
21 (S)
27 (S)
13 (R)
14 (R)
13 (R)
26 (S)
8 (R)
15 (R)
12 (R)
25 (S)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
17 (S)
0 (R)
Ceftazidime
25 (S)
15 (S)
20 (S)
16 (R)
0 (R)
0 (R)

Rifampicin
33 (S)
27 (S)
28 (S)
27 (S)
27 (S)
28 (S)
Ampicillin
24 (S)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
Ampicillin
20 (S)
10 (R)
0 (R)
0 (R)
0 (R)
0 (R)

0 (R)
0 (R)
0 (R)
0 (R)
Ciprofloxacin Gentamicin Meropenem PiperacillinTazobactam
29 (S)
20 (S)
27 (S)
25 (S)
25 (S)
18 (S)
18 (S)
25 (S)
24 (S)
13 (R)
25 (S)
21 (S)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
0 (R)
17 (R)
0 (R)
0 (R)
0 (R)
9 (R)
0 (R)

Table 2.3 Susceptibility profile of control strains and clinical isolates as determined by
disc diffusion and classified according to EUCAST guidelines. Zones of inhibition are
presented in mm. Resistant (R; Red); Susceptible (S; Green).
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2.3.2 Antibacterial testing of metal complexes
Once the susceptibility profiles of the clinical isolates were established, in vitro studies
were carried out to determine the antibacterial activity of the metal-dicarboxylate-phen
complexes against the Gram-positive and Gram-negative panels (Figure 2.3 and 2.4,
respectively). Quantitative serial broth dilutions of each complex were performed to
establish the MIC and MBC values. In addition, the simple metal salts, metal-free ligands
and prescription antibacterial agents were included. Ciprofloxacin and gentamicin were
used as controls for the Gram-positive panel as they are well-known broad-spectrum
antibiotics with different activity mechanisms and inhibition of DNA synthesis
(ciprofloxacin) and protein synthesis (gentamicin). Gentamicin and meropenem
(inhibition of cell wall synthesis) were utilised for the Gram-negative panel.
2.3.2.1 Gram-positive panel
Staphylococcus aureus
The MIC values (µg/mL) of the metal complexes and commonly used antibiotics against
S. aureus strains are displayed in Figure 2.3.A below. Except for Mn-hpda-phen, metal
complexes containing the phen ligand demonstrated a higher level of antibacterial activity
against both the control strain (ATCC 29213) and the clinical isolates (MRSA1-MRSA5)
in comparison to their non-phen precursors. The MIC value for gentamicin was 1 µg/mL
(1.74 µM) for ATCC 29213 (S. aureus) and MRSA3-MRSA5 isolates which interprets
them as susceptible to the antibiotic according to EUCAST breakpoints. Ciprofloxacin
also had a MIC value of 1 µg/mL (3.02 µM) against ATCC 29213, whilst all of the clinical
isolates were resistant to the antibiotic (>256 µg/mL) (>772 µM). The Cu(II)-phen
complexes, Cu-ph-phen (2.25 µM), Cu-oda-phen (1.35 µM), Cu2-oda-phen (0.76 µM)
and Cu-tdda-phen (1.34 µM), and Mn(II) complex Mn-tdda-phen (1.36 µM) also
produced a MIC of 1 µg/mL against ATCC 29213. The simple salts, CuCl2 and MnCl2,
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had no appreciable effects against the strain (Table A.1), and although phen alone was
able to inhibit growth, it was not as effective as the Cu(II) and Mn(I)-phen complexes.
Moreover, none of the dicarboxylic acid ligands demonstrated any inhibitory effects (data
not shown), and this is in agreement with previously reported data (Devereux et al., 2000).
This suggests that the activity of metal-phen complexes are a consequence of the whole
complex rather than its separate constituent parts. However, activity is not necessarily
dependent on the number of coordinated phen ligands present per complex. For instance,
Cu-oda-phen, Cu-tdda-phen and Mn-tdda-phen contain two phen ligands, and Cu2-odaphen contains four ligands. Mn-oda-phen has the greatest amount of phen ligands
attached (eight) but had a MIC value of 32 µg/mL (104 µM) against ATCC 29213. A subset of these complexes (Mn-oda-phen, Mn-tdda-phen and Cu2-oda-phen) was previously
examined against Mycobacterium tuberculosis, and a similar observation was made
(McCarron et al., 2018).
Cu-tdda-phen had an MBC value of 4 µg/mL (5.38 µM), which matched the MBC of
gentamicin (6.95 µM). Antibiotics are usually regarded as bactericidal if the MBC is no
more than four times the MIC value (Levison and Levison, 2009), so in this regard, the
majority of Cu-tdda-phen MBCs are four times the established MIC value (Table A.1).
Strains resistant to gentamicin had a MIC value of 64 µg/mL (100 µM) (MRSA1) and
128 µg/mL (500 µM) (MRSA2), while Mn-tdda-phen (MIC of 1 µg/mL/1.36 µM and 8
µg/mL/10.9 µM against MRSA1 and MRSA2, respectively) and Cu-tdda-phen required
a lower concentration to inhibit the growth of the isolates (MIC of 8 µg/mL/10.8 µM
against both). The similar activities of Cu-tdda-phen and Mn-tdda-phen suggest that, in
these particular cases, antimicrobial activity is independent of the nature of the central
transition metal dication. This supports previous observations that, in certain instances,
activity can be independent of the metal present (Frei et al., 2020). However, the metal
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complexes that contain an Ag(I) nucleus behaved differently from their counterparts. Agtdda-phen (6.65-13.3 µM) and Ag-udda-phen (7.81-15.6 µM) had a MIC range of 8-16
µg/mL across all of the test isolates. Their non-phen precursors, Ag-tdda (67 µM) and
Ag-udda (74 µM) maintained activity across all strains at the administered concentration
of 32 µg/mL. It was postulated that these complexes exerted their toxicity by releasing
Ag(I) ions from the complex into the growth medium. This is substantiated by the
observation that the simple metal salt, AgNO3, exerted similar activity (MIC value 4-64
µg/mL) (Table A.1). This is not surprising as silver is widely reported to have strong
antibacterial properties, particularly against S. aureus, with a multi-target mode of action
and the ability to overcome antibiotic resistance (Wang et al., 2021a).
Enterococcus faecium and Enterococcus faecalis
The MIC values of the metal complexes and commonly used antibiotics against
Enteroccous spp are displayed in Figure 2.3.B. The control antibiotics ciprofloxacin and
gentamicin had a MIC of 1 µg/mL (3.02 µM) and 8 µg/mL (18.3 µM), respectively,
against the control strain ATCC 29212, which fell within the recommended values
provided by EUCAST. In contrast, all the clinical isolates had MICs greater than the
highest concentration of antibiotics used (256 µg/mL), thus classifying them as resistant
to the antibacterial agents. Fewer metal complexes exercised antibacterial action against
the Enterococci group of isolates. Although the Cu(II)-phen complexes inhibited the
growth of all strains, considerably higher concentrations were required (16-256 µg/mL)
(12.2-443 µM). Of the Cu(II) and Mn(II) panels, Cu-tdda-phen and Mn-tdda-phen were
the most active. Both complexes established MICs of 16-64 µg/mL (21.5-87 µM) across
the bacterial strains and were superior to the control antibiotics, ciprofloxacin and
gentamicin (>256 µg/mL). Moreover, the MBCs for Cu-tdda-phen ranged from 32 µg/mL
(43 µM) to 128 µg/mL (172 µM) (Table A.2), demonstrating that not only was the
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complex able to inhibit the growth of highly resistant microorganisms at lower
concentrations than the control antibiotics but was also able to kill them at concentrations
below the MICs of the antibiotics. As with the MRSA isolates, the Ag(I) complexes
behaved differently from the other metal complexes. Ag-tdda-phen (6.65-13.3 µM) and
Ag-udda-phen (7.81-15.6 µM) had a MIC range of 8-16 µg/mL across all strains, whilst
their non-phen precursors, Ag-tdda (67 µM) and Ag-udda (74 µM), respectively, required
32 µg/mL to inhibit the growth of the bacterial isolates. The MBCs of the phen-containing
complexes, Ag-tdda-phen (26.6-53.2 µM) and Ag-udda-phen (31.2-62.5 µM), were 3264 µg/mL and their non-phen complexes had an MBC value of 128 µg/mL (271-297 µM).
The simple metal salt, AgNO3, inhibited all bacterial isolates at a concentration of 4
µg/mL, outperforming the Ag(I) complexes. However, the Ag(I) complexes were able to
kill the same bacteria at lower concentrations. Metal-free phen and the dicarboxylic acids
did not have MBC values within the test concentration range, and therefore it is postulated
that coordination of the ligands to the metal enhances the bactericidal effect.
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A

B

Figure 2.3 Gram-positive panel. Heat map displaying the mean MIC of metal
complexes, grouped according to their metal centre and antibiotic controls (ciprofloxacin
and gentamicin) for (A) Staphylococcus aureus, control strain ATCC 29213, and clinical
isolates, MRSA1-MRSA5, and (B) Enterococcus spp, control strain ATCC 29212 (E.
faecalis) and clinical isolates, VRE1-VRE6. Graph tiles that are white without a value did
not have a MIC that fell within the tested range (>256 µg/mL). Detail of the concentration
range, and its relation to colour, is displayed in the figure legend
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2.3.2.2 Gram-negative panel
Escherichia coli and Klebsiella pneumoniae
The Enterobacterales panel are represented by susceptible control strains ATCC 25922
(E. coli) and ATCC 10031 (K. pneumoniae), resistant control strains ATCC 700603 (K.
pneumoniae extended-spectrum β-lactamase (ESBL)-producer) and ATCC BAA1705 (K.
pneumoniae carbapenemase (KPC)-producer), and clinical isolates ESBL producer
(ESBL1) a metallo-β-lactamase (MBL)-producer (MBL1) and a KPC producer (KPC1).
Figure 2.4.A highlights that a reduced selection of complexes retained activity when
screened against Gram-negative bacteria and, overall, complexes containing a phen
ligand had heightened activity. Of the Cu(II) complexes, Cu2-oda-phen (48.7-194 µM)
and Cu-oda-phen (80.5-345 µM) had a MIC value in the range of 64-256 µg/mL, while
Cu-ph-phen was essentially inactive against the Gram-negative panel. Gram-negative
bacteria, unlike Gram-positive bacteria, possess a protective outer membrane (OM) which
can impede access to some antibacterial agents, which can be a limiting factor in a
chemotherapeutic treatment protocol (Impey et al., 2020). Cu-tdda-phen (MICs = 16-64
µg/mL) (21.5-86 µM), Mn-tdda-phen (MIC = 16-128 µg/mL) (21.8-174 µM) and Agtdda-phen (MIC = 8-64 µg/mL) (6.7-53.2 µM) were the most active agents from within
each representative group. The Ag(I) complexes, Ag-udda, Ag-udda-phen and Ag-tdda,
produced a similar toxicity profile as the silver salt, AgNO3 (Table A.3), across all strains,
again suggesting that the binuclear silver complexes may be exerting activity by releasing
Ag(I) ions into solution. Ag-tdda-phen generated an MBC value (64-128 µg/mL) twice
that of its MIC value (32-64 µg/mL) across the clinical isolates apart from ESBL1, which
required 4 times the MIC value (16 µg/mL) to eliminate the isolate. Transmission electron
microscopy observation of AgNO3 treated E. coli identified morphological and structural
changes and enhanced permeability in the bacterial cell envelope (RubenMorones80

Ramirez et al., 2013), suggesting that the Ag(I) complexes are exerting their antibacterial
activity in this manner.
Pseudomonas aeruginosa
When investigating the MIC of the metal complexes (Figure 2.4.B), Cu-tdda-phen (21.586 µM) and Mn-tdda-phen (21.8-87 µM) were decidedly the most active complexes from
those that harbour a Cu(II) or Mn(II) nucleus. A related activity pattern was observed
through the test strains, with ATCC 27853 having a MIC value of 16 µg/mL (21.5 µM
and 21.8 µM, respectively) for both chelates and an MBC value of 32 µg/mL (43 µM and
43.5 µM, respectively). For the Cu(II) and Mn(II) tdda-phen complexes to inhibit the
growth of the clinical isolates PA2 and PA4, a MIC value of 16 µg/mL was necessary,
whereas both of these bacterial strains were resistant to the control antibiotics,
meropenem (MIC = >256 µg/mL, >585 µM) and gentamicin (MIC = >256 µg/mL, 444
µM). Ag-tdda-phen presented with an MIC value of 8 µg/mL (6.6 µM) for ATCC 27853
and PA1, and 32-64 µg/mL (26.6-53.2 µM) across the remaining strains. The non-phen
derivative, Ag-tdda, had a MIC value of 128-256 µg/mL (106-213 µM) for all clinical
strains, indicating that the inclusion of the phen ligand caused a more potent effect.
.
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B

Figure 2.4 Gram-negative panel. Heat map displaying the mean MIC of metal
complexes, grouped according to their metal centre and antibiotic controls (meropenem
and gentamicin) for (A) Enterobacterales, control strain ATCC 29213 (E. coli), ATCC
10031 (K. pneumoniae), ATCC 700603 (ESBL+), ATCC BAA1705 (KPC+) and clinical
isolates ESBL1, MBL1 and KPC1, and (B) Pseudomonas aeruginosa, control strain
ATCC 27853, PAO1 and clinical isolates PA1-PA4. Graph tiles that are white without a
value did not have a MIC that fell within the tested range (>256 µg/mL). Detail of the
concentration range, and its relation to colour, is displayed in the figure legend.
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2.3.3 Combination effects of selected clinical isolates with lead metal-tdda-phen
complexes and antibiotics
Combination therapy is a method for restoring the clinical efficacy of antibiotics and
avoiding the development of drug resistance in the clinic. Although a single agent
antimicrobial therapy is generally preferred, combining two or more antibacterial agents
is recommended under certain circumstances. This approach would be selected for
polymicrobial infections (Stacy et al., 2016), to delay the evolution of drug resistance
(Angst et al., 2021), to reduce the dosage of individual drugs, and in turn potentially
reduce adverse effects (Niederman et al., 2021), or to potentially eliminate resistant
strains (Coates et al., 2020). However, the selection of appropriate combinatorial
treatment is critical for the successful elimination of infections. Metal-tdda-phen
complexes and control antibiotics were used to determine the interaction and potency of
the combined treatments compared to their individual activities on the selected clinical
isolates. Representative isolates were chosen from each genus, particularly strains with a
more extensive resistance profile (Table 2.3). They were as follows: S. aureus clinical
isolates, MRSA1 and MRSA2, Enterococci isolates, VRE1 and VRE6, Enterobacterales,
ATCC 700603, ESBL1, MBL1, ATCC BAA1705 and KPC1, and P. aeruginosa isolates
PA2 and PA4. Selected antibacterial agents were unique to the group of bacteria, for
instance, antibiotics chosen for VRE isolates were vancomycin and linezolid. Finally, a
representative metal complex from each different metal-containing series was selected
including the very active tdda-phen family, Cu-tdda-phen, Mn-tdda-phen and Ag-tddaphen. When drugs are combined, their effects on bacterial cells may be amplified, slightly
enhanced, weakened, or have no effect at all, so the drugs may show synergistic, additive,
indifferent or antagonistic interactions, respectively. On the basis of their FIC index, each
combination was categorized as synergistic (≤0.5), additive (>0.5 to 1), indifferent (>1 to
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<2) or antagonistic (≥2), according to the EUCAST guidelines (EUCAST, 2000). Ideally,
for the combination of metal complex with antibiotic, a synergistic effect was desired.
2.3.3.1 Combination effects in selected Gram-positive isolates
Methicillin-resistant Staphylococcus aureus (MRSA)
Ciprofloxacin is a bactericidal antibiotic of the fluoroquinolone class that targets DNA
replication (Correia et al., 2017), and gentamicin is a clinically significant
aminoglycoside antibiotic that inhibits protein synthesis (Magnet and Blanchard, 2005).
Results for the combinations of the antibiotics, ciprofloxacin and gentamicin, with Cutdda-phen, Mn-tdda-phen and Ag-tdda-phen against the clinical isolates, MRSA1 and
MRSA2, are presented in Table 2.4. All three metal-tdda-phen complexes in combination
with ciprofloxacin produced an indifferent effect. This means that the inhibitory effect of
the combined agents is the same as that of the more active drug alone, this being the
metal-tdda-phen complexes. When the complexes were co-administered with gentamicin,
the combination was synergistic in terms of the FICI value. In this context, the inhibitory
effect against the bacterium in the combination was more potent than that of the individual
agents alone.
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Antibiotic

Test complexes

Isolate
MRSA1
MRSA2
MRSA1
MRSA2
MRSA1
MRSA2
MRSA1
MRSA2
MRSA1
MRSA2
MRSA1
MRSA2

Cu-tdda-phen
Ciprofloxacin

Mn-tdda-phen
Ag-tdda-phen
Cu-tdda-phen

Gentamicin

Mn-tdda-phen
Ag-tdda-phen

FIC Index
1.5
1.5
1.5
1.5
1.3
1.5
0.05
0.13
0.27
0.07
0.02
0.04

Interpretation
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Synergistic
Synergistic
Synergistic
Synergistic
Synergistic
Synergistic

Table 2.4 The fractional inhibitory concentration (FIC) index of metal-tdda-phen
analogues Cu-tdda-phen, Mn-tdda-phen and Ag-tdda-phen in MRSA clinical isolates,
MRSA1 and MRSA2 with antibiotics ciprofloxacin and gentamicin. FICI is the sum of
the FIC (Table A.5) of the two agents used in the combination.

Vancomycin-resistant Enterococci (VRE)
Vancomycin, a glycopeptide, exerts its bactericidal effect by binding to D-alanyl-Dalanine residues of the bacterial cell wall and preventing the polymerization of
peptidoglycans (Lee et al., 2019). Linezolid is the first synthetic oxazolidinone antibiotic
with a unique mechanism of action as it appears to block the initiation of protein
production (Chen et al., 2020). All combinations of vancomycin or linezolid with the
three metal-tdda-phen complexes against the clinical isolates, VRE1 and VRE6, produced
indifferent effects (Table 2.5)
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Antibiotic

Test complexes
Cu-tdda-phen

Vancomycin

Mn-tdda-phen
Ag-tdda-phen
Cu-tdda-phen

Linezolid

Mn-tdda-phen
Ag-tdda-phen

Isolate
VRE1
VRE6
VRE1
VRE6
VRE1
VRE6
VRE1
VRE6
VRE1
VRE6
VRE1
VRE6

FIC Index
1.5
1.25
1.5
1.5
1.03
1.06
1.5
1.5
1.5
1.5
1.25
1.25

Interpretation
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent

Table 2.5 The fractional inhibitory concentration (FIC) index of metal-tdda-phen
analogues Cu-tdda-phen, Mn-tdda-phen and Ag-tdda-phen in VRE clinical isolates,
VER1 and VRE6 with antibiotics vancomycin and linezolid. FIC I is the sum of the FIC
(Table A.6) of the two agents used in the combination.

2.3.3.2 Combination effects in Gram-negative strains
Enterobacterales isolates
Ceftazidime is a third-generation cephalosporin antibiotic that exerts its bactericidal
action by inhibiting enzymes responsible for cell wall synthesis primarily through
penicillin-binding protein 3 (PBP3) (Testa et al., 2015). Meropenem is a broad-spectrum
antibacterial agent of the carbapenem class that inhibits cell wall synthesis also through
binding to PBP targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Gramnegative bacteria and PBPs 1, 2 and 4 of Gram-positive bacteria (Zandi and Townsend,
2021). The strains representing the test Enterobacterales group were ATCC 700603,
ATCC BAA1705, ESBL1, MBL1 and KPC1 isolates (Table 2.6). Co-exposure of
ceftazidime with Cu-tdda-phen or Mn-tdda-phen, and the combinations of all of the
metal-tdda-phen complexes with meropenem, caused an indifferent effect with all strains
(the inhibitory rate of the combined agents was the same as that of the more active drug
alone, that being the metal-tdda-phen complex). The addition of Ag-tdda-phen to
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ceftazidime also had an indifferent effect against ESBL1 and KPC1 strains. However, the
same combination against ATCC 700603, MBL1 and ATCC BAA1705 produced an
additive effect (the combination of agents did not increase the inhibitory effect to the
extent that was better than administering the concentration of the more active single drug
alone). The same effect was observed with the combinations of Cu-tdda-phen, Mn-tddaphen and Ag-tdda-phen with gentamicin against ESBL1. There have been numerous
reports of simple silver or silver nanoparticles (AgNPs) restoring the activity of
ineffective antibiotics against multidrug-resistant strains (Liang et al., 2018; Zou et al.,
2018; She et al., 2019). One report stated that the combination of AgNPs with ceftazidime
were synergistic against 62.50% of examined ESBL+ K. pneumoniae isolates, confirming
the inhibition of β-lactamase enzymes in isolates exposed to AgNPs (Panáček et al.,
2016).
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Antibiotic

Test complexes

Isolate
FIC Index
Interpretation
ATCC 700603
1.13
Indifferent
ESBL1
1.13
Indifferent
Cu-tdda-phen
MBL1
1.03
Indifferent
ATCC BAA1705
1.13
Indifferent
KPC1
1.50
Indifferent
ATCC 700603
1.25
Indifferent
ESBL1
1.13
Indifferent
Mn-tdda-phen
MBL1
1.06
Indifferent
Ceftazidime
ATCC BAA1705
1.13
Indifferent
KPC1
1.13
Indifferent
ATCC 700603
0.56
Additive
ESBL1
1.03
Indifferent
Ag-tdda-phen
MBL1
0.53
Additive
ATCC BAA1705
0.56
Additive
KPC1
1.13
Indifferent
MBL1
1.03
Indifferent
Cu-tdda-phen
ATCC BAA1705
1.50
Indifferent
KPC1
1.50
Indifferent
MBL1
1.06
Indifferent
Mn-tdda-phen
ATCC BAA1705
1.50
Indifferent
Meropenem
KPC1
1.13
Indifferent
MBL1
1.06
Indifferent
Ag-tdda-phen
ATCC BAA1705
1.50
Indifferent
KPC1
1.13
Indifferent
ATCC 700603
1.50
Indifferent
Cu-tdda-phen
ESBL1
0.56
Additive
ATCC 700603
1.25
Indifferent
Gentamicin
Mn-tdda-phen
ESBL1
0.56
Additive
ATCC 700603
1.50
Indifferent
Ag-tdda-phen
ESBL1
0.52
Additive
Table 2.6 The fractional inhibitory concentration (FIC) index of metal-tdda-phen
analogues Cu-tdda-phen, Mn-tdda-phen and Ag-tdda-phen in Enterobacterales clinical
isolates with antibiotics ceftazidime, meropenem and gentamicin. FIC I is the sum of the
FIC (Table A.7) of the two agents used in the combination.
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Pseudomonas aeruginosa
When the clinical isolates PA2 and PA4 were tested with the metal-tdda-phen complexes
in tandem with meropenem and gentamicin, the results were indifferent and synergistic,
respectively (Table 2.7).
Antibiotic

Test complexes

Isolate
PA2
PA4
PA2
PA4
PA2
PA4
PA2
PA4
PA2
PA4
PA2
PA4

Cu-tdda-phen
Meropenem

Mn-tdda-phen
Ag-tdda-phen
Cu-tdda-phen

Gentamicin

Mn-tdda-phen
Ag-tdda-phen

FIC Index
1.13
1.25
1.13
1.25
1.06
1.25
0.07
0.07
0.07
0.07
0.01
0.00

Interpretation
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Synergistic
Synergistic
Synergistic
Synergistic
Synergistic
Synergistic

Table 2.7 The fractional inhibitory concentration (FIC) index of metal-tdda-phen
analogues Cu-tdda-phen, Mn-tdda-phen and Ag-tdda-phen in P. aeruginosa clinical
isolates, PA2 and PA4 with antibiotics meropenem and gentamicin. FICI is the sum of the
FIC (Table A.7) of the two agents used in the combination.

2.3.4 Whole-genome sequencing of Gram-positive Staphylococcus aureus and
Gram-negative Pseudomonas aeruginosa for resistance properties to lead
metal-tdda-phen complexes
Wild type S. aureus strain ATCC 29213 and P. aeruginosa strain PAO1 were exposed to
sub-lethal concentrations of lead metal-tdda-phen complexes to induce resistance
properties (Figure 2.2). This generated distinct strains denoted as ATCC 29213_Mn and
PAO1_Mn, ATCC 29213_Cu and PAO1_Cu, and ATCC 29213_Ag and PAO1_Ag that
were exposed to Mn-tdda-phen, Cu-tdda-phen and Ag-tdda-phen, respectively. Wholegenome sequencing (WGS) was performed on all strains, and the genomes were
subsequently analyzed using the bioinformatics programme ‘Geneious Prime’. The
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genomes of the strains that received metal-tdda-phen complexes were compared to those
that received no treatment (denoted as ATCC 29213_NT and PAO1_NT).
2.3.4.1 Gram-positive Staphylococcus aureus ATCC 29213
Only one mutation was shared between the metal-tdda-phen S. aureus treated strains
(ATCC29213_Cu and ATCC29213_Ag) while concurrently absent from the non-treated
control (ATCC29213_NT). This mutation results in the replacement of threonine with
isoleucine in a conserved hypothetical protein encoded by an unnamed gene
(SAOUHSC_01873). A BLAST search revealed that this gene matched the ebh gene in
‘Staphylococcus aureus strain NCTC8325 genome assembly chromosome 1’, which
encodes a surface protein known as Ebh. The protein Ebh promotes cell growth and
envelope assembly and is a known fibronectin-binding protein (Speziale et al., 2019).
The sub-lethal exposure of Staphylococcus aureus strain NCTC8325 to metal-tdda-phen
complexes and mutant strains WGS will have to be carried out as the varying genomes
may account for the limited mutations identified.
2.3.4.2 Gram-negative Pseudomonas aeruginosa PAO1
Various mutations were identified when comparing the untreated control strain
(PAO1_NT) to the metal-tdda-phen treated strains (PAO1_Cu, PAO1_Mn and PAO1_Ag
strains) as presented in Table 2.8. One variant was identified between all metal-tdda-phen
exposed strains and was situated in an unnamed gene that encodes for a hypothetical
protein linked to a carbon-nitrogen hydrolase containing protein. A BLAST search and
computational predictions suggest that the protein exhibits N-carbamoylputresceine
amidase activity (UniProt, 2021). The protein is a crucial component in the polyamine
biosynthetic pathway, indicating that resistance to the metal-tdda-phen complexes may
be acquired through alterations in the activity levels of this pathway. Mutations in
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agmatine deiminase and N-carbamoylputrescine amidase can directly influence the rate
at which polyamines are produced. Arginine deiminase, GatB of the aspartyl/glutamyltRNA amidotransferase complex and ɣ-glutamyl phosphate reductase can all indirectly
contribute to an altered polyamine biosynthetic rate (Sekula and Dauter, 2019). The
remaining mutations (Table 2.8) were aligned to specific pathways and mechanisms
discussed below.
2.3.4.3 Mutations associated with cellular respiration
Genome analysis suggests that alterations to energy metabolism pathways contributed to
the development of bacterial resistance. Amino acid altering single nucleotide
polymorphisms (SNPs) occurred in various unspecified oxidoreductases and known
oxidases and dehydrogenases in metal-tdda-phen-treated strains. These enzymes are
heavily involved in cellular respiration (Alford et al., 2020; Lee et al., 2021). In situations
where electron acceptors in oxidative phosphorylation are unavailable, the protein Dlactate dehydrogenase may act as a temporary electron sink (Kasai et al., 2019).
Additionally, recent studies have demonstrated the ability of D-lactate dehydrogenase to
act as an electron transferring agent, transporting electrons from NADH to quinones
present in the plasma membrane (Lin et al., 2018). A mutation in the gene encoding for
D-lactate dehydrogenase, ldhA, was identified in the analysis. In addition, a SNP was
identified in an unspecified cytochrome c oxidase which acts as a terminal electron
acceptor but also has other functions in bacteria, such as promoting virulence and biofilm
growth (Jo et al., 2017). Both of these mutations indicate that cellular respiration was
affected by the metal-tdda-phen complexes.
2.3.4.4 Mutations associated with polyamine biosynthetic pathway
Amino

acid

substitutions

were

identified

in

agmatine

deiminase

and

N-

carbamoylputrescine amidase (CPA). An inhibitory mutation in agmatine deiminase
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would prevent the formation of N-carbamoylputrescine, and therefore no mutation would
be required in CPA as it would not have a substrate on which to act. Similarly, the arginine
biosynthetic pathway involves the conversion of glutamate into arginine through a series
of consecutive enzymatic reactions (Majumdar et al., 2016). Mutations were identified in
arginine deiminase, GatB of the aspartyl/glutamyl-tRNA amidotransferase complex and
ɣ-glutamyl phosphate reductase. Arginine deiminase and ɣ-glutamyl phosphate reductase
catalyse the conversion of arginine to citrulline and N-acetyl-glutamyl-5-phosphate to N–
acetyl-glutamyl-5-semialdehyde, respectively (Majumdar et al., 2016). These reactions
are essential steps in the arginine biosynthetic pathway. GatB is involved in synthesising
glutamine, a precursor to glutamate (Friederich et al., 2018). Amino acid substitutions in
each of these enzymes further support the previous postulation that an enhanced rate of
polyamine biosynthesis could contribute to the resistance of the PAO1 strain to the three
metal-tdda-phen complexes.
2.3.4.5 Mutations associated with virulence factors
Bis-(3′-5′)-cyclic dimeric guanosine monophosphate (c-di-GMP) is the principle second
messenger involved in the regulation of cell cycle, differentiation, virulence, motility,
biofilm formation and dispersion (Valentini and Filloux, 2016; Valentini et al., 2018). It
is synthesized from two GTP molecules by diguanylate cyclases (DGC) and is degraded
by phosphodiesterases (PDE). Variants in PDE, PprA, WspC, RhlA and alginate lyases
were identified in metal-tdda-phen-treated strains, suggesting that changes occurred in
the biofilm life cycle. Additionally, WspC is a methyltransferase that promotes the
activation of the Wsp pathway. This pathway is involved in regulating c-di-GMP
concentration (Maunders and Welch, 2017; Cai and Webb, 2020). Similarly, the gene
pprA encodes the histidine kinase sensor, PprA, for the two-component system PprAPprB. This system is associated with biofilm formation during high-stress conditions.
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PprA is responsible for the activation of the two-component system, and a mutation in
pprA could indicate that the activity status of the system was altered as a resistance
strategy toward the metal-tdda-phen complexes (Bhagirath et al., 2019; Wang et al.,
2019a). A mutation in rhlA was identified, a gene that codes for rhamnosyltransferase
subunit A that acts as a critical enzyme in the biosynthesis of rhamnolipid, a secondary
metabolite that is important for the maintenance of mature biofilms (Thi et al., 2020). A
SNP in an alginate lyase domain-containing protein was also observed in both PAO1_Cu
and PAO1_Mn strains. This mutation resulted in an arginine residue being substituted for
a glutamine residue. Alginate is a critical component of biofilms, providing the thick
mucoid consistency that facilitates protection against the environment and stressors.
Alginate lyase proteins degrade alginate, and this mutation may reduce the enzyme's
efficiency, allowing alginate levels to rise and promoting biofilm formation (Moradali et
al., 2017; Blanco-Cabra et al., 2020).
SNPs were identified in other virulence factors, such as nalC, which is a transcriptional
regulator responsible for the control of the mexAB-oprM operon (Braz et al., 2016),
encoding the primary efflux pump of P. aeruginosa, MexAB-OprM (Barbosa et al.,
2021). The MexAB-OprM system is responsible for the resistance to quinolones,
macrolides, chloramphenicol, tetracyclines, lincomycin, and β-lactam antibiotics
(Scoffone et al., 2021). A mutation in this protein resulted in an arginine residue replacing
a serine residue. Another notable variant was XqhA, a protein that increases the
specificity of the type II secretion system (T2SS) (Michel et al., 2007). T2SS is known to
secrete PlcH, a hemolytic toxin in which another mutation was identified, causing the
substitution of serine with an alanine (Pena et al., 2019). Finally, a mutation resulting in
the replacement of asparagine with a lysine occurred in the highly conserved bacterial
protein, ClpB. This protein is vital in the disaggregation of proteins during high-stress
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conditions (Alam et al., 2021), suggesting that the metal-tdda-phen complexes may have
triggered protein aggregation within the bacterial cell.

Variants shared between PAO1_Cu, PAO1_Mn and PAO1_Ag strains
Genomic
location

Locus tag

3473819

PA3093

Gene

Product

Amino acid
change

Polymorphism
type

-

Carbon-nitrogen
hydrolase
domaincontaining protein

G→R

SNP
(transversion)

Protein effect
Substitution

Variants shared between PAO1_Cu and PAO1_Mn strains
Genomic
location

Locus tag

Gene

Product

Amino acid
change

Polymorphism
type

Protein effect

12145

PA0008

glyS

Glycine-tRNA
ligase subunit
beta

I→S

SNP
(transversion)

Substitution

328965

PA0292

aguA

Agmatine
deiminase

I→V

SNP
(transversion)

Substitution

919457

PA0844

plcH

Hemolytic
phospholipase C

R→Q

SNP (transition)

Substitution

1044192

PA0958

oprD

Porin OprD

N→D

SNP (transition)

Substitution

1442789

PA1330

-

Short-chain
dehydrogenase

Q→E

SNP (transition)

Substitution

1709846

PA1569

-

Major facilitator
superfamily
transporter

A→G

SNP (transition)

Substitution

1743146

PA1600

-

Cytochrome c

A→G

SNP
(transversion)

Substitution

1743297

PA1601

-

Aldehyde
dehydrogenase

R→Q

SNP
(transversion)

Substitution

1932730

PA1784

-

Alginate lyase
domaincontaining protein

R→Q

SNP (transition)

Substitution

2683088

PA2402

-

Peptide synthase

A→D

SNP (transition)

Substitution

2703112

PA2420

-

Porin

I→L

SNP
(transversion)

Substitution

3665586

PA3272

-

ATP-dependent
DNA helicase

N→S

SNP
(transversion)

Substitution

3871062

PA3462

-

Sensor/response
regulator hybrid
protein

A→T

SNP (transition)

Substitution
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4149515

PA3706

wspC

Methyltransferase

P→S

SNP (transition)

Substitution

4167142

PA3721

nalC

Transcriptional
regulator

S→R

SNP (transition)

Substitution

V→I

SNP
(transversion)

Substitution

4356981

PA3891

-

ATP-binding
cassette
transporters
transporter

4475825

PA3994

-

Epoxide
hydrolase

T→A

SNP (transition)

Substitution

4803257

PA4284

recB

Exodeoxyribonuclease V
subunit beta

A→T

SNP (transition)

Substitution

4818942

PA4293

pprA

Two-component
sensor

S→N

SNP (transition)

Substitution

A→S

SNP (transition)

Substitution

5145714

PA4593

-

ATP-binding
cassette
transporters
transporter
permease

5179615

PA4621

-

Oxidoreductase

S→N

SNP
(transversion)

Substitution

5525871

PA4926

-

TGc domaincontaining protein

Q→P

SNP (transition)

Substitution

5807024

PA5158

-

Outer membrane
protein

A→T

SNP
(transversion)

Substitution

5863513

PA5208

-

Hypothetical
protein

H→N

SNP (transition)

Substitution

Variants shared between PAO1_Cu and PAO1_Ag strains
Genomic
location

Locus tag

Gene

Product

Amino acid
change

Polymorphism
type

Protein effect

172340

PA0151

-

TonB-dependent
receptor

T→A

SNP (transition)

Substitution

520509

PA0459

-

Chaperone
protein ClpB

N→K

SNP
(transversion)

Substitution

579718

PA0519

nirS

Nitrite reductase

T→S

SNP
(transversion)

Substitution

1012950

PA0927

ldhA

D-lactate
dehydrogenase

S→T

SNP
(transversion)

Substitution

1882855

PA1738

-

Transcriptional
regulator

M→V

SNP (transition)

Substitution

2176433

PA1990

pqqH

Peptidase

W→R

SNP (transition)

Substitution

2214540

PA2022

-

UDP-glucose 6dehydrogenase

Y→F

SNP
(transversion)

Substitution

3020368

PA2672

-

Type II secretion
system

N→S

SNP (transition)

Substitution
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3193266

PA2839

-

LigB domaincontaining protein

R→H

SNP (transition)

Substitution

3892506

PA3479

rhlA

Rhamnosyltransferase
subunit A

Q→P

SNP
(transversion)

Substitution

4487286

PA4007

proA

Ɣ- glutamyl
phosphate
reductase

V→A

SNP (transition)

Substitution

5193272

PA4626

hrpA

Glycerate
dehydrogenase

R→H

SNP (transition)

Substitution

6047419

PA5372

betA

Choline
dehydrogenase

A→V

SNP (transition)

Substitution

6165065

PA5474

-

Metalloproteinase

D→G

SNP (transition)

Substitution

Variants shared between PAO1_Mn and PAO1_Ag strains
Genomic
location

Locus tag

Gene

Product

Amino acid
change

Polymorphism
type

Protein effect

31334

PA0029

-

Sulfate
transporter

S→N

SNP (transition)

Substitution

1228628

PA1137

-

Oxidoreductase

D→N

SNP (transition)

Substitution
Substitution

1228637

PA1137

-

Oxidoreductase

V→L

SNP
(transversion)

1238899

PA1147

-

Amino acid
permease

V→L

SNP
(transversion)

Substitution

1710229

PA1569

-

Major facilitator
superfamily
transporter

M→I

SNP (transition)

Substitution

1800632

PA1654

-

Aminotransferase

P→A

2029517

PA1868

xqhA

Secretion protein

S→A

SNP
(transversion)
SNP
(transversion)

-

Pyruvate
dehydrogenase
E1 component
subunit alpha

R→Q

SNP (transition)

Substitution

c-di-GMP
phosphodiesterase

P→Q

SNP
(transversion)

Substitution

A→T

SNP (transition)

Substitution

3823531

PA3417

4591824

PA4108

-

Substitution
Substitution

5016474

PA4484

gatB

Aspartyl/glutamyl
-tRNA
Amidotransferase
subunit B

5823613

PA5171

arcA

Arginine
deiminase

V→I

SNP (transition)

Substitution

6254544

PA5561

atpI

ATP synthase
subunit I

A→T

SNP (transition)

Substitution

Table 2.8 Variants of interest in P. aeruginosa PAO1 treated with sub-lethal doses of Cutdda-phen (PAO1_Cu), Mn-tdda-phen (PAO1_Mn) and Cu-tdda-phen (PAO1_Cu) when
compared to the untreated strain (PAO1_NT). – denotes an unnamed gene while → refers
to the change in amino acid.
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Discussion
The rise of antimicrobial resistance (AMR) is well established and constitutes an
increasingly severe threat to public health worldwide (Destoumieux-Garzón et al., 2018;
Cassini et al., 2019). Consequently, the efficacy of conventional antimicrobial agents is
rapidly declining, leaving healthcare professionals unpropitious to treat common
infections, and hence the development of new antibacterial compounds with novel
mechanisms of action to overcome AMR represents a global challenge. A recent systemic
analysis estimates 4.95 million deaths associated with bacterial AMR in 2019, including
1.27 million deaths directly attributable to bacterial AMR alone (Murray et al., 2022).
Moreover, it is widely reported that the pipeline for new antibacterial agents is dwindling
due to a lack of funding and interest from pharmaceutical companies (Tacconelli et al.,
2018; Theuretzbacher et al., 2019; Theuretzbacher, 2020; Butler et al., 2022).
In this chapter, the antibacterial capabilities of novel copper(II), manganese(II), and
silver(I) complexes containing dicarboxylate ligands and phen in panels of clinical
isolates derived from Irish hospitals. Further investigation into the potential resistance
mechanisms by whole genome sequencing (WGS) of the lead complexes in representative
Gram-positive organism, S. aureus, and Gram-negative organism, P. aeruginosa, were
also carried out. With Gram-positive and -negative bacteria, their distinction lies in the
cell envelope composition. The scaffold of the Gram-positive cell wall consists of a thick
layer of peptidoglycan polymer embedded with teichoic and lipoteichoic acids anchored
to the cell membrane. Teichoic acids are long anionic glycopolymers that bind cations
contributing to bacterial cell surface charge and hydrophobicity, which in turn affects the
interaction of antibiotics and host defences (Brown et al., 2013). In contrast, and in the
absence of teichoic acid, the Gram-negative cell wall consists of a thin layer of
peptidoglycan. However, the outer membrane encloses this. This layer is effectively a
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second lipid bilayer containing amphiphilic lipopolysaccharide (LPS), phospholipids and
outer membrane proteins (Okuda et al., 2016). Porins are β-barrel structures that form
channels to orchestrate the movement of small hydrophilic molecules across the outer
membrane (Silhavy et al., 2010), and efflux pumps are membrane-bound proteins
responsible for the extrusion of a variety of solutes. Therefore, the outer membrane is a
very effective and selective permeability barrier and a significant obstacle in developing
antibacterial agents that are effective against Gram-negative bacteria (Zgurskaya et al.,
2016; Impey et al., 2020). In addition to this intrinsic resistance, acquired resistance is
developing rapidly, creating a further impediment in the treatment of diseases caused by
these pathogens (Peterson and Kaur, 2018; Pang et al., 2019; Khan et al., 2020).
Overall, the metal complexes incorporating the phen ligand demonstrated superior
antibacterial toxicity compared to their non-phen precursors, metal-free phen, metal-free
dicarboxylic acids or simple metal salts. The greater activity profiles of metal-phen
complexes or metal-phendione complexes (phendione is a derivative of phen), in
comparison to their non-phen analogues, have previously been reported against a range
of microorganisms (Viganor et al., 2016a; Gandra et al., 2017; Granato et al., 2017;
McCarron et al., 2018; Ventura et al., 2020). Moreover, the metal-phen complexes
containing the 3,6,9-trioxaundecanedioate (tdda) bridging dianionic ligand maintained
their potency in varying degrees across the Gram-positive and Gram-negative panels
(Figure 2.3 and Figure 2.4). The tdda ligand enhances the water solubility of the metal
complexes, strengthening their hydrophilicity and potentially increasing their uptake into
the bacterial cell and thus their subsequent antibacterial action (Ng et al., 2013, 2016).
Although generally, the inclusion of the phen ligand in the complex formulations is key
to their antibacterial action, the general exception to this was the Ag(I) complexes which
were found to be active in both their phen and non-phen containing forms. Ag(I)
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compounds have well-documented multi-modal bactericidal properties, displaying a
broad spectrum of activity across both classes of bacteria (Domínguez et al., 2020; Wang
et al., 2021a). Ag(I) ions interact with the bacterial cell envelope and destabilize the
membrane (Jung et al., 2008; McQuillan et al., 2012), coupled with nucleic acids and
proteins (Arakawa et al., 2001), and inhibit metabolic pathways (Gordon et al., 2010;
Wang et al., 2019b). Although the Ag(I) ion is generally not regarded as being redoxactive, the generation of reactive oxygen species (ROS) is also attributed to its
antibacterial activity (Lemire et al., 2013; Domínguez et al., 2020). However, it is thought
that the production of ROS indirectly occurs through the perturbation of the respiratory
electron transfer chain (Gu and Imlay, 2011), Fenton chemistry following destabilization
of Fe-S clusters or displacement of iron (Barras et al., 2018) and inhibition of anti-ROS
defences by thiol–silver bond formation (Saulou-Bérion et al., 2015). The composition
of the cell wall influences the antibacterial potential of Ag(I). The thick negatively
charged peptidoglycan layer in Gram-positive bacteria attracts/binds the metal cations
and retards their entry (Dakal et al., 2016; Domínguez et al., 2020). The complexation of
metal ions to a hydrophobic chelating ligand, such as phen, encases the cations in a
hydrophobic sleeve and enables their penetration through the cell wall and membrane of
a bacterium, thus presenting the complex to internal target biomolecules, which
ultimately inhibits cell growth or even triggers cell death (Viganor et al., 2016b). The
heightened activity of phen-containing Ag(I) complexes, compared to their non-phen
precursors, was evident in the present work with both the Gram-positive (Figure 2.3) and
Gram-negative panels (Figure 2.4). Ag(I) complexed to phen or a phen-type ligand (e.g.
phendione) have presented with additional routes in which they exert their toxicity against
microorganisms such as interacting with double-stranded DNA (Galdino et al., 2022) or
suppressing virulence (Galdino et al., 2019). Cu(II) and Mn(II)-phen complexes have
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been reported to be avid producers of ROS (Kellett et al., 2011a), which is thought to
cause cell membrane damage and thiol depletion. Oxidative and thiol stress promotes the
release of metal ions (Fe, Zn and Cu) from metalloproteins, increasing their intracellular
concentration and initiating Fenton-type chemistry, which then stimulates further ROS
generation (Schramm et al., 2019). This, coupled with the intercalation of the complexes
with bacterial DNA, would cause deformation and cleavage of the nucleic acid (Kellett
et al., 2011a; McCarron et al., 2018; Ng et al., 2018), producing cascade effects that
would eventually lead to bacterial cell death. These previous observations substantiate
the hypothesis that the current metal-tdda-phen complexes, producing high intracellular
levels of ROS, affect cellular respiration (Table 2.8). Various mutations were detected in
the mutant genome of the metal-tdda-phen-treated P. aeruginosa representative strain,
PAO1, causing amino acid changes within proteins involved in the polyamine
biosynthetic pathway. Polyamines have demonstrated the ability to reduce oxidative
damage caused by ROS (Seo et al., 2019). As previously mentioned, Cu(II), Mn(II) and
Ag(I)-phen complexes generate free radicals, which are highly reactive and unstable.
Polyamines act as ROS scavengers, stabilizing ROS and preventing ROS-induced
damage to DNA, lipids and proteins. Recent findings suggest that these organic cations
may also upregulate genes associated with the enzymatic degradation of ROS, such as
catalases and superoxide dismutases. Superoxide dismutases can degrade superoxide
radicals, while catalases can degrade hydrogen peroxide (Van Acker and Coenye, 2017;
Guillouzo and Guguen-Guillouzo, 2020).
Due to the increasing rate of AMR, metals and metal complexes have not only been
investigated as alternatives to antibiotics but also as adjuvants. There have been numerous
reports on the capacity of metals or metal-bearing compounds to synergise and potentiate
antibiotics within both in vitro and in vivo models (Kim et al., 2008; RubenMorones100

Ramirez et al., 2013; Garza-Cervantes et al., 2017; Herisse et al., 2017; Chen et al.,
2018). Within the present study, all three metal-tdda-phen complexes potentiated
gentamicin (an aminoglycoside) activity in clinical isolates of MRSA, EBSL and P.
aeruginosa in terms of their fractional inhibitory concentration (FIC) index.
Aminoglycosides are bactericidal antibiotics that inhibit protein synthesis by binding with
a high affinity to the aminoacyl-tRNA site (A site) within the 30S ribosomal subunit,
thereby inhibiting the translation process and producing truncated proteins and affecting
the cell wall composition. This increases membrane permeability and subsequently
heightens drug uptake (Kohanski et al., 2008). In studies using strains of E. coli, Herisse
et al. (2017) reported a 10-fold increase in antimicrobial activity of aminoglycosides
(gentamicin, tobramycin, kanamycin, and streptomycin) when co-administered with
AgNO3. Aminoglycosides cross the cell membrane via proton motive forces, and the
Ag(I) ion enhances their toxicity by acting independently of this process. MoronesRamirez et al. (2013) also reported the synergistic combination of AgNO3 with β-lactams,
aminoglycosides, and quinolones against E. coli, and they suggested that this was due to
intensified ROS production. One or both of the mechanisms mentioned above could also
be why the present metal-tdda-phen complexes enhanced the activity of gentamicin,
which warrants further investigation.
To summarise, of the metal complexes assessed, those incorporating the phen ligand had
superior activity to their non-phen derivatives. In addition, the three metal-phen
complexes incorporating the 3,6,9-trioxaundecanedioate as their bridging ligand broadly
maintained activity across the bacterial panel of both classes. Therefore, it was decided
to select them for further study and examination. In addition, the synergistic capabilities
with gentamicin were also further investigated, particularly within a P. aeruginosa
disease model.
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Chapter 3.

Antibacterial and anti-biofilm
examination of selected metal
complexes against Pseudomonas
aeruginosa isolated from Irish
Cystic Fibrosis patients

Chapter 3 (objective 2) is based on the following paper: O’Shaughnessy M, McCarron
P, Viganor L, McCann M, Devereux M, Howe O. The antibacterial and anti-biofilm
activity of metal complexes incorporating 3,6,9-trioxaundecanedioate and 1,10phenanthroline ligands in clinical isolates of Pseudomonas aeruginosa from Irish Cystic
Fibrosis patients. Antibiotics. 2020; 9(10):674
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Introduction
Pseudomonas aeruginosa is a ubiquitous Gram-negative bacterium that can colonise a
diversity of sites with severe clinical consequences. Isolates of P. aeruginosa are found
in nosocomial infections within immunocompromised patients, ranging from burn sepsis
(Brandenburg et al., 2019) to ventilator-associated pneumonia (Ramírez-Estrada et al.,
2016) to pulmonary infections of patients with lung afflictions such as cystic fibrosis (CF)
and chronic obstructive pulmonary disease (COPD) (Fenker et al., 2018). CF is an
inherited autosomal recessive disorder characterised by mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene located on chromosome 7, primarily
affecting the lungs. Of particular concern in Ireland is the Phe508del mutation, of which
1 in 19 Irish people are asymptomatic carriers (Farrell, 2008). Individuals with this
mutated gene suffer from a defective chloride channel protein on the epithelial cells of
the lungs, causing an imbalance of chloride ions and fluid, and therefore the production
of thick mucus and impaired mucociliary clearance of inhaled microbes resulting in
recurrent chronic respiratory infections and inflammation. P. aeruginosa is the leading
cause of infection in patients with CF, and it is more prevalent in adults (Reece et al.,
2017).
The prosperity of this microorganism is attributed to its biofilm-forming capability and
its vast repertoire of cell-associated and extracellular virulence factors controlled by
transcriptional regulators, which enables its swift adaptation to environmental changes
and host defences. Biofilms are structured multi-cellular sessile communities, organized
as micro-colonies, encased within a self-produced extracellular matrix (ECM) that forms
the scaffold for its three-dimensional architecture (Christophersen et al., 2020).
Conventional antibiotics are active against planktonic cells of P. aeruginosa that cause
acute infection but often fail to completely eradicate their biofilms, leading to persistent
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infections. It is well documented that pathogenic biofilms from patients demonstrate up
to 1000-fold reduced susceptibility compared to their planktonic counterparts due to the
protective and altered nature of the biofilm (Hughes and Webber, 2017). The formation
of these aggregated communities with their inherent resistance to antibiotics and host
immune attacks are at the root of many persistent and chronic bacterial infections.
Antibiotic treatment for patients with CF who are infected with P. aeruginosa often
relieves the symptoms but does not necessarily cure the infection (Stefani et al., 2017).
The acquisition of chronic P. aeruginosa infection is associated with worsened disease
progression and increased mortality. Moreover, the effectiveness of the antibacterial
agents to treat these pathogens is also compromised by the emergence of multidrugresistant (MDR) strains which highlight the urgent need for novel drugs that can eradicate
the robust biofilms of P. aeruginosa by acting either alone or in tandem with other clinical
therapeutic interventions.
In this chapter, selected metal complexes metal-tdda and metal-tdda-phen complexes
were tested on three clinical isolates of P. aeruginosa (CF1-CF3) derived from Irish
hospital patients with CF, both alone and in combination with gentamicin, as they
demonstrated synergistic interactions in Chapter 2. The results were compared to two
established laboratory strains (ATCC 27853 and PAO1). The effects on planktonic
growth as well as inhibition of biofilm formation and biofilm disarticulation were
assessed in terms of biofilm biomass and cell viability once treated. The anti-biofilm
effects were further probed through analysis of individual biofilm components, including
polysaccharides, eDNA and the virulence factors pyocyanin and pyoverdine that help
establish and maintain the biofilm. Finally, the toxicity of these complexes was assessed
using a CF cell model (CFBE41o-) and a well-characterised ‘healthy’ cell line (BEAS2B) to establish the selectivity of complexes to the bacteria.
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Materials and Methods
3.2.1 Test complexes
The selected metal complexes (Table 2.1) used for this chapter were [Cu(3,6,9tdda)].H2O (Cu-tdda) and {[Cu(3,6,9-tdda)(phen)2].3H2O.EtOH}n (Cu-tdda-phen),
[Mn(3,6,9-tdda)(H2O)2].2H2O (Mn-tdda) and {[Mn(3,6,9-tdda)(phen)2].3H2O.EtOH}n
(Mn-tdda-phen),

and

[Ag2(3,6,9-tdda].2H2O

(Ag-tdda)

and

[Ag2(3,6,9-

tdda)(phen)4].EtOH (Ag-tdda-phen). In order to establish that the observed biological
effects were due to the discrete complexes rather than their free ligands, 1,10phenathroline (phen) and 3,6,9-trioxaundecanedioate (tdda), and metal salts,
manganese(II) chloride (MnCl2), copper(II) chloride (CuCl2), and silver(I) nitrate
(AgNO3) were also assessed (all chemicals were purchased from the Sigma-Aldrich
company and used without further purification). The aminoglycoside antibiotic,
gentamicin (Sigma-Aldrich), was also incorporated into the study. All stock complexes
(10 mg/mL) were diluted in Tryptic Soy broth (TSB) media for desired test
concentrations.
3.2.2 Bacterial strains and culture conditions
Clinical isolates of P. aeruginosa (CF1, CF2 and CF3) from cystic fibrosis patients at
local Irish hospitals were obtained from the Department of Science TU Dublin-Tallaght
campus. Under GDPR compliance, clinical isolates were provided anonymously to the
researcher, and no patient data was processed. Standard laboratory strains ATCC 27853
and PAO1 were also included. Stock frozen cultures were maintained at −80 °C in 20%
(v/v) glycerol solutions in tryptic soy broth (TSB; Lab M). Frozen cultures were streaked
onto plates of tryptic soy agar (TSA; Lab M) and incubated overnight at 37 °C. A single
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colony of bacteria was then inoculated into TSB (50 mL) to prepare the bacterial inoculate
for the experiments (37 °C at 200 rpm).
3.2.3 Antibacterial and anti-biofilm testing of complexes on Pseudomonas
aeruginosa strains
3.2.3.1 Effects of test compounds on planktonic bacteria
All metal complexes and controls were tested for their activity on the clinical isolates
(CF1-CF3) and laboratory strains (ATCC 27853 and PAO1) of P. aeruginosa using the
standard broth microdilution method to establish their minimum inhibitory concentration
(MIC). The test complexes were two-fold serially diluted and mixed with equal volumes
(100 µL) of diluted bacteria in 96-well plates (Cruinn), thus making a final concentration
range of the complexes tested and including the antibiotic control gentamicin of between
0.5 and 256 µg/mL. The MIC measurements were recorded based on turbidity according
to EUCAST guidelines (EUCAST, 2017b) after 24 h of incubation at 37 °C with agitation.
3.2.3.2 Effects of test complexes on biofilm formation (pre-treatment)
The activity of Cu-tdda-phen, Mn-tdda-phen and Ag-tdda-phen complexes (Table 2.1)
and controls on biofilm formation of all P. aeruginosa strains were tested by measuring
cellular viability and the total biomass in the cell culture wells. For both assays, 100 µL
of the bacterial culture (made up in TSB medium) was distributed into each well of flatbottomed 96–well polystyrene microtitre plates (Cruinn) and incubated for 48 h at 37 °C
in the presence of all test compounds (100 µL), administered at a concentration range of
0.5–256 µg/mL. The supernatants from each well were removed, and the wells were then
washed three times with phosphate-buffered saline (PBS). Viable cells in the biofilm were
assessed by a fluorometric assay that measures the metabolic capacity of cells (Peeters et
al., 2008). TSB (250 µL) containing 5% (v/v) resazurin (Sigma-Aldrich) was added to
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the plates and incubated for 20 min at 37 °C. Fluorescence was measured at λexcitation
= 560 nm and λemission = 590 nm with a Varioskan LUX (Thermo Scientific) microplate
reader. Then, the resazurin stain was removed and replaced by 250 µL of 0.1% (w/v)
crystal violet solution on the same plate (Skogman et al., 2012) to evaluate biofilm
biomass. After 20 min, the crystal violet stain was removed, and the wells were washed
three times. The wells were dried, and 250 µL of 30% acetic acid (Sigma–Aldrich) was
added to release the bound crystal violet. Absorbance was measured on a Multiskan GO
(Thermo Scientific) microplate reader at 590 nm.
3.2.3.3 Effects of test complexes on the mature biofilm (post-treatment)
In addition to testing the effects of the Cu-tdda-phen, Mn-tdda-phen and Ag-tdda-phen
complexes (Table 2.1) on biofilm formation (pre-treatment) of the P. aeruginosa strains,
their ability to weaken an established biofilm was also assessed with the post-treatment
of mature biofilms. Moreover, 100 µL of the bacteria culture (in TSB) was added to each
well of flat bottomed 96–well polystyrene microtitre plates (Cruinn) and incubated for 48
h at 37 °C to allow for biofilm formation. After 48 h incubation, the test complexes and
control were added over a range of concentrations (0.5–256 µg/mL) to mature biofilms
and incubated for an additional 24 h. To the untreated control, 100 µL of fresh media was
added to the wells. Cellular viability and biofilm biomass were measured using resazurin
staining and crystal violet staining, as previously described in Section 3.2.3.2
3.2.3.4 Checkerboard assay for mature biofilms
The anti-biofilm activity of individual Cu-tdda-phen, Mn-tdda-phen and Ag-tdda-phen
complexes (Table 2.1) alone and in combination with gentamicin were evaluated against
the P. aeruginosa strains using the broth micro-dilution checkerboard technique (Odds,
2003). Mature biofilms were prepared as previously described in Section 3.2.3.2. The
preformed biofilms in the wells of separate 96-well microtitre plates were rinsed with
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PBS and 100 µL of the metal-tdda-phen complexes and gentamicin (two-fold serial
dilutions); each was added to the wells containing the biofilms. Following incubation for
24 h at 37 °C, the biofilm biomass and cell viability were measured as previously
described.
The fractional inhibitory concentration (FIC) index (FICI) for combinations of testing
agents was calculated for selected P. aeruginosa strains PAO1 and CF3, according to the
equation: FICI = FIC(metal-tdda-phen complex) + FIC(gentamicin). Where, FIC(metal-tdda-phen complex) =
(MBEC* of metal-tdda-phen complex in combination with gentamicin)/(MBEC* of
metal-tdda-phen complex alone) and FIC(gentamicin) = (MBEC* of gentamicin in
combination with metal-tdda-phen complex)/(MBEC* of gentamicin alone). The
following criteria were used to interpret the FICI: ≤0.5 synergy; 0.5–4.0 indifferent; >4.0
antagonism. *The minimum biofilm eradication concentration (MBEC) was defined as
the minimal concentration of the compound required to eradicate the biofilm.
3.2.4 Effects of test complexes on individual components of the biofilm
Selected P. aeruginosa strains, PAO1 and CF3, were incubated in the presence and
absence of Cu-tdda-phen, Mn-tdda-phen and Ag-tdda-phen complexes (Table 2.1), alone
and in combination with gentamicin. To assess the effects of biofilm formation (pretreatment), experiments were set up according to Section 3.2.3.2 with strains pre-treated
to 0.5 × minimum biofilm inhibitory concentration (MBIC). To assess the effects on
established mature biofilms (post-treatment), experiments were set up according to
Section 3.2.3.3, with biofilms grown to 48 h, then treated with 0.5 × minimum biofilm
eradication concentration (MBEC) for a further 24 h. The biofilms were harvested, and
the following components, including exopolysaccharide, extracellular DNA (eDNA),
pyocyanin and pyoverdine, were analysed using the methods described below.
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3.2.4.1 Extraction and quantification of exopolysaccharide
Extraction and quantification of exopolysaccharides were performed using a modified
protocol of Tribedi and Sil (Tribedi and Sil, 2014). Biofilms were grown on a glass
surface and extracted by gentle dislodgment using a cell scraper (25 cm, Sarstedt) and
PBS. The biofilm suspension was centrifuged at 4500 g for 15 min, and the supernatant
was collected. The resulting pellet was treated with 10 mM/L EDTA, vortexed and
centrifuged again to extract cell-bound polysaccharide. The supernatant was harvested
and mixed with the first harvested supernatant. An equal volume of chilled absolute
ethanol was added to the pooled supernatant and incubated at −20 °C for 1 h. After
centrifugation at 10,000 g for 10 min, the pellet was re-suspended in sterile water and
measured by the phenol-sulphuric acid extraction method (Dubois et al., 1951). Briefly,
1 mL of the precipitated exopolysaccharide solution was mixed with an equal amount of
chilled phenol (5%) and 5 mL of concentrated sulphuric acid. The resulting red colour
was measured at 490 nm on a spectrophotometer (Hach, Bio-Sciences).
3.2.4.2 Extraction and quantification of extracellular DNA (eDNA)
Extracellular DNA (eDNA), a vital component of the biofilm, was extracted from the
matrix using a modified enzymatic method, as reported by Wu and Xi (Wu and Xi, 2009).
To release the eDNA from the matrix, the biofilms were first exposed to cellulase (10
µg/mL, Novozymes) and α-amylase (10 µg/mL, Sigma-Aldrich) to hydrolyse the
polysaccharides and incubated at 50 °C for 30 min (Loiselle and Anderson, 2003; Fleming
et al., 2017). Proteinase K (5 µg/mL, Sigma-Aldrich) was then added to the mixture for
a further 30 min to degrade proteins, and the supernatant was sequentially filtered through
a 0.45 µm and then a 0.20 µm filter to remove residual bacteria. The eDNA was
precipitated by 1 volume of cetyltrimethylammonium bromide (CTAB, Sigma-Aldrich)
solution (1% CTAB in 50 mM Tris–10 mM EDTA, pH 8.0), incubated at 65 °C for 30
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min, followed by centrifugation at 5000 g for 10 min. Each pellet was re-suspended in
high-salt TE buffer (10 mM Tris-HCL, 0.1 mM EDTA, 1 M NaCl, pH 8.0) and 0.7
volume of cold isopropanol, and incubated at −20 °C for 3 h. After centrifugation at
10,000 g for 15 min, pellets were suspended in TE buffer (10 mM Tris-HCL, 0.1 mM
EDTA, pH 8.0) and an equal volume of equilibrated phenol:chloroform:isoamyl alcohol
(25:24:1) and centrifuged again. The upper aqueous layer was transferred to a tube with
an equal volume of chloroform:isoamyl alcohol (24:1) and centrifuged again. The
supernatant was then precipitated with 2 volumes of cold ethanol (70%) and one tenth the
final volume of sodium acetate (0.3 M), incubated at −20 °C for 1 h and centrifuged at
10,000 g for 15 min. The pellets were finally washed twice with ethanol and re-suspended
in MilliQ water. The purity of the DNA was checked by determining the ratio of
absorbance at 260 nm and 280 nm (A260/280) using a MultiskanTM GO (Thermo
Scientific) UV spectrophotometer with the µDrop plate, and the DNA was quantified
fluorometrically (Qubit 3.0 Fluorometer, Invitrogen) by using SYBR Green I (Molecular
Probes), as described by Zipper (Zipper, 2003). The size of extracellular DNA was
analysed on a 1% (w/v) agarose gel in a Tris-Borate-EDTA (TBE) buffer.
3.2.4.3 Quantification of pyocyanin
Pyocyanin is a toxic, QS-controlled metabolite produced by P. aeruginosa, enabling
biofilm formation. After a 24 h treatment, the bacterial strains were centrifuged at 4500
g for 20 min, and the cell-free supernatant was used. Pyocyanin from the supernatant was
extracted and measured by the methods of Essar et al. (Essar et al., 1990). Then, 5 mL of
filtered culture supernatant was extracted with chloroform (3 mL), vortexed and
centrifuged at 4500 g for 15 min. The chloroform phase was transferred to a fresh tube
with 1 mL of 0.2 M hydrochloric acid (HCL). After centrifugation at 4500 g for 4 min,
the top layer was collected, and its absorption was measured on a spectrophotometer
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(Hach, Bio-Sciences) at 520 nm. Pyocyanin concentrations expressed as micrograms per
millilitre (µg/mL) of culture supernatant were determined by multiplying the OD at 520
nm by 17.072 (extinction coefficient).
3.2.4.4 Quantification of pyoverdine
Pyoverdine is the main siderophore of P. aeruginosa, deployed in severely iron-limited
environments to assure sufficient supply of this essential nutrient, and is found at
increased concentrations in biofilms. After a 24 h treatment, the bacterial strains were
centrifuged at 4500 g for 20 min, and the cell-free supernatant was used to measure
pyoverdine. The relative concentration of pyoverdine in all treated supernatant with
respect to control was measured through fluorescence at an excitation wavelength of 405
nm and an emission wavelength of 465 nm (Adonizio et al., 2008) with a Varioskan LUX
(Thermo Scientific) microplate reader.
3.2.4.5 Quantification of bacteria
In addition to the biofilm components, the liquid medium with bacteria was collected and
centrifuged (4500 g for 20 min), after which the supernatant was discarded, and the pellet
was re-suspended in 1 mL PBS. Ten-fold serial dilutions of the re-suspended bacteria
were then prepared and plated on nutrient agar utilising the Miles and Misra (20 μL drop)
method. Agar plates were incubated at 37 °C for 16–18 h, after which colony-forming
unit (CFU) per mL was calculated using the formula: CFU/mL = average number of
colonies for a dilution × 50 × dilution factor.
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3.2.5 Toxicity of selected test complexes toward mammalian cell model
3.2.5.1 Cell lines
Cystic Fibrosis Bronchial Epithelial Cells (CFBE41o-) cells are transformed bronchial
epithelial cells isolated from a CF patient with the Phe508/Phe508 deletion (Gruenert et
al., 2004). BEAS-2B (SV40/adenovirus 12 transformed normal bronchial epithelium)
cells were used to represent a well-characterised ‘healthy’ cell line (Reddel et al., 1993).
Dr Gordon Cooke, Department of Science, TU Dublin-Tallaght campus, kindly donated
both cell lines.
3.2.5.2 Routine maintenance and culturing
CFBE and BEAS-2B cell lines were revived from liquid nitrogen storage and placed in
minimum essential medium (MEM, Gibco) that had been supplemented with 10% foetal
bovine serum (FBS) (Gibco) and 1% of L-Glutamine (Gibco). CFBE cells require coated
flasks and plates, while BEAS-2B cells naturally adhere to the plastic. The coating
solution for the CFBE cell line consisted of bovine serum albumin (BSA, 1 mL, SigmaAldrich), fibronectin (100 µL, Sigma-Aldrich), collagen (100 µL, Sigma-Aldrich) and
MEM (8.8 mL, Gibco), which was made fresh every two weeks and stored at 4 ºC. To
coat flasks, 3-4 mL was added to a T75 cell culture flasks (Sarstedt) and left for 1 min.
Afterwards, the coating solution was removed, and the flask was air-dried for 1 h. Both
cell lines were cultured in T75 cell culture flasks (Sarstedt) and incubated at 37 °C with
5% CO2 and 95% O2 to mimic conditions in the human body. Cells were monitored each
day until 85-90 % cell confluence was reached, and they were then sub-cultured for
routine maintenance or experimentation.
Sub-culturing involved removing the cell culture media from the monolayer of cells and
washing with PBS (Sigma-Aldrich) to remove any dead or detached cells from the
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population. 3-4 mL of trypsin/EDTA solution was added to the T75 flask, and the cells
were incubated at 37 °C for 1-2 min approximately to remove cells from their monolayer
on the base of the flask. Cells were placed in 3-4 mL of fresh culture media to deactivate
the trypsin enzyme and produce the single cell stock suspension. The stock cell solution
was used for toxicity assays and to seed different cell densities in T75 stock flasks to
maintain the cells in culture.
3.2.5.3 MTT viability assay
The cytotoxic properties of metal-tdda-phen complexes Cu-tdda-phen, Mn-tdda-phen and
Ag-tdda-phen (Table 2.1) and antibiotic control gentamicin were assessed utilising the
methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay. This method is based on
reducing the yellow MTT, by the mitochondrial enzyme succinate dehydrogenase of
metabolically active cells, to an insoluble dark purple formazan crystal (Mossman, 1983).
Therefore, the resultant product formation is directly proportional to the number of viable
cells. Hence, dead cells will be metabolically inactive and will not reduce the MTT.
Cells were seeded (1x104 cells/100 µL) in 96-well flat-bottomed clear plates and allowed
to acclimatise (37 °C with 5% CO2) overnight before exposure to the metal-phen
complexes or antibiotic control. The test complexes and control stocks (10 mg/mL) were
further diluted in MEM to desired concentrations (1-500 µg/mL) and added to the seeded
96-well plates. After 24 h, a working solution of MTT (5 mg/mL in 0.1 M PBS) (Sigma,
Ireland) was prepared and 100 μL of the solution was added to each well of the 96-well
plates after the exposed cell culture media was then removed. All plates were incubated
for 3 h, and afterwards, each well was washed with sterilised PBS (Sigma, Ireland). After
the final wash, 100 μL of DMSO (ACS grade) was added to each well, and the plates
were placed on a plate shaker for 15 min to allow the coloured formazan crystals to
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develop. The plate was then read on the MultiskanTM GO (Thermo Scientific)
spectrophotometer at 595 nm.
To establish the toxicity of the test complexes, IC50 (inhibitory concentration) values were
calculated, defined as the drug concentration that caused a 50 % reduction in the number
of viable cells (Cheng & Prusoff, 1973). In addition, the selectivity index (SI) was
calculated as follows: IC50 (mammalian cells)/MIC50 (P. aeruginosa cells).
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Results
3.3.1 The inhibition of planktonic bacterial growth
Antimicrobial susceptibility testing of {[Cu(3,6,9-tdda)(phen)2].3H2O.EtOH}n (Cutdda-phen), {[Mn(3,6,9-tdda)(phen)2].3H2O.EtOH}n (Mn-tdda-phen) and [Ag2(3,6,9tdda)(phen)4].EtOH (Ag-tdda-phen), along with their phen-free precursors, [Cu(3,6,9tdda)].H2O (Cu-tdda), [Mn(3,6,9-tdda)(H2O)2].2H2O (Mn-tdda) and [Ag2(3,6,9tdda].2H2O (Ag-tdda), and their component synthetic starting materials, 3,6,9trioxaundecanedioate (tdda), phen, the simple salts MnCl2, CuCl2 and AgNO3, and the
antibiotic gentamicin were evaluated through establishing their minimum inhibitory
concentration (MIC), in accordance with the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) guidelines (EUCAST, 2017c), and the results are
summarised in Table 3.1. In accordance with the EUCAST breakpoints, control strains
ATCC 27853 and PAO1 were susceptible to the aminoglycoside antibiotic gentamicin
with MICs of 1 µg/mL (1.7 µM) and 2 µg/mL (3.5 µM), respectively, while all the clinical
isolates were deemed resistant to the antibiotic. When all of the strains were incubated in
the presence of the Cu(II), Mn(II) and Ag(I) simple salts (effectively the free metal ions)
or in the presence of the metal-free phen ligand, no clinically relevant effects against
either control strains (ATCC 27853 and PAO1) or clinical isolates (CF1-CF3) were
observed. A similar inactivity profile was witnessed for the phen-free precursor
complexes, Cu-tdda, Mn-tdda and Ag-tdda.
The metal-tdda-phen complexes were the most active against all of the P. aeruginosa
strains compared to their non-phen precursors, simple metal salts and metal-free phen.
The three metal-tdda-phen complexes all had different activity profiles across the strains.
Of the control strains (ATCC 27853 and PAO1), gentamicin had the greatest inhibitory
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action (1–2 µg/mL) (1.7–3.5 µM), followed by Ag-tdda-phen (8–32 µg/mL) (6.6–26.6
µM), with the least active being Cu-tdda-phen, and Mn-tdda-phen (both had the same
activity of ca. 16 and 32 µg/mL) (ca. 21 and 43 µM). In contrast to these control strains,
the metal-tdda-phen complexes were active against all CF clinical isolates. Against CF1,
these three metal complexes had activity (8–16 µg/mL) (10.9–13.3 µM) comparable to
that of gentamicin and were more active than this antibiotic against CF2 (8–16 µg/mL)
(10.9–13.3 µM) and CF3 (64–128 µg/mL) (53.2–174 µM). Following the MIC
measurement, only the three metal-tdda-phen complexes and gentamicin were used in
further biological assays.
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MIC µg/mL and (µM)
Test
Compound

ATCC
27853

PAO1

CF1

CF2

CF3

Mn-tdda

>256 (737)

>256 (737)

>256 (737)

>256 (737)

>256 (737)

Cu-tdda

>256 (848)

128 (424)

>256 (848)

>256 (848)

256 (848)

Ag-tdda

>256 (542)

>256 (542)

>256 (542)

>256 (542)

>256 (542)

Mn-tdda-phen

16 (21.7)

32 (43.5)

8 (10.9)

8 (10.9)

128 (174)

Cu-tdda-phen

16 (21.5)

32 (43)

8 (10.7)

8 (10.7)

64 (86)

Ag-tdda-phen

8 (6.6)

32 (26.6)

16(13.3)

16 (13.3)

64 (53.2)

Phen

128 (710)

>256
(1420)

128 (710)

128 (710)

>256
(1420)

tddaH2

>256 (1152)

>256
(1152)

>256
(1152)

>256
(1152)

>256
(1152)

MnCl2

>256 (1294)

>256
(1294)

>256
(1294)

>256
(1294)

>256
(1294)

CuCl2

>256 (1502)

>256
(1502)

>256
(1502)

>256
(1502)

>256
(1502)

AgNO3

128 (753)

256 (1507)

>256
(1507)

>256
(1507)

256 (1507)

Gentamicin

1 (1.7)

2 (3.5)

8 (13.9)

128 (222)

>256 (445)

Table 3.1 Effects of test compounds on planktonic growth of P. aeruginosa laboratory
strains (ATCC 27853 and PAO1) and clinical isolates (CF1–CF3).

3.3.2 The inhibition and disruption of biofilm
Although bacteria are unicellular organisms, they exist in natural and clinical settings,
predominately within biofilms. To determine the capacity of the test complexes to prevent
the formation of biofilms by P. aeruginosa isolates, bacterial cells were pre-treated with
the three metal-tdda-phen complexes or gentamicin for 48 h. Similarly, the post-treatment
of established mature biofilms (at 48 h) was also carried out to compare the effect of the
compounds on developing or developed biofilms. For both pre- and post-treatment
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studies, cellular viability (resazurin stain) and biofilm biomass (crystal violet stain) were
measured. Both stains could be used sequentially on the same treated biofilm sample, as
resazurin measures only viable cells, whereby crystal violet binds to the extracellular
matrix of biofilms and stains all cells present in the biomass, with no discrimination
between live or dead cells. However, one limitation of the resazurin method is that it does
not allow for the detection of persister cells that may be present in the biofilm and
therefore was measured just to accompany biofilm biomass data.
The pre-treatment of potential biofilm-forming bacterial cells with the metal-tdda-phen
complexes and gentamicin was dose-dependent for both cellular viability (Figure 3.1 and
Figure 3.2) and biofilm biomass (Figure 3.3 and Figure 3.4), inhibiting biofilm
formation at concentrations lower than the concentration required to restrict planktonic
bacterial growth, as previously outlined (Table 3.1), and with contrasting activity
between the laboratory strains and CF clinical isolates. Gentamicin was found to inhibit
biofilm formation in strains ATCC 27853 and PAO1, upwards of 50% at a concentration
of 1.7 µg/mL (2.9 µM) and 1.9 µg/mL (3.3 µM), respectively, while it required 8.6–39.2
µg/mL (7.2–53.3 µM) of the metal-tdda-phen complexes to elicit the same response. The
activity of Mn-tdda-phen, Cu-tdda-phen and Ag-tdda-phen varied across the clinical
isolates and were either comparable (CF1) or superior to gentamicin (CF2 and CF3). For
CF1, the biomass was inhibited 50% by Mn-tdda-phen at a concentration of 4 µg/mL (5.4
µM), followed by gentamicin (4.2 µg/mL, 7.3 µM), Ag-tdda-phen (6.1 µg/mL, 5.1 µM)
and Cu-tdda-phen (8.4 µg/mL, 11.3 µM). To inhibit biofilm formation by 50% in CF2,
2.5 µg/mL (3.4 µM) of Mn-tdda-phen, 4.4 µg/mL (5.9 µM) of Cu-tdda-phen, 6.2 µg/mL
(5.2 µM) of Ag-tdda-phen and 81.3 µg/mL (141.2 µM) of gentamicin were required,
respectively, while for CF3, which formed the strongest biofilm, 26.5 µg/mL (35.6 µM)
of Cu-tdda-phen, 29.7 µg/mL (40.4 µM) of Mn-tdda-phen, 33.4 µg/mL (27.8 µM) of Ag118

tdda-phen and 116.5 µg/mL (202.4 µM) of gentamicin were required to inhibit the biofilm
formation by 50%. Interestingly, pre-treatment of the clinical isolates with sub-MICs of
gentamicin increased the biomass relative to the untreated sample, which has previously
been observed (Hoffman et al., 2005).
As antibiotics are predominantly administered in clinical practice to counteract an
existing infection, evaluating the effects on established mature biofilms (post-treatment)
provided a more pragmatic insight into the anti-biofilm activity of the test complexes.
None of the test complexes caused the complete eradication of P. aeruginosa biofilms at
the concentrations presented by cellular viability (Figure 3.1 and Figure 3.2) and biofilm
biomass (Figure 3.3 and Figure 3.4). The activity of gentamicin diminished considerably
across all strains when administered to established biofilms, a feature commonly reported
(Ciofu and Tolker-Nielsen, 2019). While gentamicin maintained moderate activity
against ATCC 27853, with the minimum biofilm eradication concentration (MBEC)
removing 50% of the biomass (MBEC50) being 19.6 µg/mL (34.1 µM), the MBEC50 for
PAO1 was considerable larger (181 µg/mL, 314 µM). At the highest concentration of
gentamicin examined (256 µg/mL, 445 µM) against the clinical isolates CF1, CF2 and
CF3, there was still approximately 52%, 67% and 98% biofilm remaining, respectively,
relative to the untreated samples. It is well known that, as a mature biofilm is established,
the extracellular matrix slows or prevents the penetration of antibiotics into the microbial
communities embedded in it. Surprisingly, against the clinical isolates, the metal-tddaphen complexes all showed similar activity (MBEC50 range ca. 12–51 µg/mL, 14–70 µM)
and were superior to gentamicin.
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Post-treatment

Pre-treatment

Figure 3.1 Cell viability – Laboratory strains. Effect of metal-tdda-phen complexes
(Mn-tdda-phen, Cu-tdda-phen and Ag-tdda-phen) and gentamicin on both inhibiting
biofilm formation (pre-treatment) and dismantling established biofilms (post-treatment)
of laboratory strains (ATCC 27853 and PAO1)
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Pre-treatment

Post-treatment

Figure 3.2 Cell viability – Clinical isolates. Effect of metal-tdda-phen complexes (Mntdda-phen, Cu-tdda-phen and Ag-tdda-phen) and gentamicin on both inhibiting biofilm
formation (pre-treatment) and dismantling established biofilms (post-treatment) of
clinical isolates (CF1-CF3).
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Pre-treatment

Post-treatment

Figure 3.3 Biofilm biomass – Laboratory strains. Effect of metal-phen complexes
(Mn-tdda-phen, Cu-tdda-phen and Ag-tdda-phen) and gentamicin on both inhibiting
biofilm formation (pre-treatment) and dismantling established biofilms (post-treatment)
of laboratory strains (ATCC 27853 and PAO1). Asterisks indicate significance (p > 0.05)
relative to the untreated control.
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Pre-treatment

Post-treatment

Figure 3.4 Biofilm biomass – Clinical isolates. Effect of metal-phen complexes (Mntdda-phen, Cu-tdda-phen and Ag-tdda-phen) and gentamicin on both inhibiting biofilm
formation (pre-treatment) and dismantling established biofilms (post-treatment) of
clinical isolates (CF1-CF3). Asterisks indicate significance (p > 0.05) relative to the
untreated control.
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3.3.3 Metal-tdda-phen complexes enhanced the anti-biofilm activity of
gentamicin
Biofilm-associated tolerance is multifactorial and is attributed to the restricted penetration
of the antimicrobial agent and the different metabolic states and virulence factors of the
microbial community within the biofilm. Current research approaches aimed at increasing
the likelihood of biofilm eradication include the use of non-antibiotic complexes, either
alone or in combination with conventional antibiotics (Lebeaux et al., 2014; Kadam et
al., 2019; Cao et al., 2020; Thi et al., 2020; Zhang et al., 2020). The combination of
metal-tdda-phen complexes (0–64 µg/mL) with gentamicin (0–32 µg/mL) was tested on
established mature (48 h) biofilms of P. aeruginosa using the checkerboard assay, and
the results are presented in Figure 3.5 for strains ATCC 27853 (A–C) and PAO1 (D–F),
Figure 3.6 for strains CF1 (G–I) and CF2 (J–L) and Figure 3.7 for CF3 (M–O). To
varying degrees, adding the metal-tdda-phen complexes enhanced the anti-biofilm
activity of gentamicin across all strains. At the highest concentration of gentamicin alone
(32 µg/mL, 55.5 µM), ca. 19–37% of the biofilm was removed from reference strains
ATCC 27853 and PAO1, whilst the same concentration of gentamicin, combined with 4
µg/mL (3.3–5.4 µM) of the metal-tdda-phen complexes, was able to degrade over 50%
of the biofilm. Increasing the concentration of the added metal-tdda-phen complexes
prompted the further disintegration of the established biofilm. Most noteworthy is the
combination of the antibiotic with Mn-tdda-phen and Ag-tdda-phen at 64 µg/mL (53.2
and 87 µM, respectively), which removed 99.6% and 99.1% of PAO1 biofilm,
respectively. The enhanced activity was also maintained across the clinical isolates, with
the combined metal-tdda-phen/gentamicin combinations presenting a dose-dependent
response. At the highest test concentration, the combination of metal-tdda-phen
complexes (64 µg/mL, 53.2–87 µM) with gentamicin (32 µg/mL, 55.5 µM) dismantled
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over 90% of the mature biofilm for all three metal-tdda-phen complexes in CF2 (93.5–
96.5% dismantled) and CF3 (93.9–99.6%), while in CF1, the combination results were:
Ag-tdda-phen (92.8%), Cu-tdda-phen (86.1%), Mn-tdda-phen (83.1%).
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Figure 3.5 Laboratory strains - Heat map representation of the percentage of biofilm removal of 48 h established biofilms of laboratory strains,
ATCC 27853 and PAO1 by combinations of metal-tdda-phen complexes with gentamicin. Mn-tdda-phen and gentamicin (A, D); Cu-tdda-phen
and gentamicin (B, E); Ag-tdda-phen and gentamicin (C, F). The heat map shows the percentage of biofilm removed with respect to the untreated
sample.
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Figure 3.6 Clinical isolates - Heat map representation of the percentage of biofilm removal of 48 h established biofilms of clinical isolates, CF1
and CF2 by combinations of metal-tdda-phen complexes with gentamicin. Mn-tdda-phen and gentamicin (G, J); Cu-tdda-phen and gentamicin
(H, K); Ag-tdda-phen and gentamicin (I, L). The heat map shows the percentage of biofilm removed with respect to the untreated sample.
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Figure 3.7 Clinical isolates continued - Heat map representation of the percentage of biofilm removal of 48 h established biofilms of clinical
isolate CF3 by combinations of metal-tdda-phen complexes with gentamicin. Mn-tdda-phen and gentamicin (M); Cu-tdda-phen and gentamicin
(N); Ag-tdda-phen and gentamicin (O). The heat map shows the percentage of biofilm removed with respect to the untreated sample.
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The fractional inhibitory concentration (FIC) index (FIC I) for combinations of metaltdda-phen complexes with gentamicin was calculated according to the equation: FICI =
FIC(metal-tdda-phen complex) + FIC(gentamicin). Results for the interactions between the metal-tddaphen complexes and gentamicin combinations in the selected P. aeruginosa strains,
PAO1 and CF3, are given in Table 3.2. The data revealed synergistic activity (FIC ≤ 0.5)
against the established mature biofilms for all metal-tdda-phen/gentamicin combinations.

Test complexes

Organism

FIC Index

Interpretation

PAO1

0.141

Synergistic

CF3

0.133

Synergistic

PAO1

0.313

Synergistic

CF3

0.156

Synergistic

PAO1

0.141

Synergistic

CF3

0.133

Synergistic

Mn-tdda-phen + Gentamicin

Cu-tdda-phen + Gentamicin

Ag-tdda-phen + Gentamicin
Table 3.2 Results of interaction studies for metal-tdda-phen/gentamicin combinations
against PAO1 (reference strain) and CF3 (clinical isolate) in established biofilms.

3.3.4 Toxicity of metal-tdda-phen complexes against mammalian cells
In vitro growth inhibitory data (IC50 values) for the metal-tdda-phen complexes against
mammalian CFBE and BEAS-2B epithelial cells are listed in Table 3.3. Both cell lines
were more tolerant of gentamicin (CFBE IC50 = 335 µg/mL, 617 µM; BEAS-2B IC50 =
320 µg/mL, 556 µM) and metal-tdda-phen complexes Mn-tdda-phen (CFBE IC50 = 306
µg/mL, 416 µM; BEAS-2B IC50 = 257 µg/mL, 350 µM) and Ag-tdda-phen (CFBE IC50
= 264 µg/mL, 219 µM; BEAS-2B IC50 = 233 µg/mL, 194 µM). Cu-tdda-phen was
remarkably more toxic to the CFBE (IC50 = 8 µg/mL, 11 µM) and BEAS-2B (IC50 = 6
µg/mL, 8 µM) cells. This toxicity profile has also been reported by Gandra et al., (2017)
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and McCarron et al., (2018). There was no significant differences between the CF and
normal cell lines.
The selectivity of compounds to microbial cells is an essential criterion for evaluating the
cytotoxic action of an antibacterial agent. This parameter is characterized by a selectivity
index (SI) value, calculated as the ratio between the IC50 for mammalian cells and the
MIC50 value for bacterial cells. The greater the SI value, the higher the selectivity of the
compound to bacteria. The SI for metal-tdda-phen complexes and gentamicin are in Table
3.3 for the CF cell line (CFBE) and healthy cell line (BEAS-2B). Aside from prescription
antibiotic gentamicin, which is known to be selective for prokaryotes by inhibiting
bacterial protein synthesis by binding to 30S ribosomes, the overall mean SI present as
Mn-tdda-phen >Ag-tdda-phen > Cu-tdda-phen. Observing the clinical isolates
individually, gentamicin's SI drops considerably compared to the reference strains. For
instance, the SI of gentamicin for ATCC 27853 was 710 for the CFBE cell line and 640
BEAS-2B cell line; however it was 1 for CF3 for both cell lines. This was to be expected
as the activity of gentamicin declined considerably against this isolate. The SI for metaltdda-phen complexes Mn-tdda-phen and Ag-tdda-phen were 5-4 and 8-7 for CFBE and
BEAS-2B, respectively. This is due to the heightened activity of these complexes towards
CF3.
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Test
Compounds

IC50 µg/mL
and (µM)

Selectivity Index (SI)

Overall
mean
SI

Mn-tdda-phen

306 (416)

ATCC
27853
38

Cu-tdda-phen

8 (11)

1

1

2

2

0

1

Ag-tdda-phen

264 (219)

66

17

33

33

8

31

Gentamicin

355 (617)

710

355

89

6

1

232

Test
Compounds

CFBE

PAO1

CF1

CF2

CF3

19

77

77

5

43

IC50 µg/mL
and (µM)

Selectivity Index (SI)

Overall
mean
SI

Mn-tdda-phen

257 (350)

ATCC
27853
32

Cu-tdda-phen

6 (8)

1

0

2

2

0

1

Ag-tdda-phen

233 (194)

58

15

29

29

7

28

Gentamicin

320 (556)

640

320

80

5

1

209

BEAS-2B

PAO1

CF1

CF2

CF3

16

64

64

4

36

Table 3.3 In vitro IC50 values presented as µg/mL and (µM) for CFBE (CF cell line) and
BEAS-2B (healthy cell line) epithelial cells and calculated selectivity values (SI) values
for the metal-tdda-phen complexes and gentamicin control. Larger SI values indicate
greater cell selectivity

3.3.5 Metal-tdda-phen complexes affect individual components of a biofilm
In biofilms, microbes are held together by a protective polymeric extracellular matrix
(ECM) comprised of polysaccharides, extracellular DNA (eDNA), and virulence factors
such as pyocyanin and pyoverdine. To understand how the metal-tdda-phen complexes
affect both the formation of biofilms (pre-treatment) and the reduction of established
mature biofilms (post-treatment), MBIC50 and MBEC50 doses were applied to P.
aeruginosa strains PAO1 and CF3, alone and in the presence of gentamicin, and the
results are presented in Figure 3.8 and 3.9.
Exopolysaccharide is an important component of the ECM for the formation and
stabilisation of the biofilm structure, and therefore the reduction of this component would
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be a beneficial target for antimicrobial agents. The pre-treatment of PAO1 and CF3 with
metal-tdda-phen complexes caused an attenuation in exopolysaccharides. Exposure to
Mn-tdda-phen caused the greatest reduction of exopolysaccharide in PAO1 (74% ± 4),
followed by Cu-tdda-phen (67% ± 1), Ag-tdda-phen (49% ± 6) and gentamicin (47% ±
9). Combined pre-treatment of Mn-tdda-phen, Cu-tdda-phen and Ag-tdda-phen with
gentamicin reduced exopolysaccharides in PAO1 by 64% ± 6, 72% ± 5 and 81% ± 5,
respectively, reducing the efficacy of Mn-tdda-phen as a single agent, but enhancing the
effect of the other two metal-tdda-phen complexes. Pre-treatment of the clinical isolate
CF3 with the test agents saw a reduction in the activity of metal-tdda-phen complexes
(52–55% ± 7) and gentamicin (38% ± 6) against the exopolysaccharides, compared to
that seen for PAO1. However, in contrast to PAO1, the Mn-tdda-phen/gentamicin
combination was the most effective (77% ± 1) at reducing exopolysaccharides in the
clinical isolate. For the post-treatment studies, the biofilms were allowed to grow for 48
h and then exposed to the test complexes for a further 24 h. For PAO1, the reduction of
exopolysaccharides by the metal-tdda-phen complexes (41–46% ± 9) was similar to that
observed for gentamicin (44% ± 9), while the combined treatment again intensified the
activity, prompting a 73–78% reduction in exopolysaccharide. For the treatment of CF3,
gentamicin was the least effective and Ag-tdda-phen the most when used singularly (the
latter complex reduced the exopolysaccharide in the biofilm by 61% ± 9). For the metaltdda-phen/gentamicin combinations, activity increased somewhat uniformly (72–77%
reduction).
Extracellular DNA (eDNA) is an essential constituent of the ECM. It facilitates biofilm
formation and enhances biofilm strength and stability by bridging divalent ions to other
components in the matrix. It has also been observed that eDNA increases the tolerance of
P. aeruginosa biofilms toward cationic antibiotics, such as aminoglycosides, by binding
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directly to the antibiotic and preventing penetration (Chiang et al., 2013). The pretreatment of PAO1 and CF3 with metal-tdda-phen complexes or gentamicin singly did
not cause any appreciable difference in eDNA content compared to the untreated sample.
The combination treatments were unilaterally more effective, with Ag-tddaphen/gentamicin inhibiting eDNA in PAO1 by 50% ± 11, Cu-tdda-phen/gentamicin by
49% ± 4 and Mn-tdda-phen/gentamicin 34% ± 6. A similar trend was observed for CF3.
Except for gentamicin, the post-treatment of established biofilms of both strains with
single metal-tdda-phen complexes was more effective than pre-treatment. A dramatic
improvement in eDNA inhibition was witnessed when both of the established biofilms
were exposed to all of the metal-tdda-phen/gentamicin combinations (66–75% reduction),
with Cu-tdda-phen/gentamicin being the most aggressive.
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A

C

Pre-treatment

B

Post-treatment

D

Figure 3.8 Effects of metal-tdda-phen complexes alone, gentamicin alone, and metaltdda-phen complexes with gentamicin on both the formation of biofilm (pre-treatment)
and reduction of established biofilm (post-treatment) of PAO1 and CF3: The percentages
of exopolysaccharide (A, B) and eDNA (C, D) remaining after treatment (relative to
untreated biofilms) are given. (*: P < 0.05, **: P < 0.01, ***: P < 0.001)

The prevalence and progression of infection by P. aeruginosa in the host is dependent
upon the secretion of numerous extracellular molecules, such as the virulent factors,
pyocyanin and pyoverdine. Pyocyanin is one of the major components dictating the
advancement of infection and biofilm formation, especially in CF patients, and is under
quorum sensing (QS) control. It is redox-active and promotes eDNA release in P.
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aeruginosa by inducing cell lysis mediated via hydrogen peroxide production. The extent
of pyocyanin production varied amongst the strains of P. aeruginosa tested. Untreated
PAO1 manufactured about 10 µM of pyocyanin, while the untreated CF clinical isolate,
CF3, produced upwards of 80 µM. The results of the pyocyanin assay are presented as a
percentage of production relative to the untreated sample for comparison (Figure 3.9).
Pre-treatment with the Ag-tdda-phen/gentamicin combination significantly reduced
pyocyanin in both PAO1 (80% ± 9) and CF3 (65% ± 6). The manganese and copper
metal-tdda-phen/gentamicin combinations also reduced pyocyanin production compared
to their treatment as a single agent. Surprisingly, the pre-treatment of PAO1 with Cutdda-phen alone actually enhanced the production of pyocyanin (106% ± 8), and
gentamicin also had a similar positive influence on CF3 (116% ± 13). In general, the
single test compounds and their gentamicin combinations were much less effective at
reducing pyocyanin production by the two mature biofilms. Although Ag-tdda-phen
alone increased pyocyanin in PAO1 (134%), the Ag-tdda-phen/gentamicin combination
caused the greatest reduction of pyocyanin (35% ± 9 in PAO1 and 49% ± 7 in CF3).
Pyoverdine, the main siderophore of P. aeruginosa, has a high affinity for ferric (Fe3+)
iron and thus is responsible for obtaining extracellular iron, an essential nutrient for
biofilm formation (Kang et al., 2018). In addition, pyoverdine can regulate the production
of multiple bacterial virulence factors. In the pre-treatment studies (Figure 3.9), it was
found that only the Ag-tdda-phen/gentamicin caused a notable reduction in pyoverdine
production (by 16% ± 5 in PAO1 and 49% ± 6 in CF3), with most of the remaining test
substances enhancing production (by up to 134%). Post-treatment of the two established
biofilms with the single metal-tdda-phen compounds had little or no effect on pyoverdine
production with respect to the control. Whilst gentamicin singly and the Mn-tddaphen/gentamicin combination caused a sizable reduction in pyoverdine in the reference
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strain (24% ± 8 and 26% ± 9, respectively) and the clinical isolate (30% ± 8 and 41% ±
9, respectively), Cu-tdda-phen/gentamicin and Ag-tdda-phen/gentamicin were only
effective against CF3 (41% ± 9 and 48% ± 7 reduction, respectively).

Pre-treatment

Post-treatment

A

B

C

D

Figure 3.9 Effects of metal-tdda-phen complexes alone, gentamicin alone, and metaltdda-phen complexes with gentamicin on both the formation of biofilm (pre-treatment)
and reduction of established biofilm (post-treatment) of PAO1 and CF3: The percentages
of pyocyanin (A, B) and pyoverdine (C, D) remaining after treatment (relative to
untreated biofilms) are given. (*: P < 0.05, **: P < 0.01, ***: P < 0.001).
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In addition to the components of the biofilm, the liquid culture they were grown in was
aspirated, and the bacterial cells present were assessed through the plate count method.
As presented in Figure 3.10, untreated PAO1 had a 7.6 × 108 colony-forming unit
(CFU)/mL, while pre-treatment with metal-tdda-phen complexes saw a slight reduction
of 7.1–5.2 × 108 CFU/mL and gentamicin had 3.9 × 108 CFU/mL. Complementing the
biofilm component data, the combination of both the metal-tdda-phen complexes with
gentamicin saw the greatest reduction of viable cells, with Ag-tdda-phen demonstrating
a one-fold reduction to 7.9 × 107 CFU/mL. Pre-treatment of CF3 with gentamicin reduced
the viable cells from 7.5 × 108 CFU/mL to 7 × 108 CFU/mL, followed by Cu-tdda-phen
(5.9 × 108 CFU/mL), Ag-tdda-phen (5.5 × 108 CFU/mL) and Mn-tdda-phen (5.4 × 108
CFU/mL). Akin to PAO1, metal-tdda-phen/gentamicin reduced viable cells in the culture
to 3.3 × 108 CFU/mL–2.2 × 108 CFU/mL. Post-treatment of PAO1 and CF3 had similar
trends, with metal-tdda-phen complexes slightly outperforming gentamicin as singular
agents. However, the combination of Mn-tdda-phen/gentamicin and Cu-tddaphen/gentamicin saw a 2-fold reduction in viable cells and Ag-tdda-phen/gentamicin a 3fold reduction.
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Figure 3.10 Viable cells were measured after pre- and post-exposure to 0.5 × MBIC and
0.5 × MBEC of metal-tdda-phen complexes alone, gentamicin alone, and metal-tddaphen complexes with gentamicin. The results are the means ± standard errors of the means
from three independent experiments, with viable counts done in triplicate. (*: P < 0.05,
**: P < 0.01, ***: P < 0.001).
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Discussion
Pseudomonas aeruginosa is the most prevalent pathogen in the lungs of cystic fibrosis
(CF) patients and the leading cause of morbidity and mortality (Stefani et al., 2017).
Ireland has the highest rate of CF per capita in the world, with approximately 7 in every
10,000 people living with the disease, almost three times the average rate in other
European countries and the United States (Cystic Fibrosis Ireland, 2018). Conventional
antibiotic treatment strategies for P. aeruginosa in CF patients are only partially effective
and contribute to antibiotic resistance. In addition, P. aeruginosa predominantly resides
in biofilms in the lungs of CF patients, which are also up to 1000 times more resistant to
antibiotic treatment than their planktonic counterparts.
This chapter investigated the antibacterial and anti-biofilm capabilities of copper(II),
manganese(II), and silver(I) complexes containing 1,10-phenanthroline (phen) and 3,6,9trioxaundecanedioate (tdda) ligands against P. aeruginosa strains isolated from the lungs
of CF patients in Irish hospitals. These metal complexes have previously shown antibacterial and anti-fungal capabilities, and including the phen ligand is key to their
antimicrobial properties. Furthermore, the tdda dianionic ligand drastically enhances the
water solubility of the complex. The results in Table 2.3 demonstrate the superior potency
of the metal-tdda-phen complexes compared to the anti-P. aeruginosa activities of the
metal-free phen, tddaH2 and the simple copper(II), manganese(II) and silver(I) salts
(essentially free metal ions). The antibiotic gentamicin was the most active compound
against the reference strains (ATCC 27853 and PAO1). Whereas the efficacy of
gentamicin was dampened across the clinical isolates (CF1–CF3), the metal-tdda-phen
complexes maintained clinically relevant activity. Taking the mean minimum inhibitory
concentration (MIC) for each bacterial strain, the order of planktonic growth inhibition
by the metal-tdda-phen complexes was Cu-tdda-phen > Ag-tdda-phen > Mn-tdda-phen.
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While the viability profile of the metal complexes within mammalian cells had the same
overall cadence, resulting in Mn-tdda-phen having the greatest selectivity index and Cutdda-phen demonstrating the worst. Gandra et al. (2017) also reported that the Mn(II)
complex was exceptionally well tolerated by the mammalian lung cell line, A549, with a
concentration capable of reducing cellular viability by 50% (CC50) of 261.67 mg/L
validating the observations within this study.
The biofilm lifecycle of P. aeruginosa is an important virulence attribute for establishing
infections in CF patients. All of the metal-tdda-phen complexes could inhibit biofilm
formation (pre-treatment) in terms of both biofilm biomass and cellular viability,
outperforming gentamicin across the three clinical isolates. Moreover, all three of the
metal-tdda-phen complexes could disrupt the established mature biofilm (post-treatment)
of the P. aeruginosa strains in a dose-dependent manner. Similar activity has previously
been reported by Viganor et al. (2016) for the related complex cations,
[Ag(phendione)2]+1 and [Cu(phendione)3]+2 (phendione = 1,10-phenanthroline-5,6dione), against 32 Brazilian clinical isolates of P. aeruginosa. Moreover, the same
phendione complexes exhibited anti-biofilm action against carbapenemase-producing
Acinetobacter baumannii, another multidrug-resistant (MDR) Gram-negative bacterium
(Ventura et al., 2020). Presently, the MIC of Mn-tdda-phen for CF3 was 128 µg/mL (174
µM), and when an established biofilm of this strain is treated at the same concentration,
it is reduced by ~79%. The MIC of both Cu-tdda-phen and Ag-tdda-phen was 64 µg/mL
(86 and 53.2 µM, respectively) for CF3, and the reduction in biofilm biomass after
treatment at this concentration was ~70% and ~51%, respectively. These anti-biofilm
studies indicated the potential for enhanced anti-biofilm activity by combining the metaltdda-phen complexes with gentamicin. At the highest concentration of the metal-tddaphen complexes (64 µg/mL) in combination with gentamicin (32 µg/mL), there was
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>90% biofilm removal for CF2 and CF3 and >83% for CF1, and the fractional inhibitory
concentration (FIC) index showed a positive synergism for all three metal-tdda-phen
complexes in the presence of gentamicin. A clinical study in Ireland on CF P. aeruginosa
clinical isolates and the same laboratory reference strains (ATCC 27853 and PAO1)
showed that tobramycin (aminoglycoside) and ceftazidime (cephalosporin) was the only
effective combination to show positive synergism (FIC ≤ 0.5) against a mature biofilm of
a single clinical isolate at a concentration of 64 mg/L, in vitro (Kapoor and Murphy,
2018). However, as mentioned earlier, the evolving antibiotic resistance is problematic
and of concern when considering combinations of established antibiotics for treating P.
aeruginosa infections in CF patients. Novel therapeutics, where resistance is less likely
to be a factor, would be favourable for future clinical interventions.
Since significant activity was evident for the metal-tdda-phen complexes, acting either
alone or in combination with gentamicin, against biofilms formed by the PAO1 reference
strain and the CF3 clinical isolate, individual components of the biofilm were tested to
see if there was a specific molecular target. These targets included exopolysaccharide and
extracellular DNA (eDNA), two critical components of the polymeric extracellular matrix
(ECM), and the virulence factors, pyocyanin and pyoverdine, found in the ECM. Many
P. aeruginosa strains can synthesise the three exopolysaccharides, alginate, Psl, and Pel,
which play an essential role in biofilm formation and stabilising its structure. Strains
isolated from CF patients are commonly found to over-produce alginate, and biofilms of
these strains have been observed to have a much higher resistance to aminoglycosides,
such as gentamicin, than their isogenic non-mucoid strain (Hentzer et al., 2001).
Additional studies have also implicated both Psl (Billings et al., 2013) and Pel (Colvin et
al., 2011) in the biofilm-associated tolerance towards aminoglycosides, thus making
exopolysaccharides an essential component of the ECM. It is thought that Psl associates
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with eDNA through hydrogen bonding to form eDNA–Psl fibres in the centre of pellicles
(Wang et al., 2015), and cationic Pel cross-links eDNA in the biofilm stalk via ionic
interactions (Jennings et al., 2015). eDNA is known to chelate divalent metal cations,
such as Mg2+, Mn2+, Zn2+ and Ca2+ (Mulcahy et al., 2008), with the latter creating strong
electrostatic interactions which give the biofilm integrity (Das et al., 2014), and there
have been biofilm studies conducted on the use of metal chelators, such as
ethylenediaminetetraacetic acid (EDTA). In this context, EDTA alone was found to be
1000-fold more destructive to a PAO1 biofilm than gentamicin, and a combination of
EDTA (50 mM) with gentamicin (50 μg/mL) caused a complete reduction of biofilm
viability (>99%) and detachment of cells (Banin et al., 2006). This chapter demonstrated
that the enhanced anti-biofilm activity of metal-tdda-phen/gentamicin combinations was
associated with a reduction in both exopolysaccharide and eDNA. It has been widely
reported that the treatment of P. aeruginosa biofilms with DNase I, an enzyme that
cleaves DNA, significantly disrupts biofilms and enhances antibiotic penetration (Tetz et
al., 2009). As CF sputum is rich in eDNA (<1–20 mg/mL), this is thus a desirable
molecular target. The copper(I) complex cation, [Cu(phen)2]+, in the presence of reducing
agents, was the first reported example of a novel artificial metallonuclease possessing
potent DNA cleavage capability (Sigman et al., 1979). Our group has previously shown
that copper(II)-dicarboxylate-phen complexes also display effective nuclease capability,
even without added reductant (Kellett et al., 2011b). In this context, treating a mature
biofilm with Cu-tdda-phen prompted the most significant decrease in eDNA in both the
reference and clinical isolates. Our data suggest that the metal-tdda-phen complexes cause
biofilm destabilization by interacting with extracellular DNA and exopolysaccharides in
the ECM, possibly through Psl. However, further studies will be required to establish the
role of Psl and Pel in these interactions. This destabilization could allow the previously
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inhibited gentamicin into the biofilm to enhance its cytotoxic action, which the viable cell
counts have further supported.
The encouraging results prompt further investigations into the ability of metal-tdda-phen
complexes to act on P. aeruginosa clinical isolates in vivo using larvae of the greater wax
moth Galleria mellonella.
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Chapter 4.

In Vivo evaluation of Galleria
mellonella larvae response to
selected test complexes

Chapter 4 (objective 3) is based on the following paper: O’Shaughnessy M, Piatek M,
McCarron P, McCann M, Devereux M, Kavanagh K, Howe O. In vivo activity of metal
complexes containing 1,10-phenanthroline and 3,6,9-trioxaundecanedioate ligands
against Pseudomonas aeruginosa infection in Galleria mellonella larvae. Biomedicines.
2022; 10(2):222.
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Introduction
The Gram-negative human pathogen, P. aeruginosa, is a noteworthy contributor to
elevated AMR prevalence and is frequently isolated from a diverse range of acute,
chronic, and biofilm-associated infections. Most strains now present as multidrugresistant (MDR), which increases morbidity in infected patients, particularly those with
cystic fibrosis (CF) (Garcia-Nuñez et al., 2017; Jurado-Martín et al., 2021). The activity
profile of manganese(II), copper(II), and silver(I) complexes incorporating 1,10phenanthroline (phen) and 3,6,9-trioxaundecanedioate (tdda) were previously presented
with effects against P. aeruginosa strains of CF patients in Chapter 3. The ability to act
on P. aeruginosa clinical isolates synergistically with gentamicin on mature biofilms
prompted the in vivo studies, using larvae of the greater wax moth Galleria mellonella,
reported within.
A critical aspect in evaluating an antibacterial drug is the pre-clinical test for toxicity and
effectiveness in suitable animal models. G. mellonella larvae are a valuable model for
assessing in vivo toxicity and mechanism of action studies of novel drugs. Low cost, ease
of handling and maintenance are desirable factors for using the larval model. They have
a relatively short life cycle (40-60 days) and can survive at 37 °C, which is an important
attribute when assessing virulence and treating human pathogens (Browne et al., 2014).
Therefore, G. mellonella has been extensively utilized to assess both pathogens and drug
responses, as presented in Figure 4.1. Such studies evaluate the pathogenicity of bacterial
and fungal pathogens (Kavanagh and Reeves, 2004; Sheehan and Kavanagh, 2019;
Sheehan et al., 2019), study biofilm formation (Borghi et al., 2014), measure the in vivo
toxicity of novel compounds (Thornton et al., 2016; Rochford et al., 2018) and determine
the in vivo efficacy of established (Krezdorn et al., 2014; Ignasiak and Maxwell, 2017)
and novel antimicrobial agents (McCann et al., 2012b; Gandra et al., 2020). Moreover,
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studies assessing G. mellonella and mammalian models have reported a correlation in the
results obtained. Jander et al. (2000) demonstrated similar virulence patterns in larvae
and mice injected with P. aeruginosa mutants, and Brennan et al. (2002) identified
corresponding virulence patterns between Candida albicans in the aforementioned
models. The generation of comparable data is due to the high degree of structural and
functional analogies across human innate immunity and the insect immune response,
composed of physical barriers and interconnected cellular and humoral responses
(Browne et al., 2013; Sheehan et al., 2018).

Figure 4.1 Applications of Galleria mellonella for pathogen and drug analysis. Adapted
from (Kavanagh and Sheehan, 2018; Pereira et al., 2020).
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Although the larvae do not have an adaptive immune system, they possess sophisticated
systems for non-self-recognition and defence reactions. The hemolymph of G. mellonella
consists of several hemocyte types, of which plasmatocytes and granular cells are the
most common. These cells are similar to human neutrophils and macrophages, involved
in phagocytosis and encapsulation, resulting in an oxidation burst (Bergin et al., 2005).
The humoral response consists of effector molecules such as antimicrobial peptides
(AMPs), opsonins, and lytic enzymes that appear in the hemolymph to remove pathogens.
In particular, AMPs have been found to destabilise membranes of invading
microorganisms (Wu et al., 2018) as a mode of action. The humoral system also includes
activating the phenoloxidase pathway resulting in melanisation species hydrogen
peroxide and superoxide during the pathogen encapsulation (Junqueira et al., 2018).
In this chapter, the pathogenicity of laboratory strains and clinical isolates of P.
aeruginosa using this in vivo model of G. mellonella and the further therapeutic potential
of manganese(II), copper(II), and silver(I) complexes incorporating 1,10-phenanthroline
(phen) and 3,6,9-trioxaundecanedioate (tdda) ligands were assessed. Pathogenicity was
characterised by the density of hemocytes and bacterial burden in the hemolymph of the
larvae at several time points during infection with the clinical strains of P. aeruginosa.
Simultaneously the ability of the metal-tdda-phen complexes alone and combined with
standard antibiotic gentamicin to interfere with the larval immune response was
demonstrated. The antibacterial activity of the metal-tdda-phen complexes, alone and
combined with gentamicin, against the P. aeruginosa laboratory strains and clinical
isolates inoculated in G. mellonella, are also presented.
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Materials and Methods
4.2.1 Pseudomonas aeruginosa strains and culture conditions
P. aeruginosa (CF1, CF2, and CF3) isolated from cystic fibrosis (CF) patients at local
Irish hospitals with multidrug-resistant mechanisms (Table 3.1) and standard laboratory
strains ATCC 27853 and PAO1 were used in this chapter. Bacterial stocks were
maintained on nutrient agar (Lab M) plates. Before experiments, a single colony was
transferred to nutrient broth (Lab M) and grown at 37 °C and 200 rpm overnight. Bacterial
cultures were adjusted by absorbance (OD600), harvested by centrifugation (2000 g), and
washed twice with phosphate-buffered saline (PBS) prior to G. mellonella inoculation
(Desbois and Coote, 2012) to remove secreted virulence factors.
4.2.2 Galleria mellonella larvae monitoring
Larvae of the greater wax moth G. mellonella (Livefoods Direct Ltd) were stored in wood
chippings at 15 °C in darkness to prevent pupation. Larvae weighing 0.25±0.05 g with no
cuticle discolouration were selected. Ten healthy larvae per treatment and controls (n =
3) were used per experimental parameter. All experiments were performed independently
on three separate occasions.
4.2.3 Test complexes
The metal complexes used for this chapter (Table 2.1) were {[Cu(3,6,9tdda)(phen)2]·3H2O·EtOH}n (Cu-tdda-phen), {[Mn(3,6,9-tdda)(phen)2]·3H2O·EtOH}n
(Mn-tdda-phen) and [Ag2(3,6,9-tdda)(phen)4]·EtOH (Ag-tdda-phen). In addition, the
free ligands, 1,10-phenanthroline (phen) and 3,6,9-trioxaundecanedioate (tdda), were
also assessed. Gentamicin (Sigma-Aldrich) was also incorporated as all three clinical
isolates demonstrated resistance to this antibiotic (Table 3.1).
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4.2.4 Galleria mellonella infection studies with Pseudomonas aeruginosa strains
4.2.4.1 Bacterial infection of G. mellonella
In the pathogenicity studies, ATCC 27853, PAO1, CF1, CF2, and CF3 were investigated
by preparing a dilution series (3x100 to 3x105 CFU/mL) of each isolate, and ten larvae (n
= 3) were inoculated through the last left pro-leg (as per Figure 4.2) into the hemocoel
using a Myjector U-100 insulin syringe (Terumo Europe NV) with 20 μL of washed
cultures. Undisturbed larvae and larvae inoculated with PBS were utilised as controls.
The injected larvae were placed in petri dishes containing wood shavings and were
incubated at 37 °C. Mortality, cuticle discolouration and response to touch were recorded
96 h post-injection.

Figure 4.2 The underneath of G. mellonella exposing all pro-legs (left). Inoculation of G.
mellonella into the last left pro-leg (right)
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4.2.4.2 Determination of hemocyte density
Hemocyte density was determined after the inoculation of larvae with laboratory strains
ATCC 27853 (at 3x104 CFU/mL) and PAO1 (at 3x100 CFU/mL) and clinical isolates,
CF1, CF2 (both at 3x103 CFU/mL), and CF3 (at 3x100 CFU/mL). A PBS control and
undisturbed larvae were included. Changes in hemocyte density were measured at 0, 2,
4, 6, 12, and 24 h post-inoculation by piercing the back of the anterior end of five larvae
(n = 3) with a sterile needle (25 gauge; BD Plastipak). Hemolymph was collected (50 µL)
into a pre-chilled tube and diluted in cold PBS containing N-phenylthiourea (SigmaAldrich) to reduce clotting and prevent melanisation (Kelly and Kavanagh, 2011). Cell
density was calculated with a hemocytometer (Neubauer Tiefe) under the microscope.
4.2.4.3 Determination of G. mellonella hemolymph burden of P. aeruginosa
Groups of five larvae (n = 3) were infected with 20 µL of ATCC 27853 (3x104 CFU/mL),
PAO1 (3x100 CFU/mL) CF1 (3x103 CFU/mL), CF2 (3x103 CFU/mL), and CF3 (3x100
CFU/mL) into the last left pro-leg (as per Figure 4.2) and incubated for 0, 2, 4, 6, 12 and
24 h. After each time point, larval hemolymph (50 μL) was extracted and serially diluted
in 450 μL of 0.9% NaCl in an iced tube. Each dilution was plated on Pseudomonas
isolation agar (Lab M) and colonies were counted after 24 h at 37 °C. Data were expressed
as CFU/mL.
4.2.5 Galleria mellonella response to metal-tdda-phen complexes +/- gentamicin
4.2.5.1 Toxicity studies
The Cu-tdda-phen, Mn-tdda-phen and Ag-tdda-phen complexes were first tested in G.
mellonella larvae to determine their toxicity levels. Stock solutions of metal-tdda-phen
complexes and gentamicin were diluted in sterile water, and the starting materials, phen
and tddaH2, were diluted in methanol (10%). 20 µL were inoculated into the G. mellonella
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larvae through the last left pro-leg (as per Figure 4.2) into the hemocoel using a Myjector
U-100 insulin syringe (Terumo Europe NV). Undisturbed larvae, larvae inoculated with
water, and larvae inoculated with methanol equivalent to the highest concentration
present in the dilutions (10%) acted as experimental controls. The larvae were placed in
petri dishes containing wood shavings and incubated at 37 °C for 96 h. Mortality, cuticle
discolouration, and touch response were recorded every 12 h post-injection.
Once the toxicity profiles of each metal-tdda-phen complex alone were established, they
were individually assessed in combination with gentamicin. The working solutions 500,
200, and 100 µg/mL of the metal-tdda-phen complexes and gentamicin were used in
varying permutations by injection (20 µl) into the last left pro-leg (as per Figure 4.2).
The larvae were placed in petri dishes containing wood shavings and incubated at 37 °C,
and mortality, cuticle discolouration and response to touch were recorded every 12 h postinjection.
4.2.5.2 Determination of hemocyte density
Hemocyte densities were measured 2, 6 and 24 h post-inoculation with metal-tdda-phen
complexes alone (200 µg/mL and 750 µg/mL) and in combination with gentamicin (200
µg/mL and 750 µg/mL). A PBS control and undisturbed larvae were included. Changes
in hemocyte density were measured as previously described.
4.2.5.3 Gene expression of immune-related genes
RNA extraction and quantification, followed by cDNA synthesis, were first carried out
on G. mellonella larvae inoculated with the metal-tdda-phen complexes alone (750
µg/mL) or in combination with gentamicin (100 µg/mL) prior to real-time PCR for the
expression of target immune-related genes. After 2, 6, and 24 h, five larvae were
submerged in liquid nitrogen and ground to a fine powder. 1 mL of TRI Reagent (Sigma-
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Aldrich) was added for the RNA extraction, and the mixture was transferred to a chilled
tube before centrifugation at 2000 g for 2 min. The supernatant was brought to a fresh
tube on ice and mixed with 200 µL of chloroform (ACS grade; Sigma-Aldrich), incubated
for 3 min at room temperature before centrifuging again at 4 °C for 15 min at 12,000 g.
The upper aqueous phase (200 µL) was carefully transferred into a tube, and RNA was
precipitated with isopropanol (500 µL) (ACS grade; Sigma-Aldrich). Tubes were then
incubated at room temperature for 10 min and centrifuged at 4 °C for 10 min at 12,000 g.
The RNA pellet was washed once in 1 mL of 75 % (v/v) ethanol (Sigma-Aldrich), allowed
to dry and re-suspended in nuclease-free water. The RNA quantification was measured
on a MultiskanTM GO (Thermo Scientific) UV spectrophotometer with the µDrop plate.
cDNA was then synthesized from the extracted RNA of each experimental condition
using the cDNA synthesis kit (Quanta Biosciences, USA). Each reaction was placed into
the SimpliAmp Thermal Cycler (Applied Biosystems) for 5 min at 22 °C, 30 min at 42
°C, and 5 min at 85 °C, followed by samples being held at 4 °C before the quantitative
real-time PCR (qRT-PCR). Primer sets (forward and reverse primer sequences detailed
in Table 4.1) (Browne, 2014) were obtained from Sigma-Aldrich, and SYBR Green I
(KAPA SYBR FAST; Sigma-Aldrich) was used as the reaction probe. The samples were
added to the 7500 Fast Real-Time PCR System (Applied Biosystems). Thermal cycling
was initiated with a pre-incubation at 95 °C for 5 min, followed by amplification for 45
cycles of 95 °C for 10 s, 60 °C for 10 s and 72 °C for 10 s, melting curve at 95 °C for 5
s, 65 °C for 1 min and 95 °C for 10 s, and cooling at 40 °C for 10 s. The assay was
performed in triplicate. The relative gene expression was calculated using the 2-ΔΔCt
method.
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Gene

Sequence (5’-3’)

Fragment size
(base pair)

S7e F
ATGTGCCAATGCCCAGTTG
131
S7e R
GTGGCTAGGCTTGGGAAGAAT
Transferrin F
CCCGAAGATGAACGATCAC
535
Transferrin R
CGAAAGGCCTAGAACGTTTG
IMPI F
ATTTGTAACGGTGGACACGA
409
IMPI R
CGCAAATTGGTATGCATGG
Galiomicin F
CCTCTGATTGCAATGCTGAGTG
359
Galiomicin R
GCTGCCAAGTTAGTCAACAGG
Gallerimycin F
GAAGATCGCTTTCATAGTCGC
175
Gallerimycin R
TACTCCTGCAGTTAGCAATGC
Table 4.1 Forward and reverse primers for genes related to the immune response of G.
mellonella.

4.2.6 Galleria mellonella response to Pseudomonas aeruginosa infection and
treatment with metal-tdda-phen complexes +/- gentamicin
4.2.6.1 Treatment of metal-tdda-phen complexes in G. mellonella infected with P.
aeruginosa
To ascertain the in vivo activity of metal-tdda-phen complexes alone, larvae were infected
with each P. aeruginosa isolate (3x100 CFU/mL for PAO1 and CF3, 3x103 CFU/mL for
CF1 and CF2, and 3x104 CFU/mL for ATCC 27853) as described above and then
administered with either Cu-tdda-phen, Mn-tdda-phen, Ag-tdda-phen or gentamicin
(100-500 µg/mL) 1 h post-infection. Undisturbed larvae and larvae infected with the
bacterial strains and PBS (untreated) were included as controls. All larvae were incubated
at 37 °C and assessed every 12 h for a total of 96 h for mortality and melanisation.
4.2.6.2 Treatment of metal-tdda-phen complexes + gentamicin in G. mellonella
infected with P. aeruginosa
Similarly to the above, larvae were infected with bacterial strains (3x100 CFU/mL for
PAO1 and CF3, 3x103 CFU/mL for CF1 and CF2, and 3x104 CFU/mL for ATCC 27853)
and after 1 h post-inoculation, they were treated with a combination of metal-tdda-phen
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complex (100 µg/mL) and gentamicin (100 µg/mL). All larvae were incubated at 37 °C
and assessed every 12 h for a total of 96 h.
4.2.7 Statistical analysis
All experiments were performed in triplicate in three independent experimental sets, and
the results are presented as the mean ± SE. All statistical analyses were performed with
GraphPad Prism 9.0 (GraphPad Software Inc., San Diego, CA, USA). Survival curves of
G. mellonella larvae experiments were generated using the Kaplan−Meier method. Twoway ANOVA was used to compare the hemocyte densities and gene expression studies.
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Results
4.3.1 Response of Galleria mellonella to Pseudomonas aeruginosa infection
The effect of infection with P. aeruginosa laboratory strains ATCC 27853 and PAO1,
and clinical isolates CF1, CF2, and CF3, over a range of 3 x 100 to 3 x 105 CFU/mL, on
survival of G. mellonella larvae is presented in Figure 4.3. Larval survival was affected
in an inoculum-dependent manner during a 96 h incubation, with the greater CFU/mL
injections causing greater larval death. All infected larvae died at the highest tested
concentration (3 x 105 CFU/mL) within a 48 h period. No death was observed in the set
of uninfected and PBS-injected larvae used as a control. G. mellonella demonstrated the
highest tolerance towards laboratory strain ATCC 27853, an inoculum size of 3 x 104
CFU/mL induced mortality rates of 46.7 ± 3.3% after 24 h and 60 ± 3.3%, 63.7 ± 5.7%
and 73.3 ± 3.3% over the following days. 3 x 103 CFU/mL produced 26.7 ± 3.3%
mortality after 24 h and 55 ± 5% by 96 h. Further dilutions (3 x 102, 3 x 101, 3 x 100
CFU/mL) produced less than 10% mortality over the entire examined time course.
Injection with clinical isolates CF1 and CF2 incited similar pathogenicity profiles. At 3 x
104 CFU/mL, 53.3 ± 6.7% of larvae died after 24 h with the injection of CF1, while 46.7
± 3.3% mortality was observed after infection with CF2. Over 90% of death was recorded
after 96 h of injection with either isolate. A ten-fold reduction in inoculum resulted in
similar mortality after 24 h (50 ± 3.3% with CF1 and 56.7 ± 3.3% with CF2) with an 80
± 5.7% mortality for both isolates by the end of the experiment. Injection with lower
dilutions (3 x 100; 3 x 101; 3 x 102 CFU/mL) resulted in a 0-26.7 ± 3.3% mortality after
24 h and 0-56.7 ± 6.7% after 96 h. Laboratory strain PAO1 and clinical isolate CF3 were
the most virulent to the larvae, with a 20 µL inoculation of 3 x101 CFU/mL causing
complete death after 24 h. This indicated the sensitivity of G. mellonella to P. aeruginosa
infection, which has previously been reported (Andrejko et al., 2014; Hill et al., 2014;
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Beeton et al., 2015). There were significant differences (P < 0.05, P < 0.01, P < 0.001)
between the virulence of the examined strains and an inoculum that caused over 50%
mortality within 48 h but not 100% mortality within 24 h were chosen for subsequent
studies.

Figure 4.3 Kaplan-Meier survival distributions for each P. aeruginosa strain (ATCC
27853, PAO1, CF1, CF2, and CF3) assessed over varying inoculum doses (3x100 to 3x105
CFU/mL). Significance was assessed through the log-rank (Mantel-Cox) test, and Holm's
correction was applied for multiple comparisons (*: P < 0.05, **: P < 0.01, ***:
P < 0.001)
156

4.3.2 Immune response of Galleria mellonella to Pseudomonas aeruginosa
infection
Alterations in the number of circulating immune cells (hemocytes) within G. mellonella
have been used to indicate the larval immune response to a pathogen (Bergin et al., 2003).
Drifting hemocytes are the initial responders to an infection, and their density can be
enhanced by stimulating those attached to the internal wall of the haemocoel or bound to
organs such as fat bodies (Kavanagh and Reeves, 2004). After the mortality studies,
alterations in hemocyte density following inoculation with P. aeruginosa strains ATCC
27583 (3 × 104 CFU/mL), PAO1 (3 × 100 CFU/mL), CF1 (3 × 103 CFU/mL), CF2 (3 × 103
CFU/mL) and CF3 (3 × 100 CFU/mL) were assessed over a 24 h period (Figure 4.4.A).
All inoculated larvae had increased levels of hemocytes relative to the initial injection (0
h). With strains PAO1 and CF3, the inocula triggered a statistically significant (P < 0.001
and P < 0.05, respectively) increase in hemocytes (12.98 ± 0.73 x106/mL and 13.86 ± 1.09
x106/mL, respectively) after 2 h. ATCC 27853 had a count of 9.69 ± 0.62 x106/mL at 2 h
while CF1 had 10.93 ± 1.31 x106/mL and CF2 had 11.06 ± 1.00 x106/mL. Infections with
all strains saw a spike in hemocyte populations after 4 h. The greatest response was
observed in larvae injected with CF3 (16.17 ± 0.94 x106/mL, P < 0.001) followed by
PAO1 (15.27 ± 1.04 x106/mL), CF1 (14.67 ± 0.66 x106/mL, P < 0.05), CF2 (13.62 ± 0.38
x106/mL, P < 0.01) and ATCC 27853 (11.64 ± 0.51 x106/mL). After 24 h of monitoring,
hemocytes populations had decreased but remained elevated compared to their initial
levels (0 h). Larvae infected with PAO1 (7.59 ± 0.71 x106/mL, P < 0.01), CF2 (8.61 ±
0.55 x106/mL, P < 0.05) and CF3 for 24 h (8.12 ± 1.06 x106/mL, P < 0.05) showed a
significant increase in hemocyte density compared to the controls, ATCC 27853 (8.81 ±
0.57 x106/mL, P > 0.05) and CF1 (8.51 ± 0.39 x106/mL, P > 0.05) were not significant.
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The infection process was also observed by enumerating P. aeruginosa CFU in the
hemolymph of the infected larvae. Larvae were infected with ATCC 27853 (3×104
CFU/mL), PAO1 (3×100 CFU/mL), CF1 (3×103 CFU/mL), CF2 (3×103 CFU/mL), and
CF3 (3×100 CFU/mL) and monitored over 24 h (Figure 4.4.B). A decrease in viable
bacterial cells was observed with initial time points (0 h to 4 h). Bacterial burden in larvae
infected with all bacterial strains increased from 4 h and 24 h analysis points, strains
ATCC 27853, PAO1, CF1, and CF2 increased to a median value >5 log10 CFU/mL while
CF3 increased to a median value >4 log10 CFU/mL.

B

A

Figure 4.4 Following the inoculation of G. mellonella with P. aeruginosa strains ATCC
27583 (3 × 104 CFU/mL), PAO1 (3 × 100 CFU/mL), CF1 (3 × 103 CFU/mL), CF2 (3 × 103
CFU/mL) and CF3 (3 × 100 CFU/mL), the (A) alteration in circulating hemocyte density
and (B) bacterial burden, was assessed over a 24 h period. Data are presented as the
mean ± SE of the three independent experiments. Statistical analysis was performed by
comparing treatments to PBS injected controls at respective time points (*: P < 0.05, **:
P < 0.01, ***: P < 0.001).
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4.3.3 Galleria mellonella response to metal-tdda-phen complexes
G. mellonella larvae were exposed to Mn-tdda-phen, Cu-tdda-phen, Ag-tdda-phen, and
gentamicin, and mean mortality (%) was assessed over 72 h (Table 4.2). No mortality
was recorded after incubation of larvae with solvent (10% methanol), PBS inoculated
larvae and larvae that were undisturbed (data not shown) at any time point. However,
larvae exposed to the solvent control did demonstrate slight to moderate melanisation, as
presented in Figure 4.5. All larvae tolerated 2-10 µg/larvae (1.6-13.59 µM) of the metaltdda-phen complex with no mortality observed over the entire experiment. Similarly,
complexes Mn-tdda-phen and Ag-tdda-phen induced no mortality at 15 µg/larvae (20.39
and 12.5 µM, respectively) while doubling the concentration (40.78 and 24.9 µM,
respectively) resulted in 6.66 ± 5.77% death for the former and 23.33 ± 5.77% death for
the latter, after exposure for 72 h. Cu-tdda-phen was the most toxic to the larvae. A
concentration of 15 µg/larvae (20.15 µM) resulted in a mortality rate of 53.33 ± 5.77%
after 72 h, and increasing the dose to 30 µg/larvae (40.3 µM) saw complete death of all
tested larvae after the same amount of time. It is well known that copper is highly toxic
to mammals, and similar studies investigating Cu-phen complexes and their derivatives
have also highlighted their lethality towards G. mellonella (McCarron et al., 2018;
Rochford et al., 2018). Although lower concentrations of Cu-tdda-phen did not induce
mortality, moderate to severe melanisation was observed. In Chapter 3, the enhanced
toxicity of Cu-tdda-phen towards mammalian cells in vitro was also presented. Gandra et
al. (2020) investigated the toxicity of one copper(II)-phen, seven manganese(II)-phen,
and three silver(I)-phen-complexes towards G. mellonella, and of this panel Mn-tddaphen (chelate 8), Cu-tdda-phen (chelate 1) and Ag-tdda-phen (chelate 10) were included.
The group also reported the low mortality rate induced in larvae by Mn-tdda-phen (13.33
± 5.77%) and Ag-tdda-phen (33.33 ± 5.77%) at high concentrations (30 µg/larvae) and
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the toxicity of Cu-tdda-phen (100% mortality), corroborating the results obtained in this
study.

Mean Mortality (%) +/- SE over time (h)
Dose µg/larvae
(µM)
24 h
48 h
72 h
2 µg (2.71 µM)
0±0
0±0
0±0
Mn-tdda-phen
4 µg (5.42 µM)
0±0
0±0
0±0
10 µg (13.59 µM)
0±0
0±0
0±0
15 µg (20.39 µM)
0±0
0±0
0±0
30 µg (40.78 µM)
0±0
6.66±5.77
6.66±5.77
2 µg (2.68 µM)
0±0
0±0
0±0
Cu-tdda-phen
4 µg (5.36 µM)
0±0
0±0
0±0
10 µg (13.41 µM)
0±0
0±0
0±0
15 µg (20.15 µM)
23.33±5.77
46.66±5.77
53.33±5.77
30 µg (40.3 µM)
76.66±5.77
83.33±5.77
100±0
2 µg (1.6 µM)
0±0
0±0
0±0
Ag-tdda-phen
4 µg (3.3 µM)
0±0
0±0
0±0
10 µg (8.3 µM)
0±0
0±0
0±0
15 µg (12.5 µM)
0±0
0±0
0±0
30 µg (24.9 µM)
3.33±5.77
23.33±5.77
23.33±5.77
2 µg (3.5 µM)
0±0
0±0
0±0
Gentamicin
4 µg (6.9 µM)
0±0
0±0
0±0
10 µg (17.4 µM)
0±0
0±0
0±0
15 µg (26.1 µM)
0±0
0±0
0±0
30 µg (52.1 µM)
0±0
13.33±5.77
13.33±5.77
2 µg (11.1µM)
0±0
0±0
0±0
Phen
4 µg (22.2 µM)
0±0
0±0
0±0
10 µg (55.5 µM)
53.3±5.8
53.3±5.8
53.3±5.8
15 µg (83.2 µM)
76.7±5.8
76.7±5.8
76.7±5.8
30 µg (166.5 µM)
100±0
100±0
100±0
2 µg (9 µM)
0±0
0±0
0±0
tddaH2
4 µg (18 µM)
0±0
0±0
0±0
10 µg (45 µM)
0±0
0±0
0±0
15 µg (67.5 µM)
0±0
0±0
0±0
30 µg (135 µM)
46.7±5.8
46.7±5.8
46.7±5.8
Table 4.2 Mean larval mortality (%) after 24 h, 48 h, and 72 h inoculations with metaltdda-phen complexes and gentamicin at a concentration range of 2-30 µg/larvae. Data are
presented as mean ± SE
Test complex
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Figure 4.5 G. mellonella representing the different levels of melanisation and cuticle
discolouration

Injection of the control antibiotic, gentamicin, at 30 µg/larvae (52.1 µM) induced 13.33
± 5.77% mortality after 48 h. Surviving larvae presented with slight to moderate
melanisation; some were slow to respond to stimulation. In addition, the larvae were
injected

with

the

metal-tdda-phen

complexes

starting

materials,

3,6,9-

trioxaundecanedioate (tdda) and 1,10-phenanthroline (phen), to ensure the recorded
effects were not a result of the free ligands alone but the complex itself. The highest dose
(30 µg/larvae, 135 µM) of tddaH2 saw 46.7 ± 5.8% of the inoculated larvae perish, while
10 µg/larvae (45 µM) resulted in a mortality of 53.3 ± 5.8% after the initial 24 h. Kellett
et al. (2011) also demonstrated that G. mellonella exposed to high concentrations of phen
(5000 and 2000 μg mL−1) had poor tolerance (100% and 90% mortality, respectively).
Interestingly the G. mellonella larvae that were exposed to lower doses of phen (2-4
µg/larvae, 11.1-22.2 µM), although they survived, showed an orange discolouration of
the cuticle post-injection (Figure 4.5). It was postulated that the orange discolouration
resulted from the phen interfering with the copper-containing enzyme phenoloxidase that
drives melanin synthesis (Sheehan et al., 2018). To identify whether metal-tdda-phen
complexes induced an immunomodulatory effect, larval hemocytes were withdrawn and
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counted after exposure to a low (2 µg/larvae) and high (15 µg/larvae) dose that did not
induce 100% mortality. At 2 h, both low and high doses prompted similar responses in
subjected larvae: Ag-tdda-phen (11.20 ± 0.47 x106/mL and 12.44 ± 0.54 x106/mL,
respectively), Mn-tdda-phen (7.95 ± 0.37 x106/mL and 11.43 ± 0.56 x106/mL,
respectively), phen (10.8 ± 0.46 x106/mL and 8.8 ± 0.24 x106/mL, respectively) and
tddaH2 (7.78 ± 0.34 x106/mL and 8.30 ± 0.55 x106/mL, respectively) showed a significant
(P<0.05) increase compared to the control (Figure 4.6). After an extended exposure to
15 µg/larvae to 6 h, Mn-tdda-phen (42.34 ± 0.95 x106/mL) and Ag-tdda-phen (32.71 ±
0.75 x106/mL) significantly enhanced hemocyte density that continued to the 24 h time
point (135.82 ± 4.29 x106/mL, 133.14 ± 2.59 x106/mL, respectively). This demonstrates
that at higher concentrations, these metal-tdda-phen complexes induce a priming effect
within the insects. There were no hemocytes when phen was assessed at 15 µg/larvae
after 24 h, and reduced hemocytes when Cu-tdda-phen (20.66 ± 0.61 x106/mL) was
examined at the same concentration. The toxicity of these compounds to larvae at this
concentration could be responsible for this response.
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Figure 4.6 Immunomodulation induced by the metal-tdda-phen complexes and
gentamicin (2 and 15 µg/larvae) in G. mellonella after 2 h, 6 h and 24 h post-injection.

Larvae treated with Mn-tdda-phen, Cu-tdda-phen, Ag-tdda-phen, and gentamicin (15
µg/larvae) were incubated for 2, 6 and 24 h prior to the assessment of immune-related
gene expression. Transferrin (iron-binding protein), IMPI (inducible metalloproteinase
inhibitor), galiomicin (defensin) and gallerimycin (cysteine-rich antifungal peptide)
genes were normalised against the expression of S7e (reference gene), and larval
treatments were compared to the PBS injected control and are presented in Figure 4.7.
Expression of transferrin and IMPI encoding genes were significantly (P < 0.05)
upregulated by Mn-tdda-phen and Ag-tdda-phen across all time points. Time-dependent
induction of both genes was observed, reaching the maximum 24 h after injection. This
suggests that these metal-tdda-phen complexes initiate an immune response in the larvae.
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Figure 4.7 Relative expression of genes involved in the immune response of G.
mellonella when exposed to metal-tdda-phen complexes, gentamicin and phen after 2 h,
6 h and 24 h post-injection. * indicate significant differences to the PBS injected control
(P < 0.05)

4.3.4 Galleria mellonella response to metal-tdda-phen complexes and
gentamicin
After toxicity studies of the metal-tdda-phen complexes and gentamicin as single agents,
the dual administration of the complexes and antibiotics were assessed within the larval
model. The lowest examined concentrations that did not induce mortality (Figure 4.5)
were examined in varying permutations of 2-10 µg/larvae and observed over three time
points (24, 48 and 72 h) (Figure 4.6). Overall the combination of agents, even at lower
doses, enhanced the toxicity towards the larvae when compared to their toxicity as
singular drugs. The highest dose of gentamicin (10 µg/17.4 µM) with Mn-tdda-phen (10
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µg/13.59 µM), Cu-tdda-phen (10 µg/13.41 µM) and Ag-tdda-phen (10 µg/8.3 µM)
resulted in 86.7, 100 and 93.3 % mortality respectively after 72 h. While the highest dose
of gentamicin (10 µg/17.4 µM) with the lowest dose of Mn-tdda-phen (2 µg/2.71 µM)
and Ag-tdda-phen (2 µg/1.6 µM) produced mortality rates of 46.7, and 53.3 %,
respectively, the combination with Cu-tdda-phen (2 µg/2.68 µM) incited 83% mortality.
The lowest concentration of gentamicin (2 µg/2.35 µM) with both Mn-tdda-phen (2
µg/2.71 µM) and Ag-tdda-phen (2 µg/1.6 µM) induced complete survival of all injected
larvae and with Cu-tdda-phen (2 µg/3.5 µM), 26.7 % mortality was noted. A high and
low and a low and high dose of gentamicin with both Mn-tdda-phen and Ag-tdda-phen
exerted a similar toxicity profile in larvae (43.3-53.3 % mortality), suggesting that a
combination of agents overstimulate the animal, irrespective of the higher concentration.
In contrast, a higher dose of Cu-tdda-phen (10 µg/13.41 µM) with a lower dose of
gentamicin (2 µg/2.35 µM) induced elevated mortality (83.3 %) than the reverse (73.3
%), suggesting that Cu-tdda-phen is driving the toxicity towards G. mellonella.
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Test agents

Dose µg/larvae (µM)
2 µg (2.71 µM) + 2µg (3.5 µM)

Mn-tddaphen +
Gentamicin

Cu-tddaphen +
Gentamicin

Ag-tddaphen +
Gentamicin

Mean Mortality (%) +/- SE over
time (h)
24 h
48 h
72 h
0±0
0±0
0±0

4 µg (5.42 µM) + 4 µg (6.9 µM)

20±5.8

20±5.8

20±5.8

10 µg (13.59 µM) + 10 µg (17.4 µM)

83.3±3.3

86.7±3.3

86.7±3.3

2 µg (2.71 µM) + 10 µg (17.4 µM)

43.3±3.3

46.7±3.3

46.7±3.3

10 µg (13.59 µM) + 2 µg (3.5 µM)

46.7±3.3

50.0±5.8

53.3±3.3

2 µg (2.68 µM) + 2µg (3.5 µM)

26.7±3.3

26.7±3.3

26.7±3.3

4 µg (5.36 µM) + 4 µg (6.9 µM)

70±5.8

73.3±3.3

73.3±3.3

10 µg (13.41 µM) + 10 µg (17.4 µM)

100±0

100±0

100±0

2 µg (2.68 µM) + 10 µg (17.4 µM)

63.3±3.3

66.7±3.3

73.3±3.3

10 µg (13.41 µM) + 2 µg (3.5 µM)

83.3±3.3

83.3±3.3

83.3±3.3

2 µg (1.6 µM) + 2µg (2.5 µM)

0±0

0±0

0±0

4 µg (3.3 µM) + 4 µg (6.9 µM )

26.7±3.3

33.3±3.3

33.3±5.8

10 µg (8.3 µM) + 10 µg (17.4 µM)

83.3±3.3

93.3±6.7

93.3±6.7

43.3±3.3
53.3±3.3
53.3±3.3
2 µg (1.6 µM) + 10 µg (17.4 µM)
10 µg (8.3 µM) + 2 µg (2.5 µM)
46.7±6.7
50±5.8
53.3±3.3
Table 4.3 Mean larval mortality (%) after 24 h, 48 h and 72 h inoculation of Mn-tddaphen and gentamicin, Cu-tdda-phen and gentamicin, and Ag-tdda-phen and gentamicin.
Data are presented as mean ± SE

To further investigate the combined effect of metal-tdda-phen complexes and gentamicin
on the immune system of the larvae, hemocytes were extracted and enumerated (Figure
4.8). The combination of Mn-tdda-phen (2 µg (2.71 µM) – 4 µg (5.42 µM)) with
gentamicin (2µg (3.5 µM) – 4 µg (6.9 µM)) elicited the greatest hemocyte response at 2
h (7.59 ± 0.38 x106/mL and 9.82 ± 0.74 x106/mL, respectively), 6 h (20.44 ± 0.61 x106/mL
and 34.67 ± 1.64 x106/mL, respectively), and 24 h (90.61 ± 2.56 x106/mL and 93.48 ±
2.04 x106/mL, respectively). Administration of Cu-tdda-phen with gentamicin to larvae
produced similar hemocyte densities at both low (2 µg (2.71 µM) + 2µg (3.5 µM)) and
high doses (4 µg (5.36 µM) + 4 µg (6.9 µM)) at 2 h (6.48 ± 0.57 x106/mL and 8.14 ± 1.24
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x106/mL, respectively) and 6 h (15.44 ± 0.56 x106/mL and 18.21 ± 0.52 x106/mL,
respectively). After 24 h, a hemocyte count of Cu-tdda-phen and gentamicin could not be
determined due to the high mortality rate. Unlike the other combinations, Ag-tdda-phen
and gentamicin induced a more pronounced hemocyte response at lower concentrations
than higher after 2 h (11.20 ± 0.47 x106/mL and 10.29 ± 0.59 x106/mL, respectively) and
24 h (75.28 ± 2.28 x106/mL and 47.92 ± 2.88 x106/mL, respectively).

Figure 4.8 Immunomodulation induced by the metal-tdda-phen complexes in
combination with gentamicin (CN) (2 µg and 2 µg/larvae, and 4 µg and 4 µg/larvae) in
G. mellonella after 2 h, 6 h and 24 h post-injection. * indicate significant differences in
relation to the PBS injected control (P < 0.05)
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The expression of transferrin (iron-binding protein), IMPI (inducible metalloproteinase
inhibitor), galiomicin (defensin) and gallerimycin (cysteine-rich antifungal peptide)
genes was assessed after larvae were exposed to a combination of metal-tdda-phen
complex (2 µg/larvae) and gentamicin (2 µg/larvae) for 2, 6 and 24 h (Figure 4.9). Similar
responses were observed to the metal-tdda-phen complexes and gentamicin as single
agents (Figure 4.7), with significant (P < 0.05) upregulation of transferrin and IMPI
encoding genes across all time points.

Figure 4.9 Relative expression of genes involved in the immune response of G.
mellonella when exposed to metal-tdda-phen complexes in combination with gentamicin
(CN) after 2 h, 6 h and 24 h post-injection. * indicate significant differences to the PBS
control (P < 0.05)
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4.3.5 Effect of metal-tdda-phen complexes in treating Pseudomonas aeruginosa
infection in Galleria mellonella +/- gentamicin
After screening the bacterial strains in the larval model, an infective dose was determined
for each strain. Larvae were inoculated with ATCC 27583 (3 × 104 CFU/mL), PAO1
(3 × 100 CFU/mL), CF1 (3 × 103 CFU/mL), CF2 (3 × 103 CFU/mL) and CF3 (3 × 100
CFU/mL) and subsequently received a single dose of the metal-tdda-phen complexes
alone (2-10 µg/larvae) (1.6-13.59 µM), gentamicin (2-10 µg/larvae) (3.5-17.4 µM) alone,
or the metal-tdda-phen complex (1 µg/larvae) (831.3 nM-1.36 µM) in combination with
gentamicin (1 µg/larvae) (1.74 µM) 1 h post-infection.
The effect of single doses of metal-tdda-phen complexes or gentamicin on survival of G.
mellonella inoculated with P. aeruginosa strains, ATCC 27853 (A-D), PAO1 (E-H), CF1
(I-L), CF2 (M-P), CF3 (R-U), are presented in Figure 4.10. Overall, the exposure to a
metal-tdda-phen complex increased survival in infected larvae. Gentamicin (10
µg/larvae) (17.4 µM) was the most effective at treating larvae infected with ATCC 27853,
which had no mortalities after 96 h when compared to the PBS control (73.33 ± 3.3%
mortality). All metal-tdda-phen complexes decreased mortality (26.7-36.7%) at the same
concentration and time point. When larvae were inoculated with PAO1, a more virulent
strain, mortality increased, except for Cu-tdda-phen treatment. G. mellonella presented
with a metal-tdda-phen complex or gentamicin increased survival dose-dependently.
Larvae administered 10 µg of gentamicin (17.4 µM) had a 23.3 ± 3.3% mortality rate.
Those exposed to Mn-tdda-phen (13.59 µM) and Ag-tdda-phen (8.3 µM) at 10 µg/larvae
prolonged survival of PAO1 infected larvae. At 48 h, the mortality rate was 26.7 ± 3.3%
of larvae presented with Mn-tdda-phen and 40 ± 5.8% of larvae subjected to Ag-tddaphen, compared to 66.7 ± 6.7% of larvae that received PBS. G. mellonella, which
encountered 10 µg (13.41 µM) of Cu-tdda-phen, showed a higher mortality rate (70 ±
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0%) at 48 h than those given PBS. Due to the toxicity of this complex in larvae, the stress
of both seemed to elevate mortality. However, a lower dose of 4 µg/larvae produced a
mortality rate of 36.7 ± 3.7 at 48 h. This was expected as Mn-tdda-phen and Ag-tddaphen presented with lower toxicity towards G. mellonella (Table 4.3) and induced the
immune response (Figure 4.8) of the larvae compared to their copper equivalent. As
presented in Table 3.1, ATCC 27853 and PAO1 were susceptible to gentamicin with
MICs of 1 µg/mL (1.7 µM) and 2 µg/mL (3.5 µM), respectively, while all the clinical
isolates (MICs of 8 µg/mL (13.9 µM) to over 256 µg/mL (445 µM)), were deemed
resistant to the antibiotic. Similarly, in the G. mellonella model, the antibiotic efficacy
against the clinical isolates decreased compared to the laboratory strains. Larvae infected
with CF3, CF2 and CF1 and subsequently treated with the highest dose of gentamicin (10
µg/larvae) (17.4 µM) saw survival recorded at 30 ± 0%, 70 ± 5.8% and 76.7 ± 3.3%,
respectively, after 96 h. At the lowest investigated concentrations of metal-tdda-phen
complexes (2 µg/larvae) (1.6-2.71 µM), mortality rates were noted at 33.3-43.3% for CF1
and CF2. This activity was not maintained with CF3. However, treatment of metal-tddaphen complexes extended survival compared to the PBS-treated larvae. After 48 h, larvae
treated with Mn-tdda-phen (5.42 µM), Cu-tdda-phen (5.36 µM), and Ag-tdda-phen (3.3
µM) at 4 µg/larvae had mortality rates of 50 ± 0%, 60 ± 5.8% and 53.3 ± 3.3%,
respectively, compared to a 66.7 ± 3.3% of larvae that received PBS. Again, this activity
profile draws similarities to the result obtained when assessed in vitro (Chapter 3); metaltdda-phen complexes were the most active against CF1 and CF2 (with MICs of 8-16
µg/mL); however, a higher concentration was needed to inhibit CF3 (MICs of 64-128
µg/mL).
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Figure 4.10 Survival (%) of G. mellonella inoculated with P. aeruginosa strains, ATCC 27853 (AD), PAO1 (E-H), CF1 (I-L), CF2 (M-P), CF3 (Q-T) and treated with 2-10 µg/larvae of Mn-tddaphen (A,E,I,M,Q), Cu-tdda-phen (B,F,J,N,R), Ag-tdda-phen (C,G,K,O,S) and Gentamicin
(D,H,L,P,T) over 96 h.
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To improve therapeutic outcomes, many clinicians recommend dual combinations of
antibiotics to increase the likelihood of achieving appropriate therapy for MDR P.
aeruginosa infections (Bassetti et al., 2018). We have also demonstrated synergistic
activity against P. aeruginosa between all three complexes and gentamicin in vitro
(Chapter 3). The efficacy of metal-tdda-phen complexes in combination with gentamicin
was measured in G. mellonella larvae infected with ATCC 27583 (3 × 104 CFU/mL),
PAO1 (3 × 100 CFU/mL), CF1 (3 × 103 CFU/mL), CF2 (3 × 103 CFU/mL) and CF3
(3 × 100 CFU/mL). A single dose of both Mn-tdda-phen (1.36 µM) and gentamicin (1.74
µM), Cu-tdda-phen (1.34 µM) and gentamicin and Ag-tdda-phen (868.5 nM) and
gentamicin at 1 µg/larvae was administered 1 h post-infection and monitored for 96 h
(Figure 4.11 and Figure 4.12). Overall, a combination of both drugs outperformed either
as a single entity. Of the combinations, larvae that received Mn-tdda-phen and gentamicin
and Ag-tdda-phen and gentamicin had the lowest mortality across all strains. Both
combinations decreased mortality by 50-53.3%, compared to the PBS-treated larvae,
while Cu-tdda-phen and gentamicin decreased mortality by 43.3-50%.
To complement the survival data, the effect of these combinations was also assessed by
analysing the larval bacterial burden of P. aeruginosa compared to the effect of their
constituent mono-therapies and PBS-treated larvae (Figure 4.11 and Figure 4.12).
Analysis after 24 h demonstrated that all combinations significantly reduced the bacterial
population in the infected larvae. G. mellonella infected with ATCC 27853 or PAO1 and
subsequently treated with metal-tdda-phen complexes in combination with gentamicin
had a 6-7 log10 CFU/mL reduction compared to PBS-treated larvae. The activity was
maintained across clinical isolates, CF1-CF3, that had 4-6 log10 CFU/mL in circulating
cells that were exposed to both metal-tdda-phen complexes and gentamicin.
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Figure 4.11 Effect of treatment with Mn-tdda-phen, Cu-tdda-phen and Ag-tdda-phen
alone (1 µg/larvae) and in combination with gentamicin (CN) (1 µg/larvae) infected with
ATCC 27853 and PAO1 on survival (left) and larval bacterial burden (right).
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Figure 4.12 Effect of treatment with Mn-tdda-phen, Cu-tdda-phen and Ag-tdda-phen
alone (1 µg/larvae) and in combination with gentamicin (CN) (1 µg/larvae) infected with
CF1, CF2 and CF3 on survival (left) and larval bacterial burden (right).
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Discussion
P. aeruginosa is a versatile opportunistic pathogen that causes severe clinical
complications due to its large genome that harbours an extensive arsenal of virulence
factors and antibiotic resistance determinants (Jurado-Martín et al., 2021). The bacterium
is well reported to swiftly adapt to conditions in the airway with exceptional metabolic
flexibility and the ability to evade host immune attacks (Riquelme et al., 2020). The
presence of P. aeruginosa is a particular threat to cystic fibrosis (CF) patients. The
deleterious impact that chronic infection has on lung function in CF has been well
described and often indicates poor clinical outcomes. P. aeruginosa infections are
becoming more challenging to treat due to the inherent resistance to many antibiotics, and
the number of MDR is increasing worldwide (Pachori et al., 2019). Moreover, persistent
P. aeruginosa infections in CF patients are due to the affinity of bacteria to form a biofilm
which is exceedingly more resistant to treatment than their planktonic form (Kovach et
al., 2017; Ciofu and Tolker-Nielsen, 2019). Thus, the previous chapter (Chapter 3)
describing metal-tdda-phen complex capabilities against established mature biofilms and
synergistic activity with gentamicin warranted the in vivo studies to further explore the
hypothesis that these complexes could be potential therapeutics for treating P. aeruginosa
infection as a mono- or combination therapy.
The use of G. mellonella larvae as a model to study pathogenicity and virulence, the
toxicity of novel complexes and their efficacy as therapies is now well established.
Entomopathogenic strains, such as ATCC 27853 and PAO1, and clinical isolates of P.
aeruginosa are highly virulent in G. mellonella with lethal doses ranging from 2 to 100
CFU, killing infected larvae within 24-48 h (Chadwick, 1967; Jander et al., 2000;
Andrejko et al., 2014; Pérez-Gallego et al., 2016; Thomaz et al., 2020). Similar
pathogenicity profiles were observed in this study. For instance, PAO1 and CF3 resulted
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in complete larvae death after 24 h at 30 CFU. Mortality assays demonstrated that the
metal-tdda-phen complexes are well tolerated by G. mellonella up to 10 µg per exposed
larvae. At the highest examined concentration (30 µg/larvae), Cu-tdda-phen was highly
toxic to the larvae, while Mn-tdda-phen was the least toxic. This was also previously
reported within our research group (Gandra et al., 2020), demonstrating the
reproducibility of this model. G. mellonella has been employed to evaluate the toxicity of
a range of agents, and the results have shown a strong correlation to those generated
utilizing mammalian models. Maguire et al. (2016). reported comparable toxicology data
(LD50) of food preservatives between insect larvae and rats. Consequently, a mammalian
model could tolerate Mn-tdda-phen and Ag-tdda-phen complexes. Furthermore, Mntdda-phen demonstrated immunomodulation properties by simulating hemocyte density
and immune-related genes, specifically antimicrobial peptides (AMPs), transferrin (ironbinding protein) and IMPI (inducible metallo-proteinase inhibitor). AMPs have been
reported to exert their antimicrobial action through permeabilizing the pathogen
membrane and thus their upregulation may aid in the clearing of an infection.
Rapidly increasing antibiotic resistance in already difficult-to-treat pathogens has
prompted a variety of studies employing G. mellonella larvae to delineate the efficacy of
therapies against these problematic bacteria (Tsai et al., 2016; Cutuli et al., 2019; Piatek
et al., 2020). Within these studies, the antibiotic susceptibility profiles of the examined
microorganisms mirror those established in vitro. Moreover, it has been shown that the
MICs of anti-pseudomonal drugs in infected larvae correlated with the susceptibilities in
patients (Hill et al., 2014; Ignasiak and Maxwell, 2017). In Chapter 3, the antibacterial
capabilities of Mn-tdda-phen, Cu-tdda-phen, and Ag-tdda-phen against P. aeruginosa
strains originating from CF patients were reported in vitro. While gentamicin was the
most effective compound against the reference antibiotic-sensitive strains (ATCC 27853
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and PAO1), it had reduced efficacy across the resistant clinical isolates (CF1-CF3).
However, the metal-tdda-phen complexes maintained clinically relevant activity.
Similarities can be seen in the treatment of infected G. mellonella larvae. Gentamicin (at
the highest tested concentration of 10 µg/larvae) had the greatest potency in treating
larvae infected with ATCC 27853 and PAO1, but its activity decreased when
administered to larvae infected with the clinical isolates, which had been classified as
resistant to the antibiotic (Chapter 3). However, mirroring the in vitro profiles, the
activity of gentamicin diminished across the clinical isolates while the activity of the
metal-tdda-phen complexes was preserved.
Although definitive treatment with a single agent would be the ideal scenario, due to the
expanding resistance profiles of P. aeruginosa, the empirical administration of antibiotic
combinations is utilised by clinicians to control pulmonary exacerbations in CF patients.
Across published guidelines, the most common combinations are an aminoglycoside or a
fluoroquinolone with an anti-pseudomonal β-lactam, which results in a synergistic
bactericidal effect (Moreno et al., 2021a). Gentamicin is a clinically important
aminoglycoside antibiotic. It inhibits protein synthesis by binding with a high affinity to
the aminoacyl-tRNA site (A site) within the 30S ribosomal subunit, thereby inhibiting the
translation process (Magnet and Blanchard, 2005). This produces truncated proteins,
affecting the cell wall composition, which increases membrane permeability and
subsequently heightens uptake of the drug (Kohanski et al., 2008). However, prolonged
treatment with gentamicin can have severe adverse effects, such as nephrotoxicity and
ototoxicity, that are thought to be dose-related, with higher concentrations causing a
greater chance of toxicity. Metal-based drugs have unique mechanisms of action in
comparison to their organic counterparts (Viganor, Howe, et al., 2016a; Claudel,
Schwarte and Fromm, 2020; Frei, 2020; Frei et al., 2020; Evans and Kavanagh, 2021;
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Wang et al., 2021; Wang and Lippard, 2005; Palermo et al., 2016). Such mechanisms
include; ligand exchange or release, ROS generation and catalytic generation of toxic
species or depletion of essential substrates (Kohanski et al., 2008; Claudel et al., 2020).
These mechanisms can be multi-modal (Wang et al., 2021a) and hugely dependent on the
metal centre and attached ligands (Frei et al., 2020). In this study, we assessed the
combination of the metal-tdda-phen complexes and gentamicin because they
demonstrated synergistic activity against P. aeruginosa strains in both planktonic (data
not shown) and biofilm forms (Chapter 3). The combined therapy of metal-tdda-phen
and gentamicin in larvae infected with all strains produced an appreciable survival rate
than those treated with the individual agents at lower concentrations. Furthermore, the
combination dampened the proliferation of bacteria within the larvae, which was
elucidated by the more extensive depletion in bacterial burden compared to single
treatments. As bacteria adapt to antibiotic treatment, higher doses are required to manage
the infection that, as previously mentioned, has been associated with severe adverse
effects in patients. The efficacy of the metal-tdda-phen/gentamicin combination at
clearing an infection, especially of the resistant clinical isolates, at lower doses is
interesting in this regard. Although gentamicin is a bactericidal antibiotic, it is not
possible to deduce if the combination is also working in this manner. However, due to the
already established antibacterial effects of complex Mn-tdda-phen and its presented
capability to induce an immune response through enhancement of hemocytes and immune
related genes, it can be postulated that this complex might have several processes for
aiding the clearance of an infection.
In conclusion, the data presented here suggest that Mn-tdda-phen and Ag-tdda-phen can
clear a P. aeruginosa infection at concentrations that are non-toxic toward G. mellonella
larvae. It is thought to be multi-modal, acting directly on the bacteria and stimulating
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cellular and humoral responses that work concomitantly to clear an infection. Although
more research is required to understand the mechanisms by which the complexes exert
their antibacterial properties, this study has highlighted that substituting the metal centre
alters the toxicity level and immunomodulation properties. Combinations of metal-tddaphen complexes with gentamicin restored the activity of the antibiotic against clinical
isolates that were resistant to it, presenting an alternative combination therapeutic
approach with greater efficacy.
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Chapter 5.

Overall discussion and future
perspectives
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The rise of antimicrobial resistance (AMR) threatens global health through significant
morbidity, mortality, and global economic loss. Currently, in 2022, the coronavirus
disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) has been one of the most significant challenges of our time and has
overwhelmed healthcare systems internationally. Simultaneously, it has highlighted the
vulnerability of humanity to a world without adequate treatment for a pathogen.
Moreover, the pandemic has exacerbated the existing AMR crisis. There are many
avenues to address the now dubbed ‘silent pandemic’ of AMR and require a global ‘One
Health’ approach. This concept recognises that human, animal and environmental health
are all connected and therefore requires a multi-sectorial and transdisciplinary approach
from local to global levels to tackle the issue of AMR (Destoumieux-Garzón et al., 2018).
A common approach is reducing antimicrobial use in agriculture and humans. However,
this creates a paradox as the depletion in prescriptions reduces sales and therefore reduces
interest from pharmaceutical companies to invest in novel antimicrobial agents.
Consequently, the current antibacterial clinical pipeline is inadequate to treat the
mounting infections caused by multidrug-resistant pathogens (Butler et al., 2022). There
is now an increased interest in ‘non-traditional’ approaches to antibacterial therapy that
explore different avenues compared to ‘traditional’ organic molecules that target
pathogens. These agents can prevent or treat bacteria through several modes of action,
including directly or indirectly inhibiting growth, inhibiting virulence, inhibiting or
removing biofilm, alleviating resistance, restoring the natural gut microbiome, or
boosting the immune system to clear or manage their infections (Rex et al., 2019;
Theuretzbacher and Piddock, 2019; Langendonk et al., 2021). Of the 12 new antibacterial
agents approved for clinical use since 2017, the WHO reported that only one compound,
cefiderocol, meets one of their innovation criteria (absence of known cross-resistance,
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new target, a new mode of action, and/or new class) (WHO, 2021) that also has activity
against all three critical carbapenem-resistant priority pathogens (Table 1.3). Cefiderocol
is a siderophore-conjugated cephalosporin that promotes the formation of chelated
complexes with ferric iron and facilitates siderophore-like transport across the outer
membrane of Gram-negative bacteria using iron transport systems, accumulating in the
periplasmic space (Zhanel et al., 2019; Wang et al., 2022).
Interdisciplinary researchers in biology and inorganic chemistry have been investigating
novel metal-bearing drugs and assessing their therapeutic potential to tackle resistance
providing a realistic alternative to the ‘traditional’ antibiotic (Mukherjee and Sadler,
2009; Reece and Marimon, 2019; Claudel et al., 2020; Frei et al., 2020; Nasiri Sovari and
Zobi, 2020; Evans and Kavanagh, 2021). A wealth of research reports the enhanced
activity of metals complexed to organic ligands such as 1,10-phenanthroline (phen)
(Dwyer et al., 1969; McCann et al., 2012b; Viganor et al., 2015, 2016b; Gandra et al.,
2017; McCarron et al., 2018; Galdino et al., 2019; Ahmed et al., 2022). The purpose of
this research project was to investigate further the antibacterial potential of novel
manganese(II)-, silver(I)- and copper(II)-phen complexes.
As presented in Figure 5.1, the first objective (Chapter 2) was screening a panel of metal
complexes incorporating dicarboxylate and 1,10-phenanthroline (phen) ligands against a
panel of Gram-positive and Gram-negative WHO priority pathogens that also
significantly impact the Irish healthcare system. Metal-complexed phenanthrolines
presented an enhanced toxicity profile across examined pathogen panels juxtaposed to
their non-phen derivatives and starting materials. The chelates incorporating 3,6,9trioxaundecanedioate (tdda) and phen (metal-tdda-phen) were the most effective across
the broadest range of tested strains and were therefore chosen for additional testing. The
three complexes, Cu-tdda-phen, Mn-tdda-phen and Ag-tdda-phen, presented synergistic
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activity when co-administered with the antibiotic gentamicin against S. aureus and P.
aeruginosa clinical isolates that were resistant to the prescription drug alone. To elucidate
the molecular targets of the metal-tdda-phen complexes in reference, S. aureus and P.
aeruginosa strains were exposed to sub-lethal doses of the three complexes and
subsequently whole-genome sequenced (WGS). However, there were complications with
S. aureus mutant data, discussed in Section 2.3.4, mutant P. aeruginosa genome
presented with changes in proteins involved in cellular respiration, the polyamine
biosynthetic pathway, and virulence mechanisms suggestive of the potential mechanisms
of action. However, the effect on one pathway could have a knock-on effect on others and
more in-depth analysis at a protein level is required to assess exact molecular targets.
Even so, these mechanisms suggest a novel mode of action to ‘traditional’ antibiotics, a
criterion on the WHO antibacterial innovation list (WHO, 2021).
The water-soluble metal-tdda-phen complexes presented with good to moderate activity
across the bacterial panels and were therefore chosen for subsequent analysis. As they
had enhanced activity profiles in S. aureus and P. aeruginosa strains (Chapter 2), a cystic
fibrosis (CF) disease model was used further to investigate the potential therapeutic
capabilities of the complexes. S. aureus is the most prevalent pathogen in the lungs of CF
patients in childhood, while P. aeruginosa is the most abundant in adulthood (CF Registry
of Ireland, 2019). P. aeruginosa is an avid biofilm-forming bacterium, and evolving
resistance to antibiotics is problematic and of concern when considering the treatment of
its infections in CF patients (Beswick et al., 2020). Targeting the biofilm and virulence
properties has gained considerable attention as an anti-pathogenic strategy; thus, this
work offers a significant perspective (Thi et al., 2020; Langendonk et al., 2021).
Moreover, the metal-tdda-phen complexes eluded this potential on a genotypic level from
the WGS data.
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For the second objective (Chapter 3), the metal-tdda-phen complexes were assessed
against clinical isolates of P. aeruginosa derived from Irish CF patients. The effects of
the metal complexes on planktonic growth, biofilm formation, and mature biofilm alone
and combined with the prescription antibiotic gentamicin were investigated. Metal-tddaphen complexes were able to disrupt biofilm, which prompted further investigation into
their effect on individual components to potentially decipher elements of their mechanism
of action. Metal complexes were able to destabilize the biofilm by interacting with
extracellular DNA and exopolysaccharides in the extracellular matrix, possibly through
Psl. This destabilization could allow the previously inhibited antibiotic gentamicin into
the biofilm to enhance its cytotoxic action and was further supported by the viable cell
counts. The potentiating activity of all three metal-tdda-phen complexes with gentamicin
is of great interest as this may resensitise the bacteria to concentrations of the antibiotic
to which it was previously resistant (Ahmed et al., 2020). This also has excellent potential
for treating persister cells, a subpopulation of non-replicating and metabolically quiescent
bacteria that become highly tolerant to antibiotics and are very problematic in treating
exacerbations in chronic infections (Ciofu and Tolker-Nielsen, 2019). For instance, a new
class of glycopolymers includes polycationic poly-N (acetyl, arginyl) glucosamine
(PAAG), a polycationic biopolymer currently in Phase I clinical trials in the treatment of
CF patients. It has been shown to eradicate P. aeruginosa persister cells effectively
(Narayanaswamy et al., 2018) and improve mucus clearance of the lungs of CF patients
by chelation of Ca2+ without any harmful effect on tissue (Garcia et al., 2022).
Other novel treatment strategies are being trialled and optimized for CF patients, and
numerous studies have compared mono- and combination-antibiotic therapies (Anderson
et al., 1978; Tang et al., 2018). Amongst the many alternative therapeutic approaches
documented are the guluronate polymer OligoG (derived from alginate), a simple thiol
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cysteamine, a novel synthetic peptide, nitric oxide and gallium(III) compounds (Smith et
al., 2017; Moreno et al., 2021b). Ga3+ metal ions have been shown to disrupt biofilm
formation and protect against P. aeruginosa infections in vitro in human serum (Bonchi
et al., 2015), mouse models (Kaneko et al., 2007; DeLeon et al., 2009) and humans (Goss
et al., 2018). Moreover, there is a decreased likelihood that P. aeruginosa can develop
resistance to gallium compared to the classic small-molecule antibiotics (Ross-Gillespie
et al., 2014). Additional studies showed that co-encapsulation of Ga3+ with gentamicin in
liposomes was more effective than gentamicin alone for eradicating P. aeruginosa in both
planktonic and biofilm forms (Halwani et al., 2008). There is clearly scope for the
development of novel metal complexes, either acting alone or in combination with
antibiotics, as a new therapeutic regime for P. aeruginosa infections in CF patients.
For the final objective (Chapter 4), the anti-pseudomonal activity of metal complexes
was further explored within the in vivo model of the larvae of Galleria mellonella, in
combination with gentamicin. Metal-tdda-phen complexes maintained activity against the
CF isolates at concentrations that were tolerated by the larvae. The complexes are thought
to be multi-modal, acting directly on the bacteria but also through stimulating both the
cellular and humoral responses that work concomitantly to clear an infection. The
combined therapy of metal-tdda-phen and gentamicin in larvae infected with all strains
produced an appreciable increase in survival and dampened proliferation of bacteria
within the larvae. This provides an opportunity to streamline the identification and
evaluation of novel antimicrobial agents in a valuable preclinical in vivo model at a time
when there is a desperate need to accelerate the development pipeline. Although
promising, a well-validated CF in vivo model is still required, such as a cystic fibrosis
transmembrane conductance regulator (CFTR) knockout animal, to fully assess the metaltdda-phen/gentamicin anti-infective therapeutic potential (Semaniakou et al., 2019).
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Figure 5.1 A schematic overview of the research presented in this thesis. Steps 1, 2, and
3 (corresponding to chapters 2, 3 and 4) explain the progression of the project from initial
screening (step 1) to testing lead complexes in both in vitro (step 2) and in vivo (step 3)
models.
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In this body of work, metal-tdda-phen complexes presented activity against clinical
isolates of P. aeruginosa. Across the inhibitory, WGS, anti-biofilm and in vivo data, the
activity of the complex was independent of the metal centre. In fact, within the sequencing
data, the three complexes had only one common mutation. Although Cu-tdda-phen
demonstrated good to moderate activity, the same concentrations were extremely toxic
within both an in vitro (Chapter 3) and in vivo model (Chapter 4), culminating in a low
selectivity index. The copper complex could inhibit the formation of a biofilm and
disperse an established biofilm with suggested enhanced activity toward eDNA within
the matrix and pyocyanin production to a lesser extent. Therefore, this complex may be
better suited for disinfection of implantable medical devices or topical applications.
However, it should be noted that the synergistic nature of the anti-biofilm effect with
gentamicin allows the use of much lower concentrations of the metal complex and
antibiotic than those used individually.
Mn-tdda-phen and Ag-tdda-phen were well tolerated by mammalian cell lines and the G.
mellonella larvae while maintaining activity, promoting good clinical utility. The
manganese derivative was observed to reduce exopolysaccharides in both forming and
mature biofilms, enhanced immune response in exposed larvae through elevated
haemocytes and antimicrobial peptides, reducing the bacterial load in infected larvae and
overall increasing their survival. Ag-tdda-phen also generated the same activity profile
but with less efficiency and significantly reduced pyocyanin production when combined
with gentamicin. Manganese, like copper, is a trace element and excessive levels in the
body can cause poor bone health and neurological symptoms (Evans and Kavanagh,
2021), and chronic exposure may cause infertility (Claudel et al., 2020). While silver does
not have significant toxic side effects in humans when administered in low doses, chronic
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exposure can lead to deposits in the skin, causing skin pigmentation known as argyria
(Evans and Kavanagh, 2021).
Although P. aeruginosa predominates in the lungs of adolescent CF patients, it does not
colonise the airways alone. The interactions within the microbiota of the lungs have been
shown to reduce susceptibility to antibiotics and affect patient health. Moreover, the
virulence of P. aeruginosa is influenced by its co-colonisers in the CF lung microbiome
(Reece et al., 2021). Their impact on polymicrobial communities should be investigated
to garner greater insight into the metal-tdda-phen complexes treatment efficacies of
exacerbations in CF patients. Drug development is a complex, expensive, and arduous
process. As previously mentioned, pharmaceutical companies are abandoning the
investment in antibiotics and instead funding lifetime diseases that require daily
medication. A metal drug presented with an anti-virulence activity to dampen the effects
of a chronic disorder may appear more lucrative to them. In addition, the potential to
resensitise bacteria to an antibiotic such as gentamicin, which regulatory agencies have
already approved, may also strengthen the proposal to encourage funding (Skwarczynski
et al., 2022). To expand the current knowledge highlighted in this thesis elucidating the
specific cellular targets of these compounds would further aid their potential clinical
development. While the WGS data highlighted the potential mechanisms by which the
metal-tdda-phen complexes act, proteomic analysis is required to verify the effects of the
mutations on a phenotypic level (Slavin et al., 2017; Zielinski et al., 2021). In addition,
ICP-MS, a sub-cellular fractionation coupled with mass spectrometry, would also be a
valuable tool for localising either intact, disassociated or alternative metal-phen
complexes within the cell or biofilm (Wang et al., 2021a).
In conclusion, this work highlights the therapeutic potential of metal-tdda-phen
complexes not only alone but also in combination with gentamicin in both in vitro and in
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vivo models. However, research is still required to understand the pharmacological,
toxicological, and pharmacokinetic impacts of the drugs. The data presented in this thesis
warrant further investigation into the antimicrobial activities of the metal-tdda-phen
complexes.
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6.1.1 MICs and MBCs of metal complexes and controls against Staphylococcus
aureus panel
Staphylococcus aureus
Compounds

ATCC 29213

MRSA1

MRSA2

MRSA3

MRSA4

MRSA5

MIC

MBC

MIC

MBC

MIC

MBC

MIC

MBC

MIC

MBC

MIC

MBC

0.5

1

>256

-

>256

-

>256

-

>256

-

>256

1

4

64

256

128

>256

1

4

1

4

1

4

1

64

32

128

32

128

32

128

32

128

32

128

>256

-

>256

-

>256

-

>256

-

>256

-

>256

-

Cu-oda-phen

1

64

16

128

16

128

16

128

16

128

16

128

Cu2-oda-phen

1

64

16

128

16

128

16

128

8

128

16

128

>256

-

>256

-

>256

-

>256

-

>256

-

>256

-

1

4

8

32

8

32

8

32

4

32

8

32

>256

-

>256

-

>256

-

>256

-

>256

-

>256

-

32

256

128

>256

128

>256

128

>256

128

>256

128

>256

>256

-

>256

-

>256

-

>256

-

>256

-

>256

-

Antibiotic controls
Ciprofloxacin
Gentamicin
Copper(II) complexes
Cu-ph-phen
Cu-oda

Cu-tdda
Cu-tdda-phen
Manganese(II) complexes
Mn-bda
Mn-bda-phen
Mn-pda
Mn-pda-phen

4

16

32

256

32

256

16

128

8

128

16

128

>256

-

>256

-

>256

-

>256

-

>256

-

>256

-

4

16

128

>256

128

>256

128

>256

128

>256

128

>256

Mn-hpda

>256

-

>256

-

>256

-

>256

-

>256

-

>256

-

Mn-hpda-phen

>256

-

>256

-

>256

-

>256

-

>256

-

>256

-

Mn-oda

>256

-

>256

-

>256

-

>256

-

>256

-

>256

-

32

128

64

256

128

>256

128

>256

128

>256

128

>256

>256

-

>256

-

>256

-

>256

-

>256

-

>256

-

1

32

1

64

8

128

8

128

8

128

8

128

Ag-udda

32

128

32

128

32

128

32

128

32

64

32

128

Ag-udda-phen

16

64

16

64

16

64

16

64

16

64

16

64

Ag-tdda

32

64

32

64

32

128

32

64

32

64

32

64

Ag-tdda-phen

4

32

8

32

8

64

8

32

8

32

8

32

CuCl2

>256

-

>256

-

>256

-

>256

-

>256

-

>256

-

MnCl2
AgNO3

>256

-

>256

-

>256

-

>256

-

>256

-

>256

-

4
64

16
>256

16
128

128
>256

16
128

64
>256

16
128

64
>256

16
128

64
>256

16
128

64
>256

Mn-hxda
Mn-hxda-phen

Mn-oda-phen
Mn-tdda
Mn-tdda-phen
Silver(I) complexes

Controls

Phen

Table A.9 Minimal inhibitory concentration (MIC) and minimal bactericidal
concentration (MBC) values obtained for Staphylococcus aureus sub-panel exposed to
novel metal complexes and their controls using the broth micro-dilution assay. Values are
presented as µg/mL.
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6.1.2 MICs and MBCs of metal complexes and controls against Enterococcus
spp panel
Enterococcus faecalis and Enterococcus faecium
Compounds

ATCC
29212
MIC MBC
Antibiotic controls
Ciprofloxacin
1
2
Gentamicin
8
32
Copper(II) complexes
Cu-ph-phen
32
128
Cu-oda
>256
Cu-oda-phen
16
128
Cu2-oda-phen
64
128
Cu-tdda
>256
Cu-tdda-phen
16
32
Manganese(II) complexes
Mn-bda
>256
Mn-bda-phen >256
Mn-pda
>256
Mn-pda-phen
32
64
Mn-hxda
>256
Mn-hxda>256
phen
Mn-hpda
>256
Mn-hpda>256
phen
Mn-oda
>256
Mn-oda-phen
32
128
Mn-tdda
>256
Mn-tdda16
32
phen
Silver(I) complexes
Ag-udda
32
128
Ag-udda8
32
phen
Ag-tdda
32
64
Ag-tdda-phen
8
32
Controls
CuCl2
>256
MnCl2
>256
AgNO3
4
16
Phen
64
>256

VRE1

VRE2

VRE3

VRE4

VRE5

VRE6

MIC

MBC

MIC

MBC

MIC

MBC

MIC

MBC

MIC

MBC

MIC

MBC

>256
>256

-

>256
>256

-

>256
>256

-

>256
>256

-

>256
>256

-

>256
>256

-

256
>256
256
256
>256
64

>256
>256
>256
128

256
>256
32
256
>256
16

>256
256
>256
32

256
>256
128
256
>256
64

>256
>256
>256
128

128
>256
128
128
>256
64

>256
>256
>256
128

256
>256
128
256
>256
64

>256
>256
>256
128

256
>256
256
256
>256
64

>256
>256
>256
128

>256
>256
>256
>256
>256
>256

-

>256
>256
>256
>256
>256
>256

-

>256
>256
>256
>256
>256
>256

-

>256
>256
>256
>256
>256
>256

-

>256
>256
>256
>256
>256
>256

-

>256
>256
>256
>256
>256
>256

-

>256
>256

-

>256
>256

-

>256
>256

-

>256
>256

-

>256
>256

-

>256
>256

-

>256
>256
>256
64

>256

>256
>256
>256
32

128

>256
>256
>256
64

>256

>256
>256
>256
32

>256

>256
>256
>256
32

>256

>256
>256
>256
32

>256

32
16

128
64

32
16

128
64

32
16

128
64

32
16

128
64

32
16

128
64

32
16

128
64

32
16

128
64

32
16

128
64

32
16

128
64

32
16

128
64

32
16

128
64

32
16

128
64

>256
>256
4
128

128
>256

>256
>256
4
128

128
>256

>256
>256
4
128

128
>256

>256
>256
4
128

128
>256

>256
>256
4
128

128
>256

>256
>256
4
128

128
>256

Table A.10 Minimal inhibitory concentration (MIC) and minimal bactericidal
concentration (MBC) values obtained for Enterococcus sub-panel exposed to novel metal
complexes and their controls using the broth micro-dilution assay. Values are presented
as µg/mL.
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6.1.3 MICs and MBCs of metal complexes and controls against resistant
Enterobacterales panel
ATCC 25922

ATCC 10031

Compounds
MIC
Antibiotic controls
Meropenem
0.03
Gentamicin
0.5
Copper(II) complexes
Cu-ph-phen
>256
Cu-oda
>256
Cu-oda-phen
64
Cu2-oda-phen
64
Cu-tdda
>256

Enterobacterales strains
ATCC
ESBL1
MBL1
700603
MIC MBC MIC MBC MIC MBC

ATCC
BAA1705
MIC MBC

KPC1
MIC

MBC

MBC

MIC

MBC

0.12
1

1
16

4
64

1
16

4
64

2
>256

8
-

>256
>256

-

128
2

>256
8

>256
>256

-

>256
>256
-

>256
>256
64
64
>256

>256
>256
-

>256
>256
128
128
>256

>256
>256
-

>256
>256
128
128
>256

>256
>256
-

>256
>256
128
128
>256

>256
>256
-

>256
>256
256
256
>256

>256
>256
-

>256
>256
>256
>256
>256

-

Cu-tdda-phen
16
32
Manganese(II) complexes
Mn-bda
>256
Mn-bda-phen
32
64
Mn-pda
>256
Mn-pda-phen
32
64

32

64

32

64

64

256

16

256

64

256

>256

-

>256
128
>256
128

>256
>256

>256
>256
>256
>256

-

>256
>256
>256
>256

-

>256
>256
>256
>256

-

>256
>256
>256
>256

-

>256
>256
>256
>256

-

Mn-hxda
Mn-hxda-phen
Mn-hpda
Mn-hpda-phen
Mn-oda
Mn-oda-phen

>256
32
>256
>256
>256
64

64
>256

>256
128
>256
>256
>256
>256

>256
-

>256
>256
>256
>256
>256
>256

-

>256
>256
>256
>256
>256
>256

-

>256
>256
>256
>256
>256
128

>256

>256
>256
>256
>256
>256
>256

-

>256
>256
>256
>256
>256
>256

-

Mn-tdda
128
Mn-tdda-phen
16
Silver(I) complexes
Ag-udda
16
Ag-udda-phen
16
Ag-tdda
16

>256
32

>256
32

128

>256
128

>256

>256
64

128

>256
32

128

>256
64

128

>256
128

>256

32
32
64

32
64
64

64
128
256

64
32
64

128
64
128

64
16
64

128
64
128

32
32
64

128
>256
128

16
32
64

128
>256
128

32
64
64

128
>256
128

8

32

16

32

64

16

64

32

64

64

128

64

128

16
>256
>256
64

32
>256

16
>256
>256
64

32
>256
>256
64

128
>256

32
>256
>256
128

128
>256

32
>256
>256
64

128
128

16
>256
>256
128

128
>256

32
>256
>256
128

256
>256

Ag-tdda-phen
Controls
AgNO3
CuCl2
MnCl2
Phen

32
>256

Table A.11 Minimal inhibitory concentration (MIC) and minimal bactericidal
concentration (MBC) values obtained for Enterobacterales sub-panel exposed to novel
metal complexes and their controls using the broth micro-dilution assay. Values are
presented as µg/mL.
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6.1.4 MICs and MBCs of metal complexes and controls against Pseudomonas
aeruginosa panel

Compounds

ATCC 27853
MIC
MBC
Antibiotic controls
Meropenem
0.5
2
Gentamicin
1
4
Copper(II) complexes
Cu-ph-phen
>256
Cu-oda
>256
Cu-oda-phen
64
>256
Cu2-oda-phen
64
>256
Cu-tdda
>256
Cu-tdda-phen
16
32
Manganese(II) complexes
Mn-bda
>256
Mn-bda-phen
>256
Mn-pda
>256
Mn-pda-phen
>256
Mn-hxda
>256
Mn-hxda-phen
>256
Mn-hpda
>256
Mn-hpda-phen
>256
Mn-oda
>256
Mn-oda-phen
64
128
Mn-tdda
64
128
Mn-tdda-phen
16
32
Silver(I) complexes
Ag-udda
64
128
Ag-udda-phen
16
32
Ag-tdda
128
256
Ag-tdda-phen
8
32
Controls
>256
CuCl2
>256
MnCl2
16
32
AgNO3
64
>256
Phen

PAO1
MIC MBC

Pseudomonas aeruginosa
PA1
PA2
MIC
MBC
MIC
MBC

PA3
MIC
MBC

PA4
MIC
MBC

1
2

4
8

2
16

8
128

>256
>256

-

4
>256

16
-

256
>256

>256
-

>256
>256
64
64
128
32

>256
>256
256
64

>256
>256
128
128
>256
32

>256
>256
64

>256
>256
128
128
>256
64

>256
>256
256

>256
>256
128
128
>256
16

>256
>256
256

>256
>256
256
256
>256
64

>256
>256
256

>256
>256
>256
>256
>256
>256
>256
>256
>256
64
>256
32

128
64

>256
>256
>256
>256
>256
>256
>256
>256
>256
128
128
32

>256
>256
64

>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
64

128

>256
>256
>256
>256
>256
>256
>256
>256
>256
128
128
32

>256
>256
128

>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
64

256

32
32
128
32

256
64
256
64

128
32
128
8

256
128
256
32

256
16
256
32

>256
64
>256
64

128
32
256
32

256
128
>256
64

>256
32
>256
64

128
128

>256
>256
256
64

-

>256
>256
16
64

64
>256

>256
>256
64
128

128
>256

>256
>256
32
128

128
>256

>256
>256
128
128

>256
>256

>256

Table A.12 Minimal inhibitory concentration (MIC) and minimal bactericidal
concentration (MBC) values obtained for Pseudomonas aeruginosa sub-panel exposed to
novel metal complexes and their controls using the broth micro-dilution assay. Values are
presented as µg/mL.
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6.1.5 FICs of metal-phen complexes with antibiotics against Staphylococcus
aureus
Antibiotic
Ciprofloxacin

Metal complex
Cu-tdda-phen
Mn-tdda-phen
Ag-tdda-phen

Gentamicin

Cu-tdda-phen
Mn-tdda-phen
Ag-tdda-phen

Isolate
MRSA1
MRSA2
MRSA1
MRSA2
MRSA1
MRSA2
MRSA1
MRSA2
MRSA1
MRSA2
MRSA1
MRSA2

FIC
Metal complex Antibiotic Index
1.00
0.02
1.02
1.00
0.02
1.02
1.00
0.00
1.00
1.00
0.02
1.02
1.00
0.02
1.02
1.00
0.02
1.02
0.03
0.00
0.04
0.13
0.01
0.13
0.25
0.00
0.25
0.06
0.00
0.07
0.03
0.00
0.04
0.06
0.00
0.07

Table A.13 The fractional inhibitory concentration (FIC) and the FIC index (FIC I) for
metal-tdda-phen complexes against a selection of methicillin-resistant Staphylococcus
aureus isolates

6.1.6 FICs of metal-phen complexes with antibiotics against Enterococci
isolates
Antibiotic
Vancomycin

Metal
complex
Cu-tdda-phen
Mn-tdda-phen
Ag-tdda-phen

Linezolid

Cu-tdda-phen
Mn-tdda-phen
Ag-tdda-phen

Isolate
VRE1
VRE6
VRE1
VRE6
VRE1
VRE6
VRE1
VRE6
VRE1
VRE6
VRE1
VRE6

FIC
Metal complex
Antibiotic
1.00
0.06
1.00
0.06
1.00
0.06
1.00
0.03
1.00
0.02
1.00
0.02
1.00
0.06
1.00
0.06
1.00
0.06
1.00
0.03
1.00
0.02
1.00
0.02

Index
1.06
1.06
1.06
1.03
1.02
1.02
1.06
1.06
1.06
1.03
1.02
1.02

Table A.14 The fractional inhibitory concentration (FIC) and the FIC index (FIC I) for
metal-tdda-phen complexes against a selection of vancomycin-resistant Enterococci
isolates
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6.1.7 FICs of metal-phen complexes with antibiotics against Enterobacterales
Antibiotic

Metal
complex

Isolate

FIC
Metal complex
Antibiotic
Ceftazidime
ATCC 700603
1.00
0.13
ESBL1
1.00
0.13
Cu-tdda-phen
MBL1
1.00
0.03
ATCC BAA1705
1.00
0.13
KPC1
1.00
0.50
ATCC 700603
1.00
0.25
ESBL1
1.00
0.13
Mn-tdda-phen
MBL1
1.00
0.06
ATCC BAA1705
1.00
0.13
KPC1
1.00
0.13
ATCC 700603
0.50
0.06
ESBL1
1.00
0.03
Ag-tdda-phen
MBL1
0.50
0.03
ATCC BAA1705
0.50
0.06
KPC1
1.00
0.13
Gentamicin
ATCC 700603
0.50
1.00
Cu-tdda-phen
ESBL1
0.50
0.06
ATCC 700603
0.25
1.00
Mn-tdda-phen
ESBL1
0.50
0.06
ATCC 700603
0.50
1.00
Ag-tdda-phen
ESBL1
0.50
0.02
Meropenem
MBL1
1.00
0.03
Cu-tdda-phen ATCC BAA1705
1.00
0.50
KPC1
1.00
0.50
MBL1
1.00
0.06
Mn-tdda-phen ATCC BAA1705
1.00
0.50
KPC1
1.00
0.13
MBL1
1.00
0.06
Ag-tdda-phen ATCC BAA1705
1.00
0.50
KPC1
1.00
0.13
Table A.15 The fractional inhibitory concentration (FIC) and the FIC index (FIC I)
metal-tdda-phen complexes against a selection of resistant Enterobacterales isolates
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Index
1.13
1.13
1.03
1.13
1.50
1.25
1.13
1.06
1.13
1.13
0.56
1.03
0.53
0.56
1.13
1.50
0.56
1.25
0.56
1.50
0.52
1.03
1.50
1.50
1.06
1.50
1.13
1.06
1.50
1.13
for

6.1.8 FICs of metal-phen complexes with antibiotics against Pseudomonas
aeruginosa
Antibiotic

Metal complex

Isolate

FIC
Metal complex
Antibiotic Index
Meropenem
PA2
1.00
0.13
1.13
Cu-tdda-phen
PA4
1.00
0.25
1.25
PA2
1.00
0.13
1.13
Mn-tdda-phen
PA4
1.00
0.25
1.25
PA2
1.00
0.06
1.06
Ag-tdda-phen
PA4
1.00
0.25
1.25
Gentamicin
PA2
0.06
0.01
0.07
Cu-tdda-phen
PA4
0.06
0.01
0.07
PA2
0.06
0.01
0.07
Mn-tdda-phen
PA4
0.06
0.01
0.07
PA2
0.01
0.00
0.01
Ag-tdda-phen
PA4
0.00
0.00
0.00
Table A.16 The fractional inhibitory concentration (FIC) and the FIC index (FIC I) for
metal-tdda-phen complexes against a selection of resistant Pseudomonas aeruginosa
isolate
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